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It is essential that systematic reviews are methodologically robust to minimise 
bias and well reported so users can have confidence in the findings. Limitations in 
the quality of published systematic reviews prompted my research into 
methodological aspects with the aim of improving the robustness of systematic 
review evidence.  
I undertook an international Delphi consultation, with 200 experts agreeing a 
minimum data set for systematic review protocol registration. PROSPERO was 
designed and implemented based on the 22 required and 18 optional items 
identified as key protocol registration elements. An evaluation of the utility of the 
register at one year showed registration was feasible, with growing international 
engagement and positive feedback from the survey of users. I was subsequently 
involved in the consensus development of reporting guidelines for systematic 
review protocols leading to publication of the 17-item PRISMA-P checklist.  
PROSPERO became a resource for methodological research, and I undertook an 
examination of outcome reporting bias, previously only possible in Cochrane 
reviews. In comparing the details in 96 published reviews with their PROSPERO 
records, 32% had discrepancies in their primary outcome and 39% did not specify 
a primary outcome. Having a favourable result or positive conclusion did not 
increase the risk of a discrepancy in outcome reporting.  
Registration records can be the only publicly available source of planned methods, 
leading to my methodological study comparing registration data with protocol 
reporting guideline requirements. In a random sample of 439 PROSPERO records 
for reviews of health interventions, 53% (14,469/227,279) of the elements 
compared were classified as reported. This indicates that PROSPERO records are 
not a substitute for public access to a full protocol. 
The research landscape has changed rapidly over the last decade and there is a 
need to revisit and clarify or re-purpose the roles of the systematic review 
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6. Introduction 
Health care policy and practice should be informed by the best available research 
evidence.1, 2 The volume of primary research evidence being published is such that 
busy clinicians and policy makers struggle to keep up to date.3 In addition, many 
are not prepared or equipped to accurately judge the quality and reliability of the 
research.4-6 Variations in findings between studies of the same topic can lead to 
confusion and the potential for clinicians to believe they are following best 
practice while actually providing sub-optimal care or causing harm.7 Systematic 
reviewing was developed as a rigorous research method for bringing together 
existing evidence to answer a specific question. The use of a systematic approach 
to the identification, selection, appraisal and synthesis of the evidence, aims to 
reduce the risk of biases, thereby providing reliable, robust findings. Systematic 
review evidence now underpins clinical policy and practice.8, 9 Issues with the 
robustness of systematic review evidence led to my research to facilitate 
improvement in transparency of systematic review methods and quality of 
reporting. My six papers, published between 2011 and 2020, show progress 
through building and evaluating a prospective register of review protocols, 
publishing a protocol reporting guideline, to the use of both in methodological 
research. 
In research, robustness may be compromised by bias, which occurs when 
systematic error is introduced into the research process, consciously or 
unconsciously. Such errors can be introduced in the design, conduct, analysis or 
reporting of the study. Depending on what the error is and where it occurs, the 
reliability of the research findings may be affected to a greater or lesser extent. 
Researchers need to take steps to minimise the risks of bias wherever possible. 
Readers of published research need to consider how biases have been addressed 
and what the impact might be on the findings. This can be challenging: a mapping 
study in 2010 identified 235 terms for biases in the literature.10 
It was recognised from before the launch of The Cochrane Collaboration in 1992 
that the same scientific principles that applied to the design, conduct, analysis and 
reporting of primary research should also be applied to systematic reviews.7 
Systematic reviewers need to deal with the biases of primary studies included in 
reviews while at the same time avoiding the introduction of bias in their own 
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research.11 However, as the number of systematic reviews published increased, 
empirical studies demonstrated the extent of bias in the application of review 
methods. Compounding this problem was a lack of transparency through poor 
reporting and the existence of unnecessary duplication of effort where multiple 
reviews addressing the same question were published without clear justification, 
such as new trial evidence.12-16 Increasing awareness led to international efforts to 
try and address these problems. 
The international EQUATOR (Enhancing the QUAlity and Transparency Of health 
Research) Network, was set up in 2008 with the aim of,  
“improving the reliability and value of published health research 
literature by promoting transparent and accurate reporting and wider 
use of robust reporting guidelines.”17  
EQUATOR activities include: supporting the development of systematic review 
and clinical guidelines; making reporting guidelines readily available to users; and 
promoting the routine use of such guidelines by researchers, editors and peer 
reviewers.  
In 2009, the Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines were published, to aid the reporting of reviews.18, 19 Fifteen of 
the 27 PRISMA checklist items are for elements that should be included in the 
review protocol. Item 5 indicates that the existence and availability of a review 
protocol should be reported and registration details provided if available. The 
authors of the PRISMA guidelines were aware that the publication and 
registration options for systematic review protocols were at that time limited. 
Nonetheless, they wanted to encourage such activities given the essential role the 
protocol plays in producing robust reviews. To assess whether a review has been 
well conducted but poorly reported or is a poorly conducted review, access to the 
planned methods is needed. 
Developing and making publicly available a protocol setting out the methods in 
advance of carrying out a systematic review helps to minimise the risk of bias and 
aids accurate and complete reporting.20-22 The protocol should then be followed 
throughout the review process. Where amendments to a protocol become 
necessary, the reason for the change should be justified and documented, 
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including the stage of the review when the change is made. By specifying criteria 
in advance of seeing the results of the searches for relevant studies, many 
potential biases may be minimised. By making the protocol publicly available 
researchers can provide transparency in their methods, allowing readers such as 
peer reviewers and clinical guideline developers to compare what was planned 
with what was done. 
At the time I started my research the options for making review protocols publicly 
available were mainly limited to organisations such as the Cochrane and Campbell 
Collaborations, the Joanna Briggs Institute and the websites of major funders such 
as the USA Agency for Healthcare Research and Quality (AHRQ), the Canadian 
Institutes for Health Research and the UK National Institute for Health Research 
(NIHR). Support for prospective registration of systematic review protocols 
gathered momentum.18, 19, 23  In 2010, as a member of an international advisory 
group I announced our intention to develop a prospective register of systematic 
review protocols and my first two papers report on, “Establishing a minimum 
dataset for registration” and “The nuts and bolts” of developing the register.24-26  
PROSPERO, international prospective register of systematic reviews was launched 
in February 2011 and my third paper reports, “PROSPERO at one year: an 
evaluation of its utility”.27 
The fourth paper in this thesis is the, “Preferred reporting items for systematic 
review and meta-analysis protocols (PRISMA-P) 2015 statement”.28 In addition to 
improving the standard of reporting, the guideline aimed to confirm the essential 
role a protocol plays in rigorous review methods and included calls to 
stakeholders for actions to ensure widespread implementation. 
Protocol registration and the reporting guideline initiatives shared the goal of 
improving the quality of systematic reviews through their stated function. In 
addition, it was anticipated that the protocol register would become a resource 
for research on various aspects of systematic review methods and quality. 
PRISMA-P provided a standard against which completeness of protocol reporting 
could be assessed. In January 2014, the Lancet launched a series of publications 
by international experts on increasing value and reducing waste in research. 
Under-reporting, biased and incomplete reporting were identified as key 
contributors to waste.29 The papers identified the provision of trial and review 
protocol reporting guidelines and systematic review protocol registration as 
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important new initiatives for improving quality.30, 31 My fifth paper, “A third of 
systematic reviews changed or did not specify the primary outcome: a PROSPERO 
register study”, demonstrates that the register quickly became a useful resource 
for research.32 
Growing references to PROSPERO records as protocols in the methods literature 
prompted me to think about whether it had been appropriate to suggest in paper 
two that registrations could potentially have similar utility to producing and 
publishing a systematic review protocol.26 Calls for registration carried the implicit 
requirement that a protocol be prepared,18, 19, 23 and key sources for review 
methods 20, 33, 34 and reporting guidelines 19, 28 make a distinction between 
preparing a protocol and registration. My final paper is, “An assessment of the 
extent to which the contents of PROSPERO records meet the systematic review 
protocol reporting items in PRISMA-P”.35  
This integrative chapter presents my research in chronological order and in the 
context in which each study was undertaken. It would perhaps have been more 
logical to develop the protocol reporting guidelines first and then the register. 
However, at the time of developing the register few review protocols were 
published other than within the Cochrane Collaboration and reporting of the 
existence of a protocol although improving was still inadequate.13 It was unclear 
how often a priori methods were documented in any form and the thought was 
that public availability of key methods would be better than the status quo. We 
would at least have some indication of the volume of reviews being undertaken 
and a record with a named contact should the review never be published. In 
considering the changing research landscape, attitudes and technology I reflect on 
the distinction between a protocol and its registration.  
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7. Prospective registration of review protocols 
Identification of poor reporting and biases in systematic reviews led to the idea of 
protocol registration, and ultimately to the launch of PROSPERO the international 
prospective register of systematic review protocols. The first three papers in this 
thesis present the rationale, development and one-year evaluation of 
PROSPERO.25-27  
7.1 Biases affecting systematic reviews 
Systematic review evidence became increasingly influential following the 
establishment of the Cochrane Collaboration in 1992.7 In recognition of the need 
to avoid unnecessary duplication and ensure research resources were 
appropriately allocated, calls for primary studies to start and end with a 
systematic review of the current literature were made.36, 37 Used by clinicians to 
keep up to date with the latest developments in their field, reviews also became 
the bedrock of clinical guideline development.9, 38 The information presented in 
reviews therefore had to be detailed, methodologically sound and the findings 
reliable. However, by 2010, there was empirical evidence of biases in the conduct 
of published systematic reviews and growing recognition of the need to improve 
the completeness and consistency of review reports.13, 15 
A key issue highlighted was outcome reporting bias, where outcomes are 
selectively reported once the results are known and choice is therefore influenced 
by the nature and direction of the results. Omitting or misrepresenting pre-
specified outcomes can distort the evidence and has been found to occur in 
reports of both primary studies and in systematic reviews. Review integrity can be 
affected in two ways. Firstly, the systematic review methods used need to 
account for the possibility of outcome reporting bias in included primary studies.16 
Kirkham et al (2010) found that, after adjustment for outcome reporting bias in 
the primary studies in 42 Cochrane meta-analyses with a statistically significant 
result, eight (19%) became non-significant and 11 (26%) would have 
overestimated the treatment effect by at least 20%.16 Secondly, review authors 
need to avoid selectively reporting the outcomes of their review. The planned 
primary outcome should be reported as such, even if it turns out not to be the 
most interesting finding. A second study by Kirkham et al (2010) comparing 
planned outcomes in Cochrane protocols with their published review found at 
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least one outcome discrepancy in 22% (64/288) of reviews, most of which (75% 
(48/64)) related to the primary outcome of the review.15  
Cochrane reviews are considered to be of a high standard as they adhere to a 
strict and transparent process. They are guided by methods set out and regularly 
updated in the Cochrane Handbook; facilitated by dedicated software such as 
RevMan, Archie and Covidence; and overseen by experienced methodologists and 
clinical specialty focussed editorial teams.21, 39 Crucially including a priori access to 
the full protocol. If these issues were occurring in Cochrane reviews, there had to 
be concerns about the existence and prevalence of similar problems in non-
Cochrane systematic reviews. The inability to easily access protocols for non-
Cochrane reviews was a barrier to transparency in review methods and a risk to 
the validity of review evidence.40 
Another concern at the time was publication bias, where the nature of the 
findings or the direction of effect influences whether a study is published or not.41 
Whether through failure to get a manuscript accepted or a lack of inclination or 
time to write up non-significant or negative findings, there is evidence that studies 
with a significant finding are more likely to be published.11, 12, 15, 42 This results in an 
overall imbalance in the published literature in favour of positive results. 
Publication bias in primary studies has been shown to impact the pooled summary 
estimate in systematic reviews.42 Measures for reviews to combat publication bias 
in primary studies include searching for and inclusion of unpublished studies and 
an assessment of risk of publication bias as part of the systematic review 
methods.42 These were not measures routinely reported in reviews.13 Because it 
was not known how many non-Cochrane reviews were being undertaken, it was 
not possible to establish how many were published. So, whether systematic 
reviews were also prone to publication of those with significant positive results 
could not be established. 
Clinical trial registration had been introduced in response to growing empirical 
evidence of bias in methods and lack of transparency about trials being 
undertaken.12, 43 Prospective trial registration aimed to make planned methods 
permanently available irrespective of whether the study was subsequently 
completed or published. In addition, having the outcomes recorded prospectively 
facilitated the identification of outcome reporting bias in trials, where differences 
in priorities were reported in trial results papers.44, 45 Identification of similar 
15 
quality issues prompted calls for systematic review protocol registration to 
provide the same transparency.18, 19, 23  
7.2 The role of protocol registration  
Compounding the problems of biases, lack of access to a protocol and incomplete 
or ambiguous reporting of completed reviews made assessment of validity of 
findings difficult. Many of the methods to deal with publication bias need to be 
considered at the protocol development stage of a systematic review. If 
information is not available, it is not possible to assess whether a review has been 
well conducted but poorly reported or whether it is a poorly conducted review. In 
either case it is hard to justify relying on the findings.13, 14 There were two ways to 
try and improve access to planned methods: publish protocols and register 
protocols. In 2009 there were limited options and few drivers for publication of 
non-Cochrane review protocols, and no protocol reporting guidelines. In the 
absence of access to a protocol, prospective registration of key methods from a 
protocol could enable comparison of some planned aspects with the final review. 
Particularly helpful if the key items include how the authors propose to minimise 
the risk of publication bias and specify the intended outcomes. Protocol 
registration could also identify the systematic review as having a planned 
approach. However, there were also no dedicated registration options (some 
trials registers accepted review protocols, but the information fields were in-
appropriate for such a different research methodology). Review protocol 
registration had the potential to encourage the production of a protocol and even 
if this was not published, enable authors to make their methods prospectively and 
publicly available. However, in retrospect, the distinction between preparing and 
ideally publishing a review protocol and registering a review protocol could have 
been more clearly articulated.  
7.3 Designing and building the protocol register 
The Centre for Reviews and Dissemination (CRD) had a track record in undertaking 
high quality systematic reviews in healthcare and running three highly accessed 
databases of health research.46, 47 With support and funding from the National 
Institute for Health Research (NIHR), I took the lead in developing PROSPERO, an 
international register of systematic review protocols.48 The first paper presented 
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in this thesis reports on the development of the register and details the 
registration process (Figure 1).26  
My starting point was to look at how trial registration was set up and the issues 
encountered, with a view to identifying where similar issues might arise in 
applying this to systematic reviews and mitigating them where possible. A driver 
behind the international adoption of clinical trial registration was the obligation 
placed on researchers to conduct their research ethically and report the finding 
honestly in return for the altruism of study participants.44, 49 Although research 
ethics approval is not required for the secondary use of data, researchers 
undertaking reviews also have a moral and ethical duty to ensure their use of 
participant data is honest and accurate and fully reported.50 This includes the 
production, registration and adherence to a review protocol. Helpfully, the 
International Committee of Medical Journal Editors set out a list of requirements 
for trials registration required for publication in member journals.49 Similarly, the 
World Health Organisation set standards for registers to be included in the 
International Clinical Trials Registry Platform.45, 51-55 
Development of reporting guidelines anticipates that an ‘executive group’ will 
facilitate the work emphasising the importance of stakeholder buy-in.56 For 
development of the registry I was involved in setting up, and being a member of, 
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an international advisory group. It was important to ensure members could 
provide expertise in different fields and types of reviews, including clinical and 
public health, epidemiology, Cochrane and non-Cochrane reviews. In addition, 
members had experience of international trials registers. This reflected the 
intention for the register to be broad in its inclusion criteria. However, this was a 
new initiative and we had no way of knowing the likely response or volume of 
registrations. We therefore decided that during development and initial 
registration we would focus on registration of protocols for reviews of healthcare 
interventions. The scope for inclusion would be expanded as and when this 
proved desirable and possible. Advisory group members ensured that throughout 
development, their particular area of interest was catered for. 
Based on the approach used by clinical trials registers, the key elements I 
identified as necessary for the register to function were:  
• A searchable web-based interface 
• Free open public access to search and view records 
• Free to register systematic review protocol details 
• A minimum dataset 
• A mechanism for confirming records are in scope and complete 
• Entries have a permanent unique identification number assigned 
These items could all be built into the database and public interface. The most 
challenging step was identifying what items registrations should contain.  
7.4 Identifying a minimum registration dataset 
The second publication in this thesis details the research undertaken to develop 
the minimum dataset (Figure 2).25 There are different methodological approaches 
to establishing consensus agreement such as the nominal group technique, 
involving a panel of 9-12 experts, or a value-weighting survey where participants 
allocate points to indicate their priorities.57-59 The Consensus Development 
Conference method, started in the USA in the 1980’s, sought consensus through a 
public, face to face discussion of the issues.60 However, the most frequently used 
method, particularly in clinical guideline development, is the Delphi technique. 
The original Delphi methodology was developed in the 1960’s 61, 62 and involved 
deriving a group decision from a set of invited experts.57 My approach was to 
combine a modified Delphi technique with aspects of the Consensus Development 
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Conference method. This combination allowed for inclusion of a wide range of 
stakeholders and international participation. It provided an anonymised and 
therefore non-competitive opportunity for all stakeholder groups to engage with 
the process and for me to capture the opinions of large numbers of participants. 
 
 
A number of organisations such as the Institute for Healthcare Improvement, the 
Cochrane Collaboration and CRD had documented in their respective guides to 
review methods, the elements they required in a systematic review protocol. The 
first modification for the consultation was to use these publications to compile a 
comprehensive list of items for use as a starting point. This by-passed the first 
stage of a Delphi where participants would have been asked to contribute ideas to 
develop this list. The focus of the exercise could then be on identifying the 
protocol items most relevant to a registration record. Other modifications to the 
methods related to who was invited to participate, and that they were not asked 
to confirm participation in advance. Although a face to face public discussion was 
not feasible, it was possible with an electronic survey to include as many 
participants as possible. So, in addition to directly emailing a list of experts around 
the world, cascading of the survey link was encouraged through relevant 
organisations and individuals. With these modifications I aimed not only to 
identify the registration dataset, but also make our intention to develop a register 
known, gauge the level of support for registration and promote wide engagement 
and ownership. 
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A threshold of 70% or greater agreement was set for inclusion of items as 
Required or Optional fields, as indicated in responses. This figure was selected 
being greater than two-thirds of opinions indicating a clear majority. The first 
round of the consultation resulted in two of the initial 40 items being dropped 
and five being merged. The majority of participants felt that it was not possible to 
anticipate publication date and that if an economic analysis was going to be 
undertaken it should be included in fields such as title, review question and 
outcomes. Primary and secondary outcomes were considered essential while 
recording the measures to be used was not: outcomes and measures were 
merged. Further ‘compromise’ surrounded the different elements of the planned 
data synthesis: leading to methods for exploring heterogeneity and the rationale 
for use of techniques being merged into the field for data synthesis. Two items 
were added in response to participant suggestions: contact phone number and 
other registration details. The latter was thought to be important particularly to 
avoid duplication of registration of Cochrane reviews; the planned mechanism for 
automatically uploading these was later implemented. 
The Ottawa Statement set out three requirements for trial registration: 
acquisition of a unique registration ID; registration of the original protocol and 
any amendments; and thirdly registering the trial results.44 In the advisory group 
we discussed at length whether in addition to adding a link to a publication of the 
completed review, authors should be able to add the results to their record. 
However, we had major concerns that simply reporting results, with no 
explanation or context, no discussion or supporting information would be 
detrimental to the register and compound the issues of poor reporting already 
identified in the literature.12, 13, 16 It may also have reduced the incentives for 
researchers to publish a full report of their findings. Subsequent developments 
through calls for open access to results and the availability of data repositories 
has provided alternatives.63, 64 This includes making datasets available for scrutiny, 
replication and/or use for further research or updates, however there are a now a 
number of these sites, such as FigShare, Open Science Framework (OSF), and 
OwnCloud, all of which need to be searched.64  
PROSPERO was launched on 11th February 2011, offering free registration and 
public access for searching. Scope for inclusion was for, 
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“systematic reviews of the effects of interventions and strategies to 
prevent, diagnose, treat and monitor health conditions for which 
there is a health-related outcome.”  
The registration form contained 22 required items and 18 optional items. The 
stated aims of PROSPERO were: 
“to provide a comprehensive listing of systematic reviews 
registered at inception to help avoid duplication and reduce 
opportunity for reporting bias by enabling comparison of the 
completed review with what was planned in the protocol.” 48 
For the register to achieve these aims, it was necessary to raise awareness and 
encourage registrations. Following guidance for development of dissemination 
strategies,20 and implementing reporting guidelines,56 PROSPERO was formally 
launched with press releases from the Minister for Health and the Director of 
NIHR. Other activities included obtaining endorsements from research, funding 
and commissioning organisations, publishers and journals and publication of 
articles by supporters.48, 65-67  To encourage implementation, publishers such as 
BMJ, PLoS, and BMC recommended their journal editors request protocol 
registration details with manuscripts of systematic reviews.48 After initial piloting 
with their HTA Programme, NIHR made registration mandatory for all reviews 
they fund that meet the inclusion criteria.68, 69 Promotion continued with 
conference presentations, blogs and letters.23, 67, 70-73 
7.5 Assessing the utility of PROSPERO at one year 
Protocol registration was a novel intervention in the systematic review process, so 
I planned an evaluation of progress after one year of operation and the resulting 
paper is the third in this thesis (Figure 3).27 The evaluation presented statistics 
about users of the registration process, usage of the site, and the findings of a 
survey of users and those the register was aimed at.  
During development of the database, I considered the routine data and outputs 
that would be needed to monitor progress of the register and registrations. This 
made collating and presenting data on aspects related to registrations such as 
numbers registered or rejected, and countries where reviews were being 
undertaken, relatively straightforward. However, available analytics to show web 
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traffic and usage patterns was more challenging in interpretation and consistency 
of presentation. For example, internet provider addresses could represent a single 
individual or an entire organisation such as a university or hospital. Likewise, 
length of visit could be measured in seconds, so it was unclear how useful a visit 
to a page had been for a user.  
 
Obtaining unbiased, honest, and representative feedback from users was also 
challenging. The use of online surveys was becoming routine and users of 
PROSPERO were assumed to have access to the internet and be computer literate. 
As for the Delphi exercise I decided on an open survey where the link to the 
questions could be shared and responses anonymous to encourage expression of 
all views. The survey was sent to the list of Delphi participants and to users who 
had signed up for an account with PROSPERO as occasional contact by email was 
part of the terms. 
The survey was reported as far as possible in accordance with the Checklist for 
Reporting Results of Internet E-Surveys (CHERRIES).74 The findings of both parts of 
the evaluation were positive and showed both growth in registrations and 
satisfaction with the process. However, no data were found or reported to show 
whether PROSPERO was achieving the aim of reducing duplication. There was 
undoubtedly a risk of bias from undertaking this evaluation ‘in-house’ as I and the 
Advisory Group authors had a vested interest in PROSPERO being seen to be 
achieving its aims. Those who had taken part in the Delphi and created a 
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PROSPERO account were also likely to be supportive of the initiative. Respondents 
would have variations in their priorities, for example commissioners versus 
researchers who had registered a review, information specialists versus 
statisticians. However, while largely positive, the survey feedback did result in 
changes being made, such as the widening of scope to include reviews of reviews 
and methodological reviews with at least one outcome of direct patient or 




8. Quality of reporting of systematic review protocols 
Following the launch of PROSPERO and growing opportunities to publish review 
protocols, the need for a template providing succinct guidance on what should be 
reported in a review protocol became apparent. The fourth paper presented in 
this thesis is the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis Protocols (PRISMA-P) 2015 statement (Figure 4).28 I set out here the 
rationale for the guideline and my involvement in its development. 
 
 
8.1 Reporting research 
The World Medical Association Declaration of Helsinki - Ethical Principles for 
Medical Research Involving Human Subjects states, “Authors have a duty to make 
publicly available the results of their research on human subjects and are 
accountable for the completeness and accuracy of their reports.”75 Researchers 
have a duty to publish the results of studies, whatever the findings. It is unethical 
to undertake research, particularly with voluntary participants, and not share the 
results publicly and with participants.50 I believe this also holds true for systematic 
reviews, as the data from included studies derives from those same participants. 
In addition, systematic reviews have the ability to inform decisions in health and 
social care policy and practice, so should be conducted and reported to the 
highest standards.  
The publication of a paper in a peer reviewed journal is the primary mechanism 
for getting the results of research into the public domain. The paper may also be 
the only evidence that the research was undertaken and provide the only source 
of information on which to judge the quality of the methods and reliability of the 
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findings. The quality and completeness of reporting of both clinical studies and 
systematic reviews were known to need improving.13, 76-79 Poorly reported 
research may or may not have been poorly conducted; without sufficient 
information about the planned methods, the reliability of the findings remains 
uncertain. 
8.2 Improving the quality of reporting 
One of the most important and influential attempts to improve the standard of 
research reporting started with the Consort statement, first published in 1996, 
which provided guidance for reporting RCTs.80 This was followed by guidelines for 
reporting many other study designs, including in 2000, QUOROM for meta-
analyses of RCTs.81 Evidence subsequently showed that the use of the CONSORT 
statement was associated with improved reporting of RCTs.82 
In identifying and bringing together all published reporting guidelines in the 
EQUATOR Network, it became apparent that although there were many 
guidelines, their methods of production varied.83 To address this, “Guidance for 
developers of health research reporting guidelines” was published in 2010.56  
A Cochrane systematic review found some evidence of the effectiveness of 
journal endorsement on the use of the CONSORT statement by authors of RCTs 
published in medical journals.84 However a subsequent review of 101 other 
reporting guidelines, found insufficient evidence to determine whether or not 
journal endorsement had an effect on completeness of reporting.85 The Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA 
statement was published in 2009.19 In a scoping review of evaluations of the 
uptake and impact of PRISMA, Page et al (2017) found that for many items, 
reporting was suboptimal.86 Intuitively, if followed, guidelines should improve 
completeness of reporting, but understanding the effectiveness of reporting 
guidelines is complex. To start with the validity of the guidelines needs to be 
understood. The methodology for their development and whether they include 
guidance on all aspects of a study and in sufficient detail for replication are 
important. For example, studies of interventions need to report both the details 
of the intervention and how it was actually delivered in the study.77, 87 If the latter 
is not indicated as necessary in a guideline it may compound reporting problems. 
To facilitate research into whether reporting guidelines achieve their aim, journals 
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need not only to endorse reporting guidelines, but also encourage if not require 
their use.86 A starting point could be to provide peer reviewers with instructions 
on how to use the relevant reporting guideline; identified as information not 
provided by 116 health research journals.86, 88 
8.3 PRISMA-P reporting guidelines  
Prior to the development of PRISMA-P, reporting guidelines for systematic review 
protocols, publication and/or registration of non-Cochrane review protocols was 
rare, and opportunities to do so were limited. The majority of systematic reviews 
being published were non-Cochrane reviews and few reported following a 
protocol.13 What was unknown was the reason for not reporting a protocol in the 
review paper: it may have been incomplete reporting or a lack of understanding 
of the need for a protocol. A steering committee formed to lead on developing 
systematic review protocol reporting guidelines. They followed the guidance for 
developing reporting guidelines and first identify the need.56 In preparing a list of 
potential items for consensus discussion, the second step, the steering committee 
would usually have carried out a Delphi exercise. However, as with PROSPERO, 
existing robust sources existed. These included the consensus exercise I 
conducted for PROSPERO, the SPIRIT and PRISMA checklists and the Institute of 
Medicine standards for systematic reviews.18, 19, 25, 34, 89, 90 I was invited by the 
steering committee to join the PRISMA-P reporting guideline development group 
during the planning phase. The consensus meeting was held in June 2011, at the 
AHRQ headquarters in Washington DC. I presented the PROSPERO consensus 
exercise, shared the feedback on specific items provided by participants in the 
Delphi and the rationale for decisions made by the PROSPERO Advisory Group 
that led to the final registration list. The rest of the two-day meeting was devoted 
to an item by item discussion of the PROSPERO and, where relevant, PRISMA 
checklists to agree if and how they should be incorporated into the reporting 
guideline. By the end of the two days, we reached general agreement on all items. 
I made critical comments on the drafts of the statement paper which was 
published in 2015.28 I was also a group author on the subsequent elaboration and 
explanation paper.91 The reporting checklist recommended 17 numbered items, 
26 including sub-items, be reported in a systematic review protocol. The items 
were categorised as administrative, introduction and methods. To facilitate 
transfer of information once a review was completed, PRISMA-P items followed 
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the PRISMA template as far as possible. While the key methodological items for 
registration were included, the requirements were more in-depth than for 
PROSPERO, a reflection of their different purposes.  
The statement paper (Paper 4) has over 5,000 citations and has been accessed 
over 225,000 times (October 2020). Journals have endorsed the use of PRISMA-P, 
as encouraged in the statement paper. However, as has been shown for journal 
endorsement of other reporting guidelines, this is only part of the answer to 
improving the reporting.88, 92-94 We therefore included in the statement paper a 
section on implementation, recognising that work beyond publication is necessary 
if change is to be affected.83 We identified a range of stakeholders, proposed 
actions they could take and indicated what the potential benefits of those actions 
might be.28 In a comprehensive scoping review of interventions to improve 
adherence to reporting guidelines Blanco et al (2019) identified a wide range of 
strategies available to different stakeholders.95 However,  they conclude that most 
of the strategies require research to establish their effectiveness. Future evidence 
of what works to encourage complete reporting should help inform ways to 
improve the quality of reporting of review protocols and the content of 
PROSPERO records. Improving completeness and quality of reporting would then 
facilitate research to assess the quality of the planned methods. 
The launch of PRISMA-P promoted the importance of producing a review protocol 
that addresses all the potential methodological issues that may arise when the 
review is carried out and then register the protocol as a separate action. There 
were by that time more opportunities for publishing protocols but the simplicity 
of a free open access registration process and a lack of understanding that doing 
both is best practice may be hard to overcome.  
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9. PROSPERO and PRISMA-P as resources for research 
As the number of registrations in PROSPERO increased, so the database 
developed as a resource for methodological research. For the first time it was 
possible to examine the planned methods of non-Cochrane systematic reviews. 
Papers 5 and 6 in this thesis were undertaken four years apart and explore two 
different aspects of review methods. My studies are presented here with other 
methodological research facilitated by PROSPERO and PRISMA-P. 
9.1 Assessing outcome reporting bias using PROSPERO data 
As already detailed, there was strong empirical evidence of outcome reporting 
bias in Cochrane reviews, generally considered to be of the highest standard.12, 15, 
96 PROSPERO provided the means to explore concerns about the quality and 
robustness of non-Cochrane reviews, which form the majority of published 
systematic reviews. The fifth paper in this thesis investigated outcome reporting 
bias in non-Cochrane systematic reviews (Figure 5).32  
 
Choosing the most appropriate outcomes for a systematic review is part of the 
development of a review question. The recommended approach is to collate all 
potential outcomes then prioritise them to identify the outcomes that will provide 
the answer to the problem in a way that is meaningful to the end user.20, 97 The 
Cochrane Methodological Expectations of Cochrane Intervention Reviews 
standards include three categories of outcomes: critical, important and not 
important in relation to clinical/policy decision making.33 Essentially, primary 
outcomes should facilitate clinical decision making, including identifying potential 
harms; secondary outcomes are of lesser importance and usually provide 
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information that could explain the effects seen in the primary outcomes. 
Cochrane advocate excluding outcomes of little or no importance to avoid over-
whelming and potentially misleading readers.97 
Having stated the primary and secondary outcomes in the protocol, they should 
be reported as such in the review. As already described, outcome reporting bias is 
more likely to occur when the outcomes are reported in a way that differs from 
the original intent.  
By late 2013, PROSPERO contained almost 2,500 registrations, making a study of 
outcome reporting bias viable. In collaboration with a review team including 
researchers in Canada, Australia and the UK, I was involved in and contributed to 
all aspects of producing paper 5 of this thesis, from initial concept to final 
publication. In this research we aimed to find out if, and to what extent, outcome 
reporting bias occurred in non-Cochrane reviews using PROSPERO data.32 We also 
took the opportunity to assess the quality of reporting of the included reviews. 
In preparing the study protocol we drew on methods used in other studies with 
the aim of standardising classifications.15, 40, 98 For changes in how planned 
outcomes were reported these were: new inclusion; exclusion; upgrade; and 
downgrade. Similar classifications for meta-analysis results and for conclusion 
statements were also used. We focussed on reviews of interventions with meta-
analyses so we could examine the association between the level of significance of 
meta-analysis results and the direction of any changes in outcome reporting. For 
the assessment of the methodological quality of the systematic reviews we used A 
MeaSurement Tool to Assess systematic Reviews (AMSTAR).99, 100 The best 
validated measurement tool available at the time, AMSTAR has since been revised 
in light of limitations.101 
Having contributed to the study design and protocol, I was involved in developing 
the data extraction form, in particular in relation to the information that was 
requested in PROSPERO records, and subsequently undertook data extraction 
from the registration record and the publication. One of the methodological 
aspects I led on was specifying the data set to use. We wanted to include records 
where the status had been updated to show the review had been completed and 
published. These records therefore had more than one version; all versions 
remaining available in PROSPERO for transparency. As changes to any part of the 
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record could be made at the time of updating, there was no guarantee that the 
methods had not been altered after the results were known. My advice was to 
use the version that was live immediately prior to the record being updated to say 
the review was completed. This should have ensured we were using a priori 
registration details. Lack of resources meant we did not search to identify 
PROSPERO records that had not been updated to say completed and published. As 
has been subsequently demonstrated, PROSPERO record are frequently not kept 
up to date by their owners.102 However in the first few years, it appeared that 
Named Contacts, the owners of records, were in the main recording progress to 
publication. This may have been because those who knew about the option of 
protocol registration were more methodologically alert and there may also have 
been a novelty factor as with many innovations. Certainly a different approach 
would be needed now, given Rombey et al’s (2019) findings that 49 out of 75 
(65.3%) published reviews were still registered as ‘ongoing’.102 
After applying eligibility criteria to the 140 potentially relevant PROSPERO records, 
96 registration/published review pairings were included in the study.32 We 
explored a number of hypotheses, using methods of analysis that would facilitate 
comparison with similar work in Cochrane reviews.15, 16 We found that 32% of the 
non-Cochrane systematic reviews examined had a discrepancy between the 
primary outcome in the review compared to their registration record. Having a 
favourable and statistically significant meta-analysis was not associated with a 
significant increased risk of adding or upgrading (RR, 2.14; 95% CI: 0.53, 8.63) or 
decreased risk of downgrading (RR, 0.76; 95% CI: 0.27, 2.17) an outcome. 
Likewise, having a positive conclusion was not related to a significant increased 
risk of adding or upgrading (RR, 0.89; 95% CI: 0.31, 2.53) or decreased risk of 
downgrading (RR, 0.56; 95% CI: 0.29, 1.08) an outcome. These results were 
consistent with a review of studies examining discrepancies in outcomes in 
Cochrane reviews.103 We also observed that over a third of the review reports did 
not specify a primary outcome; and that both the included studies and the 
reviews themselves used multiple outcomes and measures. Both issues that 
PROSPERO and PRISMA-P try to direct researchers away from during the 
development and reporting of the protocol.  
Seventy-two (75%) of the reviews met our cut off score of 8 or more out of a 
possible 11 using the AMSTAR tool to assess methodological quality.100 We 
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suggested that journals consider focussing on publishing registered reviews as 
they appeared to be of high methodological quality: a cautious recommendation 
in the absence of a comparator. However, consistent key omissions in reports 
were: conflicts of interest; no assessment of publication bias where it would have 
been appropriate; and not considering quality or risk of bias in the conclusions. All 
are items covered in the PRISMA reporting guidelines and should have been 
picked up by journal editors and peer reviewers. 
Our report was the first to present data and results for non-Cochrane reviews 
registered in PROSPERO. The characteristics of included reviews presented in the 
paper were interesting in their own right. A more robust sample size however, 
would have enabled exploration of possible sources of heterogeneity and sub-
group analyses. While demonstrating new accessibility to non-Cochrane reviews 
and their key protocol details, our data on primary outcome reporting and 
methodological quality provides baseline data for future studies as the volume of 
registrations grows. 
9.2 Assessing PROSPERO record content using PRISMA-P 
A surprising finding of the Kirkham et al (2010) study of outcome reporting bias in 
Cochrane reviews was that 24 out of 297 reviews (8%) did not have a protocol in 
the relevant section of the Cochrane Library.15 The case for non-Cochrane reviews 
is worse. The study of outcome reporting bias (Figure 5), found that of the 96 
reviews included, 91 (95%) had not published their protocol in a journal, making 
their PROSPERO registration the only source for planned methods.32 More 
recently, Viguera-Guerra et al (2019) report that, although the number of review 
protocols published in journals is increasing, most review protocols are only 
registered in PROSPERO.104 Registrations may contain a protocol as an 
attachment, but this is rare and the file can be ‘hidden’ until the review is 
published. This means PROSPERO records are frequently the only access to a 
priori methods for comparison with the final report for publishers, peer reviewers 
and others interested in assessing the potential for bias. However comprehensive 
a registration, the contents of records are not assessed for methodological 
completeness, appropriateness or rigor, whereas a published protocol is subject 
to the editorial and peer review process, although this has been shown to be a 
flawed and inadequate process.105-108 A lack of clarity in understanding the roles of 
a protocol and registration may contribute to this situation. 
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In the absence of a publicly available protocol, ideally the registration would have 
to be sufficiently detailed to allow comparison with the review report. In Paper 6, 
I undertook a comparison study to assess the extent to which the contents of 
PROSPERO records include the items listed in PRISMA-P and to establish whether 
PROSPERO records can act as the sole public record of the planned review 
methods (Figure 6).35 It was important to first establish the level of detail being 
provided in PROSPERO records, so future research exploring the methodological 
rigour in registrations could focus to where data could be found. 
In this study I assessed a random sample of 2018 PROSPERO records with no 
related protocol against reporting items for systematic review protocols listed in 
PRISMA-P 2015. The choice of registration year was to allow time for the 
reporting guidelines to become widely known. Some of the PRISMA-P items were 
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either not asked for in PROSPERO or could not be extracted to match specific 
reporting items. Nineteen of the 26 PRISMA-P items and sub-items were relevant. 
Where the description included more than one specific item of the information, 
these were identified and listed as 63 elements. Assessment was undertaken at 
both the overall 19 item level and for the 63 elements, with presence of an 
item/element scoring 1 and absence scoring 0.  
The primary outcome for the study was the compliance of PROSPERO registration 
records with PRISMA-P reporting items. The outcome measures were the overall 
scores for the assessed dataset at item and element levels. Demographics from 
the assessed dataset were presented with the non-assessed records from the 
2018 dataset. I chose to limit inclusion to systematic reviews of healthcare 
interventions as both PROSPERO and PRISMA-P were originally designed 
specifically for reviews of interventions. I posted the detailed study protocol on 
the Open Science Framework (OSF) prior to sight of the dataset.109 It is important 
to provide transparency in the conduct and reporting of all research, including 
methodological studies.  
There were 2,194 eligible registration records and 439 (20%) of these were 
randomly selected for assessment. Six records were later excluded meaning 433 
were included in the analysis. There were no substantial differences between the 
assessed and not-assessed datasets, suggesting we had a representative data set. 
None of the PROSPERO records assessed against the eligibility criteria reported on 
all elements in each of the items recommended for a systematic review protocol 
in the PRISMA-P guidelines. The mean total score for individual PROSPERO records 
for the 19 items, was 4.8, the standard deviation 1.8, the median 4, and range 2 to 
11. Considering all items across all the assessed records, only 25% (2081/8227) of 
the items were scored as reported. The mean total score for individual PROSPERO 
records for the 63 elements of the reporting guidelines was 33.4, the standard 
deviation 5.8, the median 33 and the range 18-47. Overall, 53% (14,469/27,279) 
of the elements were considered as reported. 
There were no significant differences in any of the pre-defined subgroup 
comparisons of: the stage of review at registration; whether or not information 
was reported on source of funding, sponsorship or support and where none was 
indicated; and whether or not the relevant box in the registration form had been 
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ticked to indicate a meta-analysis was planned. Scores for the ten countries and 
topics with the highest number of assessed records, and for number of authors 
indicated that none of these factors had a marked influence on the number of 
PRISMA-P items or elements reported in PROSPERO records. 
The iterative process of developing a protocol allows for consideration of how an 
increasing number of issues will be addressed in the review.20 Once finalised or 
near to completion the key methodological details should be registered.19 In 2011 
when PROSPERO was launched, there were few options for publishing protocols 
and the ability to register protocol details on a free open access database 
provided what might have been seen as an alternative. It may then be considered 
inappropriate to expect a registration record to meet the PRISMA-P criteria. 
However, one of the stated aims of registration is to enable comparison of 
planned methods with the final report. It would therefore seem reasonable to 
expect the mandatory fields in PROSPERO to be fully completed, but this was not 
the case. My study found that some key methodological details were relatively 
frequently reported, but much of the information recommended in PRISMA-P was 
missing from registrations. While reporting was unsurprisingly more frequent for 
items that are mandatory in PROSPERO there were still gaps. Of particular 
concern is the lack of detail related to outcome measures, assessment of risk of 
bias and quantitative analysis methods. PROSPERO records are unlikely to meet all 
the PRISMA-P recommended items, given the differences in purpose between a 
protocol and registration. However, it is important to understand what 
information is available where registration is the only public source. It may be 
reasonable to expect researchers using the register in this way to provide 
sufficient information. The role of the protocol and registration may need 
clarifying. 
Eligibility criteria and type of analysis planned are separate required fields in 
PROSPERO and were most frequently reported in registration records. However, 
study selection process (Item 26 Data extraction (selection and coding) in 
PROSPERO), which is optional, was also a more frequently reported item. This 
finding may be a reflection of a lack of experience and understanding of review 
methods, with familiar items such as eligibility criteria being reported, while 
missing items which may require more in-depth methodological knowledge such 
as naming the statistical method, how study results will be converted to the same 
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format and how missing data will be handled in the synthesis. Or it could be an 
indication of what the researchers themselves feel is important to register. It 
should be remembered that registrants of the included records were providing 
details required to register their review and that only some of the items are 
mandatory. As the included registrations did not have links to a protocol, I 
assumed they were the only public source of a priori methods, but this may not 
have been the case.  
PRISMA-P is a reporting guideline and not a rating scale so the assessments for 
paper 6 involve a degree of subjectivity. Examining the elements within the 
PRISMA-P items has highlighted where there are consistent gaps in reporting. This 
has the potential to aid the PROSPERO administrators in checking these fields 
more closely for new applications and requesting further information where this 
is insufficient. However, the administrators are not methodologists and simply 
check for ‘sense’: further training and possibly clarification for applicants and 
administrators of what is required may not result in significant improvements. 
Other potential responses to the findings of this study are to: promote calls for 
comprehensive protocol documents to be uploaded with registrations; raise 
awareness in the reviewing community through training and dissemination of 
information of the importance of preparing and making a protocol available, as 
well as registering it focussing on the areas not currently well reported; encourage 
journal editors and peer reviewers to identify and comment on short comings in 
provision of a priori methods. The findings could also be used as a prompt to 
review of the roles of the review protocol and registration and consider whether 
the register should be redesigned to better achieve its purpose. 
Systematic review protocol registration on PROSPERO provides the opportunity 
for researchers to be transparent in their planned methods and efforts to 
minimise bias. However, my findings indicate that in the absence of a publicly 
available protocol, there is a considerable shortfall in the items reported, even 
where mandatory, compared to those expected in a PRISMA-P compliant 
protocol. Where registration is the only source of a priori methods, this presents 




9.3 PROSPERO and PRISMA-P use in the literature 
PROSPERO has facilitated a growing number and wide range of methodological 
studies. Tsujimoto et al (2017) found that only 60/284 (21%) of reviews had 
registered their protocols, though the proportion was increasing over time.110  
They went on to find no statistically significant association between outcome 
reporting bias and registration. Page et al (2018) in an analysis of a random 
sample of PROSPERO registrations found that no information about the primary 
outcome other than the domain (e.g. timing, effect measures) was pre-specified 
in 44/150 records (29%).111 Sideri et al (2018) found reviews registered in 
PROSPERO were associated with higher review quality.112 Other studies have used 
PROSPERO data to look at: registration characteristics as predictors for 
publication;113 the time and number of researchers needed to conduct systematic 
reviews;114 the planned use of risk of bias tools;115 the reporting of adverse 
outcomes;116 and compared a range of planned methods in PROSPERO records 
with published reviews.117, 118 Whether and how often editors or peer reviewers 
access registration records (or indeed protocols) when examining a final report, is 
not known. Comparison with protocol or registration details was not identified as 
an activity peer reviewers are encouraged to do in any of the journal instructions 
to peer reviews examined by Hirst and Altman (2012).88 
Noticeable in the growing literature is how often registration records are referred 
to and/or treated as protocols.115-119 Delgado and Delgado (2017) refer to 
registrations as protocols without clarifying if the registrations contained a full 
protocol.120 Viguera-Guerra et al (2019) talk about PROSPERO as a protocol 
repository, and while the uploading of a protocol file is facilitated, this is rarely the 
case.104 A further example is Farrah et al (2019) who consistently refer to 
‘PROSPERO protocols’.115 The interchangeable use of ‘registration’ and ‘protocol’ 
may be a reflection of and/or promoting a wider understanding that they are 
indeed interchangeable. Allers et al (2018) rightly question whether PROSPERO 
registration alone is sufficient and can replace published systematic review 
protocols.119 Paper 6 of this thesis shows that registration is currently not a 
substitute for a comprehensive protocol.35  
An advantage of registration on a dedicated database, is the ability to search a 
single site for existing and on-going reviews. Success in avoiding unplanned 
duplication of reviews, an aim of PROSPERO, is difficult to assess. There are a 
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number of papers highlighting duplication of reviews and meta-analyses.121-123 
However, what is unknown is how frequently a search of PROSPERO has resulted 
in a review question no longer being pursued or being amended to avoid 
duplication. Sigurdsun et al (2020) found redundant meta-analyses are common in 
genetic epidemiology and suggest more widespread registration of protocols on 
genetic topics would aid identification of pre-existing efforts.124 Sadly, the 2281 
registrations for systematic reviews on Covid-19 related topics in humans (2 
October 2020) would suggest that there is still a lack of understanding about the 
need to consider on-going and published reviews when refining a review 
question.48 
Although PRISMA has been used in a number of publications to assess the quality 
of reporting of reviews,86 there is currently limited use of the PRISMA-P reporting 
guideline to assess protocols. A study of the publicly available peer reviews of 53 
published systematic review protocols based their assessment on the PRISMA-P 
items and found: 342 comments (76%) suggested more transparency was needed 
in the planned methods and 108 (24%) suggested a protocol amendment.106 They 
found authors had implemented, in the published protocol, the suggestions for 
more transparency in 291 (85.1%) and protocol amendments in 80 (73.7%). The 
same paper identified that, paradoxically, PROSPERO (in the instructions for 
researchers) urges caution in the timing of registration, and PRISMA-P 
recommends including the registration details in the protocol. Although not 
contradictory, these instructions could be revised for more clarity. 
Also of interest in the literature is the apparent use of PRISMA-P as a 
methodological guide: “The data were analysed according to the PRISMA-P 
guidelines.”125 and “…assessed articles for study inclusion using the Preferred 
Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) 
for data reporting.”126  Perhaps a review of the respective roles of review 
reporting guidelines and methodological texts is also needed.  
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10. Discussion 
The publications in this thesis were undertaken across a time span starting from 
where there were limited options for publication or registration of systematic 
review protocols, to a time where there is a heavily subscribed register and 
guidelines for reporting them. This has, in just a few years, provided a rich data 
source for methodological research providing insight into reporting issues and 
where further research is needed.  
As a response to calls for improved transparency and reduction in waste in 
research, PROSPERO may be considered to be succeeding in its purpose, at least 
in some respects. In October 2019, over 54,800 non-Cochrane reviews were 
registered on PROSPERO, and even if records do not contain all the details that 
they ideally should,35 this provides more information than was previously 
available. There are a number of reasons why reported data may be incomplete. 
These include lack of clarity and/or possibly understanding about the purpose and 
requirements of a protocol and of protocol registration; a lack of knowledge 
about specific aspects of review methods; concerns about developed ideas being 
‘stolen’; and lack of time. Completeness may also be influenced by motivation for 
registering, for example if in response to a mandate from funders or journals and 
seen as an additional burden.85 Although the itemised registration format is 
thought to promote more complete reporting in trial registration,95 it is not 
known whether in PROSPERO this promotes more complete reporting or 
engenders a ‘tick-box’ approach.  
While the completeness of PROSPERO records falls short of what ideally should 
appear in a protocol,35 for the purposes of registration, the finer methodological 
details may not be so necessary. For example, statistical analysis plans are not 
required in trial registration, so review protocol registration may not require full 
details of the planned synthesis. There may be an argument that the aim of 
providing sufficient information in a registration record to facilitate comparison 
with the final review report was over ambitious.  By making registration 
requirements so detailed, the differences between a protocol and registration 
may have been further obscured.  
Examining the chronology of the development of tools to improve the conduct 
and reporting of systematic reviews demonstrates the need for action. PROSPERO 
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was developed in 2009/10 at a time when opportunities for publishing review 
protocols were very limited and it was unclear how many non-Cochrane reviews 
were being undertaken and how many had protocols.25, 26 There are now 
numerous free to use, open access platforms where protocols may be made 
public if time and cost stand in the way of journal publication. PRISMA-P was 
developed a few years later as opportunities for publishing protocols started to 
open up and demands for increased transparency grew. The cost of publishing 
protocols makes non-peer reviewed posting on an open data website attractive. 
However, there is an argument that, while also far from a perfect system,107, 108, 127 
high quality peer review may be more important and valuable for ensuring sound 
methods in research protocols than for the final manuscript. The protocol stage is 
when missing and/or flawed methods can be corrected. Of course, there are 
differences between protocols produced for projects for major funders, who have 
their own internal checks, and reviews that have no independent or external 
input. Obtaining editorial and peer review comments on a protocol paper that are 
mindful of reporting guidelines is another reason why the registration record is 
not currently a replacement for a published protocol. However, my research 
shows the need to revisit and then clarify or re-purpose the roles of the 
systematic review protocol and protocol registration. There are three key areas 
where research is needed to shape the future for PROSPERO. 
• Methodological issues  
Important areas for investigation include: whether protocols are registered at an 
early enough stage in the review process to establish whether they are truly a 
priori; repeating the study on outcome reporting bias to address some of the 
limitations such as precision, with a larger sample size and generalisability by 
inclusion of other fields/topics; examining the effects of other types of bias such 
as selection and publication bias; and assessing the quality of systematic review 
protocols. 
• Research on registration 
The volume of records on PROSPERO, and the international reach and range of 
topics covered, mean that the database provides a rich data source supporting 
research on research. For registration, the starting point is a mapping review of 
the existing methodological literature examining aspects of systematic review 
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protocols, particularly those utilising PROSPERO data, and identifying suggested 
improvements related to protocols and registration. Such a review could help 
formulate an agenda for open debate in the systematic review community around 
the future for protocol registration.  
• The future of publishing and registering protocols 
Technological advances over the last 10 years have significantly changed the 
publishing landscape, access to information and ways of collaborating. Text 
mining, machine learning technologies and open data repositories present new 
opportunities for transparency in carrying out research and facilitating more 
research on research. For example, technological interventions could be designed 
to improve the quality of protocol reporting and registration and facilitate closer 
alignment.  
Drivers for change are the widespread recognition that limited research resources 
need to be used wisely to maximise value and processes designed to minimise 
researcher burden.29, 128 My research has increased transparency in systematic 
reviews and provided evidence to stimulate future research and promote debate 
to further improve the reliability of review evidence.   
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12. Abbreviations and glossary 
AHRQ Agency for Healthcare Research and Quality 
AMSTAR A MeaSurement Tool to Assess systematic Reviews 
Archie Cochrane's central database for managing contact details and 
documents 
BMC BioMed Central 
BMJ British Medical Journal 
Campbell 
Collaboration 
A non-profit organization that promotes evidence-based 
decisions and policy through the production of systematic 
reviews and other types of evidence synthesis in: Business & 
Management, Climate Solutions, Crime & Justice, Disability, 
Education, International Development, Knowledge Translation 






Cochrane is a global independent network of researchers, 
health professionals, patients, carers and policy makers. It 
includes 53 review groups based at research institutions 
worldwide. The group conducts systematic reviews of health-
care interventions and diagnostic tests and publishes them in 
the Cochrane Library https://www.cochranelibrary.com  
Covidence Software for the management of systematic reviews from 
import of citations, through initial and full text screening, data 
extraction and risk of bias to the export of a file compatible 
with most statistics packages  www.covidence.org 
CRD Centre for Reviews and Dissemination (Originally called NHS 
CRD, then CRD as scope of work expanded; NIHR CRD when 
core funded by NIHR; now known as CRD) 
CRD 
databases 
Database of Abstracts of Reviews of Effects (DARE)  
NHS Economic Evaluation Database (NHS EED) 




The EQUATOR (Enhancing the QUAlity and Transparency Of 
health Research) Network is an international initiative that 
seeks to improve the reliability and value of published health 
research literature by promoting transparent and accurate 
reporting and wider use of robust reporting guidelines 
https://www.equator-network.org  
FigShare Open content platform for sharing research datasets 




An international research organisation that develops and 
delivers evidence-based information, software, education and 
training designed to improve healthcare practice and health 
outcomes https://joannabriggs.org  
NIHR National Institute for Health Research 
OSF Open Science Framework: platform for sharing research 
datasets 
OwnCloud Client–server software for creating and using file hosting 
services 
50 
PLoS Public Library of Science 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analysis  
PRISMA-P Preferred Reporting Items for Systematic Reviews and Meta-
Analysis - Protocols 
PROSPERO An international prospective register of systematic reviews 
(PROSPERO is not an acronym) 
RCTs Randomised Controlled Trials 
RevMan Review Manager: the software developed by Cochrane to 
support preparing and maintaining systematic reviews. 
RR Risk Ratio 
SPIRIT Standard Protocol Items: Recommendations for Interventional 
Trials 
UK United Kingdom 
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The nuts and bolts of PROSPERO: an international
prospective register of systematic reviews
Alison Booth1*, Mike Clarke2, Gordon Dooley3, Davina Ghersi4, David Moher5,6, Mark Petticrew7 and
Lesley Stewart1
Abstract
Background: Following publication of the PRISMA statement, the UK Centre for Reviews and Dissemination (CRD)
at the University of York in England began to develop an international prospective register of systematic reviews
with health-related outcomes. The objectives were to reduce unplanned duplication of reviews and provide
transparency in the review process, with the aim of minimizing reporting bias.
Methods: An international advisory group was formed and a consultation undertaken to establish the key items
necessary for inclusion in the register and to gather views on various aspects of functionality. This article describes
the development of the register, now called PROSPERO, and the process of registration.
Results: PROSPERO offers free registration and free public access to a unique prospective register of systematic
reviews across all areas of health from all around the world. The dedicated web-based interface is electronically
searchable and available to all prospective registrants. At the moment, inclusion in PROSPERO is restricted to
systematic reviews of the effects of interventions and strategies to prevent, diagnose, treat, and monitor health
conditions, for which there is a health-related outcome.
Ideally, registration should take place before the researchers have started formal screening against inclusion criteria
but reviews are eligible as long as they have not progressed beyond the point of completing data extraction.
The required dataset captures the key attributes of review design as well as the administrative details necessary for
registration.
Submitted registration forms are checked against the scope for inclusion in PROSPERO and for clarity of content
before being made publicly available on the register, rejected, or returned to the applicant for clarification.
The public records include an audit trail of major changes to planned methods, details of when the review has
been completed, and links to resulting publications when provided by the authors.
Conclusions: There has been international support and an enthusiastic response to the principle of prospective
registration of protocols for systematic reviews and to the development of PROSPERO.
In October 2011, PROSPERO contained 200 records of systematic reviews being undertaken in 26 countries around
the world on a diverse range of interventions.
Keywords: Systematic review protocol, register, PROSPERO
Background
Following the 2010 publication of the PRISMA state-
ment advocating registration of systematic review proto-
cols [1,2] and in response to user demand and increased
recognition of the importance of accurate prospective
registers of research [3], the Centre for Reviews and Dis-
semination (CRD) at the University of York in England
began to develop PROSPERO, an international prospec-
tive register of systematic reviews. The objectives were
to reduce unplanned duplication of systematic reviews
and to provide transparency in the review process with
the aim of minimizing reporting bias [4]. The develop-
ment process recognized both the academic need for a
register and the practical requirements of creating and
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maintaining one, and was able to take advantage of
CRD’s existing database infrastructure and information
technology (IT) platform supporting the Database of
Abstracts of Reviews of Effects (DARE), the NHS Eco-
nomic Evaluations Database (NHS EED) and the Health
Technology Assessment (HTA) database [5].
Methods
A small international advisory group was formed to help
guide the development of the register. The members of
the group brought systematic review expertise, including
Cochrane, Campbell, and the Evidence-based Practice
Centre (EPC) program review methods, experience of
clinical trials registers, and authorship of the PRISMA
statement [1,2].
The advisory group sought the opinions of a wide
range of people for whom the register would be rele-
vant, including clinical and academic researchers, com-
missioners, and journal editors, through an international
consultation process. A two-round electronic modified
Delphi survey was used to identify the minimum dataset
(Required fields) for PROSPERO and to identify what
would represent useful but not essential data (Optional
fields) [6]. Participants in the survey were also asked
their views on aspects of the functionality of the register.
The feedback from the Delphi process and pilot testing
were used to develop PROSPERO. This article describes
the process of registration that is now in place.
Results and discussion
Design of the register
The web-based register offers open public access; regis-
tering a review and searching the register is free of
charge. (Figure 1) The register is electronically search-
able; open to all prospective registrants; requires the
submission of a minimum data set; and has a validation
mechanism to ensure that entries fall within scope and
are complete. A unique identification number is issued
for each review protocol accepted for registration which
becomes part of the review identity and facilitates link-
age between the registration record and subsequent
publications. PROSPERO records are permanent and an
audit trail of any changes to the record is maintained.
This allows readers to see how the review has developed
or changed over time.
Feedback from many of the 266 participants who
completed one or both of the Delphi surveys confirmed
the need to balance collection of sufficient information
to achieve the objectives of the register, with making
sure the registration process was not overly burden-
some. The process of registering a review has been
made as straightforward, intuitive and user friendly as
possible, for example through the use of drop down
menus for several items.
A nominated ‘Named contact ’ is responsible for
ensuring that the information submitted is accurate
and kept up to date, including provision of a link to
the report of the review when it is completed. Because
detailed information about the planned methods is
needed, the Named contact should be the principal
investigator or lead researcher, but is not necessarily
the ‘author’ since the protocol may not (and the full
review will not) have been published at the time of
registration. This requirement for a single contact per-
son should encourage review teams to nominate one
person to this role and so help avoid a review being
registered more than once.
Scope for inclusion
The long term aim is to have broad inclusion criteria for
PROSPERO, such that any systematic review that has a
health related outcome will be eligible. However, to
reach this aim without making the process too complex
or time consuming, a stepped approach is being taken.
The initial focus for inclusion is on systematic reviews
of the effects of interventions and strategies to prevent,
diagnose, treat, and monitor health conditions, for
which there is a health related outcome. This includes
systematic reviews undertaken before and after clinical
trials to help design the trial or to place the results in
context [7]. The inclusion of other reviews will be
phased in over time.
Systematic reviews that are regarded as ‘rapid reviews’
will be accepted if they meet the inclusion criteria and
researchers can complete the application within the
time frame of the review and in accordance with the
requirements of PROSPERO.
Scoping reviews and reviews of reviews are not being
included at this time, but this decision will be re-consid-
ered in the future. The decision to exclude these types
of knowledge syntheses was based on practical consid-
erations: it is not clear if the initial registration template
will be suitable for much broader types of knowledge
syntheses where the methods vary and may not be as
well defined as those that use well-accepted systematic
review methodology.
Reviews of methodological issues will not be included
in PROSPERO as the findings are likely to relate to
recommendations about changes in methods rather than
direct effects on health outcomes [8]. Methods reviews
often cross boundaries between health and other areas,
and like other types of knowledge syntheses, are also
likely to require a different data entry structure. A cen-
tralized database of such reviews would be useful, but is
outside the current aims and remit of PROSPERO. Like-
wise, systematic reviews of animal studies are excluded
as they involve studies with different methodologies and
objectives.
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The inclusion of protocols for Cochrane Reviews is
desirable to ensure a comprehensive overview of
ongoing systematic reviews. To minimize additional
work for authors of Cochrane Reviews, an electronic
mechanism for their automatic upload from The
Cochrane Library is being developed. Contact authors
will simply be asked to verify that the information has
been transferred accurately to the PROSPERO data-
base. To avoid future duplication, Cochrane Reviews
are therefore not registered independently on
PROSPERO.
Timing of registration
As registration requires the completion of a minimum
dataset, it can only take place after key issues have been
considered, preferably as part of the development of the
review protocol. For PROSPERO to achieve its aim of
providing transparency and helping identify potential
bias, registration should ideally take place before formal
screening against inclusion criteria has begun, this being
an early point at which bias could be introduced. How-
ever, the systematic review process is iterative by nature
and some experimentation with searching is likely to be
essential in developing the review. It also has to be
recognized that researchers are often aware of some of
the potentially eligible studies, and have an opinion on
whether they are likely to include or exclude these,
some time before they start formal screening.
Registering a review too soon might lead to multiple
amendments to records as the protocol and the plans
for the review are finalized; registration late in the pro-
cess may mean that the aim of publishing methods
before any results are known is not achieved. A practi-
cal approach to the timing of registration has been
taken, initially. Registrants are asked to indicate the
stage of progress of the review at the time of registra-
tion, and at any subsequent revisions, by selecting the
relevant stage from a list, with the option of adding
further information in a free text field. All records and
revisions are automatically dated when published in
the register.
In recognition that authors of reviews that are already
underway during PROSPERO’s first year might wish to
register them, systematic reviews that have not pro-
gressed beyond the point of completing data extraction
are being considered for inclusion. The issue of timing
of registration will be reviewed as part of a planned eva-
luation of the register in 2012.
Figure 1 PROSPERO website homepage.
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Registering a review
Registrants need to ‘Join’ PROSPERO to obtain a user-
name and password, which are then used to sign in
and activate the ‘Register a review’ option. Selecting
this option opens a page detailing a summary of the
inclusion criteria, to help users to avoid wasting time
on inappropriate submissions. Once registrants are
satisfied that their review fulfills the inclusion criteria,
a single click opens a new electronic registration form.
(Figure 2)
There are four sections to the form: title and time-
scale; review team details; methods; and general infor-
mation. All the ‘Required’ fields in each section are
indicated by an asterisk (*) in the on-line form and
below, and these must be completed before the regis-
tration can be submitted. A registration application
can be saved and returned to at any time, to add or
edit information before submission. Information can
be entered by typing directly into the form or by past-
ing from another document. Once all the required
information has been provided, the ‘Submit’ option is
activated.
The PROSPERO registration form
1. Review title and timescale
The first section in a PROSPERO entry asks for the title
of the review in English* and the original language if
this is not English. Registrants are asked to give the
anticipated or actual start date* and the anticipated
completion date for the review*. Unless ‘fixed’ by a fun-
der, these dates can be difficult to estimate. However,
they are operationally necessary for scheduling auto-
matic updates and reminders, as well as for the integrity
of the record. The dates can be revised at any time by
submission of an amendment. The Delphi consultation
revealed some differences of opinion about when a
review ‘starts’. For PROSPERO purposes this is consid-
ered to be when screening studies for inclusion begins,
although it is recognized that a large amount of essential
work takes place before this.
2. Review team details
This section includes address, phone, and email* contact
details for the Named contact*. These fields are automa-
tically completed from the ‘Join’ information, but can be
edited. For example, information in optional fields can
Figure 2 PROSPERO registration form.
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be deleted so that it does not appear in the public
record.
The organizational affiliation of the review*, funding
sources/sponsors* and conflicts of interest* were cate-
gorized as essential details by respondents to the consul-
tation. The names of review team members and their
organizational affiliations and information about colla-
borators were considered by respondents to the Delphi
survey to be useful indicators of the range of skills and
experience of those undertaking the review, but not
essential to the register.
3. Review methods
There are 15 fields to capture the review methods, 12 of
which are ‘Required’*:
Review methods fields • Review question(s)*
• Searches*
• URL to search strategy








• Data extraction, (selection and coding)
• Risk of bias (quality) assessment*
• Strategy for data synthesis*
• Analysis of subgroups or subsets*
The structure aims to facilitate data entry for regis-
trants while also providing users of the database with
consistent, clear access to the planned methods for a
review. Registrants are asked to provide sufficient detail
to allow comparison of planned methods with the sub-
sequent published review. The information to be pro-
vided will vary according to the type of review and the
topic, and not all fields will be relevant to all reviews
(with ‘not relevant’ being an acceptable response, where
appropriate). Within the registration form, brief instruc-
tions are given for what is required for each field and
users can access expanded guidance with examples
either within the information tabs for each field or from
the ‘About’ pages on the PROSPERO site.
The review methods fields were agreed through the
Delphi consultation and are based on the protocol
requirements for a variety of reviews of the effects of
interventions, ranging from a straightforward compari-
son (for example, a drug versus a placebo) to the assess-
ment of complex interventions (for example, smoking
cessation), hence the inclusion of a field such as Con-
text. To achieve the long term aim of a broad scope for
PROSPERO, it is anticipated that other templates may
need to be developed in consultation with experts in
particular fields (such as for reviews of qualitative
research).
4. Review general information
Additional general information about the type of review,
language, countries involved, other registration details,
dissemination plans, keywords and existing reviews on
the same topic by the same authors were identified as
useful but not essential during the consultation.
Respondents to the consultation suggested that other
registration details be recorded, but that these should
not be mandatory. This would allow appropriate cross-
linkage, and help avoid registration duplication. This
information has been incorporated into the registration
form as one of the 18 optional fields.
Respondents also agreed that where a protocol had
been published for a review and was publicly accessible,
the citation and URL should be included in the PROS-
PERO record. The challenges and opportunities for pub-
lishing protocols vary across different areas of health
and social care, with limited scope up to now to publish
review protocols outside The Cochrane Library. How-
ever, the launch of the journal Systematic Reviews
should improve this situation.
While publication of review protocols is recommended
and encouraged, submission of a review to PROSPERO
is not dependent on it. ‘Publication’ is considered in a
wider sense than inclusion in a peer reviewed journal.
For example, protocols made available on organizational
websites are acceptable and can be linked to from
PROSPERO. Alternatively, registrants can submit a pdf
of their protocol, which will be hosted on a CRD web
server and linked to from within the register record. In
either case, the named contact is responsible for the
integrity and maintenance of the protocol. If a protocol
is not available in a published record, users of PROS-
PERO are advised to get in touch with the named con-
tact for any further information they wish to obtain
about the review.
The Current review status* field is an administrative
requirement to indicate the progress of the review
through the process from design to full review.
Registrants can add any further information they think
relevant to their registration in a free text field. The last
field is for recording details of the final report or publi-
cation when the review has been completed.
Administration of submissions
On submission, registrants receive an automated email
confirming receipt and outlining the administration pro-
cess. Submitted application forms are checked for elig-
ibility for PROSPERO, which includes consideration of
the current stage of review. Forms are also examined for
clarity of content, for example whether: the information
provided makes literal sense; the information has been
Booth et al. Systematic Reviews 2012, 1:2
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entered in the correct field; the information given is not
contradictory; or only partial information is provided in
a required field. Submissions are approved and pub-
lished on the register, returned to the applicant for clari-
fication, or rejected. The checks made do not constitute
peer review or imply approval of the methods proposed
for the review being registered.
Applications are reviewed within five working days of
submission and details of the final decision are sent to
the named contact in a confirmation email. In the case
of accepted records, a unique ID number is given in the
email. All records published in PROSPERO remain per-
manently available through the register.
Recording protocol amendments
Protocol development is an iterative process and legiti-
mate changes and amendments to the registration
record may be necessary. It is particularly important for
transparency to document and justify major changes to
methods, particularly those which could be seen as
potentially introducing biases through increased knowl-
edge of potentially eligible studies, resulting, for exam-
ple, in the narrowing of objectives or the addition of
new outcome measures.
Registrants can access and update their records at any
time via a ‘My PROSPERO records’ page, except during
the PROSPERO administration phase, when access to
the record is locked. The named contact is tasked with
recording any major changes or substantial amendments
to the planned methods in the PROSPERO record. This
is done by making the necessary changes in the record,
updating the stage of review and re-submitting it. A
‘Revision note’ facility requires a brief outline of the
changes and the reason for making them to be recorded.
This is made available in the public record, as part of
the audit trail for the PROSPERO entry.
The most recent version of a record appears in the
public interface, with previous versions marked as
‘Archived’ and made accessible through dated links on
the record page.
On completion of a registered review
There was strong support in the Delphi consultation for
PROSPERO to include publication details or details of
where unpublished results could be viewed, once the
review is completed. It was considered that such links
would be hard to maintain, but the consensus was that
this would be necessary to provide a complete thread
for a systematic review. However, there was also con-
cern that the register should not become a new database
of completed reviews. The addition of details of the
completed review is an option available to registrants.
There are currently no plans for the PROSPERO
administration team to be responsible for identifying
publications or adding links within PROSPERO records.
Email reminders are sent to the named contact on the
completion date entered in the PROSPERO record, ask-
ing for an anticipated publication date (or revision to
the completion date). The named contact is prompted
to add a statement if the review will not be published,
including brief details of the reason. This can be entered
in the final report/publication field.
If a registered review is not to be completed, the
option of ‘Abandoned’ can be selected and brief details
of the reason why recorded in a free text field, for dis-
play in the public record.
If a registered review is completed and a critical
abstract for its publication is included in the Database
of Abstracts of Reviews of Effects (DARE), a link to the
DARE abstract will be added to the PROSPERO record.
As part of the consultation, participants were asked
about the inclusion of summary results in the PROS-
PERO record, given that a sizeable proportion of
initiated systematic reviews are never published [9].
Some major concerns were expressed. These included
that publishing results on the register could jeopardize
subsequent peer review publication; and that, as publica-
tion can take a long time, it may be seen as an alterna-
tive and delay or prevent more formal publication by
some review teams (for example, where their funding
has ended). It was also thought that if researchers had
not published the review, it was likely they would have
lost interest and would not provide this information
anyway. Of more concern was the inability to check the
validity of the data posted, and the potential lack of con-
text for it, which might be misleading if users of PROS-
PERO read the record and not the full publication of
the review. In light of these concerns, it was decided
that summary results would not be included in PROS-
PERO records, at this time.
Updating an existing review
The intention of including protocol details for updates
to existing reviews prompted a discussion on how to
deal with these updates, and how to decide if the modi-
fications to an existing protocol constitute a new review
rather than an update. The advisory group agreed on
the following definitions, which are included in PROS-
PERO’s guidance notes:
What is an update of a review?
Updating a systematic review is a discrete event during
which efforts are made to identify and incorporate new
evidence into a previously completed systematic review
[10].
An ‘update’ may be any modified version of a review
that includes the findings of a more recent search than
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the previously completed version of the review. It can
still be considered an update even if the new search
reveals no additional studies. Any newly identified stu-
dies should be assessed and, if appropriate, incorporated
into the updated review. An update might also be an
opportunity to conduct new analyses or add additional
information to the review.
What constitutes a new review rather than an update?
It can be difficult to decide whether an update to a
review is in fact a new review. There is little published
guidance on this. PROSPERO adopts a pragmatic
approach. If changes to the review questions or methods
are so substantial that they require major changes to the
original protocol, this should be regarded as a new
review rather than an update.
Examples that would constitute a new review:
• addition of new treatment comparisons, for exam-
ple, direct comparison of different drugs, when the
old review included only comparisons of drug with
placebo
• substantial changes to the population being stu-
died, for example, adding adults to a review that was
previously restricted to children
• exclusion criteria in the old review become inclu-
sion criteria in the new review
• introduction of new analysis techniques, for exam-
ple, a switch from aggregate data meta-analyses to
individual participant meta-analyses.
Updates of registered reviews will retain the original
number and the version history will be available, which
will mean that links to the full audit trail and the exist-
ing review will be readily accessible to users.
Conclusions
Current and future developments
PROSPERO was launched in February 2011 by the UK
Health Minister Lord Howe and at an international
meeting in Vancouver, Canada organized by the Cana-
dian Institute for Health Research (CIHR).
Initial publicity efforts have gone into raising aware-
ness of PROSPERO among those commissioning and
undertaking reviews. There has been an enthusiastic
international response to the development of PROS-
PERO, alongside support for the principle of systematic
review protocol registration from organizations, includ-
ing the International Network of Agencies for Health
Technology Assessment (INAHTA), The Cochrane and
Campbell Collaborations and the Guidelines Interna-
tional Network (G-I-N). A number of commissioning
organizations, such as the UK National Institute for
Health Research (NIHR) and the Canadian Institute of
Health Research (CIHR), are making registration a
requirement for all their grant holders who are under-
taking relevant systematic reviews.
Public Library of Science journals and the Systematic
Reviews journal support the prospective registration of sys-
tematic reviews and their instructions to authors ask that
the registry number be included in the abstract of the
reports of all prospectively registered systematic reviews.
Other journals are being encouraged to follow suit.
In October 2011, eight months after launch, PROS-
PERO contained 200 records of systematic reviews
Figure 3 Countries where registered reviews are being undertaken.
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being undertaken in 26 different countries (Figure 3) on
a diverse range of interventions.
Feedback from users is welcome (to crd-register@york.
ac.uk) as part of an ongoing process of improvement
and refinement. A detailed evaluation of the registration
process is planned for early 2012. The findings of this
will be used to make an initial assessment of PROS-
PERO’s fitness for purpose and guide the next stages in
its ongoing development.
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Abstract
Background: In response to growing recognition of the value of prospective registration of systematic review protocols, we
planned to develop a web-based open access international register. In order for the register to fulfil its aims of reducing
unplanned duplication, reducing publication bias, and providing greater transparency, it was important to ensure the
appropriate data were collected. We therefore undertook a consultation process with experts in the field to identify a
minimum dataset for registration.
Methods and Findings: A two-round electronic modified Delphi survey design was used. The international panel surveyed
included experts from areas relevant to systematic review including commissioners, clinical and academic researchers,
methodologists, statisticians, information specialists, journal editors and users of systematic reviews. Direct invitations to
participate were sent out to 315 people in the first round and 322 in the second round. Responses to an open invitation to
participate were collected separately. There were 194 (143 invited and 51 open) respondents with a 100% completion rate
in the first round and 209 (169 invited and 40 open) respondents with a 91% completion rate in the second round. In the
second round, 113 (54%) of the participants reported having previously taken part in the first round. Participants were asked
to indicate whether a series of potential items should be designated as optional or required registration items, or should not
be included in the register. After the second round, a 70% or greater agreement was reached on the designation of 30 of 36
items.
Conclusions: The results of the Delphi exercise have established a dataset of 22 required items for the prospective
registration of systematic reviews, and 18 optional items. The dataset captures the key attributes of review design as well as
the administrative details necessary for registration.
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Introduction
A protocol should be an integral part of a systematic review, and
is important because it pre-specifies the objectives and methods to
be used. Having a protocol can help restrict the likelihood of
biased post hoc decisions in review methods, such as selective
outcome reporting (because it specifies outcomes of primary
interest, how information about those outcomes will be extracted,
and the methods that might be used to summarize the outcome
data quantitatively). An examination of 47 Cochrane reviews
revealed indirect evidence for possible selective reporting bias for
systematic reviews. Almost all (n = 43) contained a major change,
such as the addition or deletion of outcomes, between the protocol
and the full publication [1]. However, whether (or to what extent)
the changes reflected bias, as opposed to unreported but legitimate
changes in methods as the review methods were developed, was
not clear. For example, the protocol might have aimed to include
specific outcomes, which were then found to be absent from all of
the included studies, leading the reviewers to remove these
outcomes from their final review. Similarly, setting out inclusion
and exclusion criteria prior to author knowledge of the available
studies reduces the potential for selective inclusion based on study
findings. Publication of a protocol additionally promotes trans-
parency of methods and, as it facilitates identification of reviews
that are in process, reduces the potential for unplanned
duplication and allows public review of the planned methods.
Capturing the key elements of a systematic review at the
protocol stage (or at the design stage if there is no formal protocol)
and making these publicly available has similar utility to producing
and publishing systematic review protocols. Additionally, a register
providing a single point of access should be of great benefit in
avoiding unplanned duplication of effort. The issuing of a unique
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identifier linked to a permanent registration record allows
comparison of final reports of reviews with what was planned at
registration.
Support for prospective registration of systematic review
protocols has been gathering momentum, reflected in a number
of recent publications [2,3,4,5]. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that
evaluate healthcare interventions advocates registration and the
PRISMA 2009 Checklist requires protocol registration details, if
available, to include a registration number and details of the
existence of and access to the protocol [2,3].
Until now there has been no widely adopted process to register
systematic reviews formally, outside of specific collections of
reviews, such as those produced by the Cochrane Collaboration.
Recognising the need for registration, the Centre for Reviews and
Dissemination (CRD), in collaboration with an international
Register Advisory Group, took the initiative in establishing
PROSPERO, an international prospective register of systematic
reviews with health outcomes that is freely accessible online (www.
crd.york.ac.uk/PROSPERO).
The aim of PROSPERO is to prospectively register systematic
reviews at the protocol stage; capturing the key attributes of the
protocol or plan; maintaining an audit trail of any subsequent
protocol amendments; and adding details of final publications,
including peer-reviewed articles, and other documents as they
become available. This will provide a permanent public record
and unbiased listing of registered reviews. PROSPERO can
therefore assist in planning new reviews and updating existing ones
by providing stakeholders with information about reviews already
in the pipeline. This should help to reduce unplanned duplication
of effort and to optimise often limited use of research funds.
It will also provide transparency of process, and facilitate
comparison between planned methods and reported results
enabling readers to make judgements about the importance of
any discrepancies [6]. Ultimately this may serve to discourage bias
in the conduct and reporting of reviews.
To achieve these aims, the register needs to capture and make
available relevant information related to potential for bias in a
timely, transparent, and accessible way. At the same time it
should be user friendly and not overly burdensome for those
completing the registration details. It also needs to be able to
accommodate methodological variations between different types
of systematic reviews. The development team recognised that
support for and use of the register would require the involvement
of a range of interested parties including, for example, clinical
and academic researchers, commissioners and journal editors. An
international consultation was therefore undertaken with the
primary objective of establishing the minimum dataset required
for registration of systematic reviews at the protocol stage. A
secondary objective was to raise awareness of the development of
the register.
Methods
The international Register Advisory Group consists of a small
number of key individuals recruited by CRD to assist in taking
forward the development of the register. The advisory group
members collectively have a wide range of systematic review
experience with a variety of methodological interests and
significant statistical expertise. In addition members have a
detailed knowledge of the Cochrane Collaboration approach to
registration of review protocols; experience of clinical trials
registers and authorship of the PRISMA statement. The advisory
group proposed the use of a Delphi exercise to establish the
minimum dataset and subsequently guided each stage of the
process.
Design
A modified Delphi exercise was carried out to obtain opinions
from international experts in the field of systematic review about
which individual constituents of a review protocol should be
included in a registration record. The Delphi technique is a
method of collecting in a structured and iterative way, the
anonymous, individual opinions of a panel with relevant expertise
in the topic where a consensus is required. The basic principle is
for the panel to receive successive questionnaires, each one
containing the anonymous responses to the previous round, and
for them to modify their responses until a consensus is reached
[7,8,9]. We modified the basic Delphi technique for practical
reasons.
The survey population of interest had a high level of Internet
and email access, were likely to be familiar with the use of
electronic online submission processes and to use email as the
principal mode of communication. We aimed to include wide
international participation, minimise cost, and ensure accurate
and efficient collection and analysis of responses. The question-
naires were therefore administered electronically using on-line
survey software Survey Monkey (www.surveymonkey.com).
Participants
The opinions of international experts in health and social care
involved in undertaking, commissioning, or developing methods
for systematic reviews, or in guideline development, were sought,
as were those of healthcare journal editors.
Two lists of participants were prepared; a core panel of
individuals, and an ‘open list’ of organisations, groups, and
electronic mailing lists. The initial circulation list for the core panel
contained 350 names. These individuals were nominated by
members of the register Advisory Group or identified through
existing networks (e.g., the PRISMA Group, the International
Network of Agencies for Health Technology Assessment; and
International Committee of Medical Journal Editors). Email
addresses were collected from personal contact lists and publicly
available sources (e.g., organisational websites). All emails were
personalised to individuals.
The open list included groups such as Guidelines International
Network and the Health Technology Assessment International
Information Resources Group, for onward dissemination to their
members and electronic mailing lists (e.g., Cochrane Methods
Groups and the Coordinating Editors of Cochrane Review
Groups; LIS-MEDICAL and EVIDENCE-BASED-HEALTH,
and World Association of Medical Editors). The open invitation
was also posted on websites (e.g., CRD, National Institute for
Health Research (NIHR), Cochrane Collaboration, Committee on
Publication Ethics) and placed in newsletters (e.g., CRD,
Cochrane Collaboration, NIHR). Details of the exercise were
published in a Lancet comment paper, which directed readers to
the CRD website for further information. This appeared in the e-
version of the Lancet during the survey [10] and in the print
version at a later date [11].
Separate response collectors were used within Survey Monkey
for the two different types of invitation. Anyone responding on a
link cascaded by a core panellist would have been included in the
core panel collector.
The second round was sent to everyone in the core panel again,
including non-responders unless they had requested removal from
the list. In addition those from the open list who completed the
first round and supplied their email addresses were added to the
Consultation on Dataset for Protocol Registration
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revised core panel list. Again, separate collectors were used for the
core panel and open lists. The second (final) round of the survey
required participants to indicate whether they had taken part in
the first round. It was accompanied by a summary report on the
responses to the first round (available from http://www.york.ac.
uk/inst/crd/projects/register.htm).
All responses were anonymous; it was not possible to tell who
responded or to link names to responses even when individuals
informed us they had responded. It was hoped that this would
encourage participation in both rounds and expression of personal
opinion, rather than conforming to group opinion or dropping out
after the first round [9].
In order to assess representation of different stakeholder groups
and identify any differences in the responses between them, simple
demographic details were requested in each questionnaire. These
were designation; membership of organisations; health area of
interest; review method of interest; number of systematic reviews
authored; number of systematic reviews in which involved other
than as author; proportion of work that relates to methodology;
country; and English as a first language.
Instrumentation
The exercise was limited to two rounds, although provision had
been made for subsequent rounds if these were judged necessary
by the register Advisory Group. The questionnaires were piloted
before distribution.
The time in which the questionnaires were ‘open’ for responses
was limited to two weeks for each round. Reminder emails were
sent to all members of the core panel approximately one week
before the close of each round.
A mixture of ‘pick lists’, pre-specified response options, and free
text responses were used to facilitate ease of response and analysis
of data from a wide consultation, with large numbers from diverse
groups, many of whom may not have English as their first
language. In order to ensure that sufficient data were collected and
that key areas addressed fully, ‘pick list’ questions were made
mandatory. That is respondents had to make a choice before they
could submit their answers. It was not mandatory to put anything
into the free text boxes.
The questionnaires were prepared by CRD with advice from
the register Advisory Group. None of those involved in designing,
administering or advising on the questionnaires completed the
survey.
The focus for the questions, the language, and explanations
used were informed by lessons learned from the development of
trials registers, and in particular the requirements for registers as
set out by the WHO trials register platform (http://www.who.int/
ictrp/en/) [12].
Question formulation
A pragmatic decision was taken not to approach panellists in
advance to ask for their participation. This was to minimise the
burden on named individuals who were likely to have limited time
to devote to the process. For the same reason, we drew up a list of
candidate items for inclusion in the minimum data set based on
established guidance for writing systematic review protocols
[13,14,15,16], the PRISMA statement [3] and information from
the WHO trials registry (http://www.who.int/ictrp/en/).
The first round questionnaire sought preferences for 41
candidate items as to whether they should be included in the
minimum data set. Respondents were asked to indicate whether
they thought each item was ‘Essential’, ‘Desirable’ or ‘Not
necessary’. The focus for responses was on the inclusion of data
that would help identify ongoing reviews and enable assessment of
bias when the review was completed. Opinions on the scope of the
register, allocation of unique ID; timing of registration, dealing
with amendments to protocols, publications, and updating of
reviews, and existence of other protocol registers were also sought.
However, these items relating to the development and implemen-
tation of a register are not presented in detail here, but are
included in the summary reports, available at http://www.york.ac.
uk/inst/crd/projects/register.htm.
The second round questionnaire set out suggestions for which
items should be mandatory and which should be optional, based
on the register Advisory Group’s interpretation of the first round
responses. Participants were asked to ‘Agree’, or ‘Disagree’ with
the suggested categorisation, to state that an item was ‘Not needed’
or state that they had ‘No opinion’. If they disagreed with a
categorisation, they were asked to indicate the direction of the
disagreement, e.g., that an item suggested as compulsory should be
down-weighted to optional. Again the focus for responses was to
identify the minimum dataset to achieve the aims of registration.
As with the first round questionnaire, free text boxes for comments
and suggestions were provided but not mandatory.
The majority vote for ‘Essential’ or ‘Desirable’ in the first round
was used to categorise fields as ‘Required’ or ‘Optional’,
respectively for the second round questionnaire.
Analysis
All responses were collated in ‘Survey Monkey’ for tabulation
and analysis. A summary report on each round was compiled and
circulated to both distribution lists (available from http://www.
york.ac.uk/inst/crd/projects/register.htm).
Where possible, decisions were based on achieving consensus at
a designated level of 70% agreement. This level of consensus was
agreed by the Advisory Group as being greater than two-thirds of
opinion, indicating a clear majority. Other decisions were made
taking into consideration the distribution of alternative responses.
Ethical approval
Formal written consent was not sought; submission of
completed questionnaires was taken as implied consent. The
research was approved by the University of York Humanities and
Social Sciences Ethics Committee (HSSEC 12-2009/10).
Results
Responses and respondents
The first round core panel list included 327 direct invitations, 12
were excluded as their emails were returned as undelivered,
making the initial list 315. Five people declined to take part and
were removed from the mailing list.
The second round core panel list included 322 direct invitations,
four were excluded (three emails were returned as undelivered and
one was known to be unavailable while the survey was open),
making the list 318. One declined to take part and was removed
from the mailing list.
A separate collector was set up for the open list invitation to
participate. Both the first and second round questionnaires were
sent to a general contact at 15 different organisations, and to a
named contact for internal circulation in five other organisations
or groups.
There were 194 (143 invited and 51 open) respondents with a
100% completion rate in the first round and 209 (169 invited and
40 open) respondents with a 91% completion rate in the second
round. Of those who took part in the second round, 113 (54%)
said they had taken part in the first round; 72 (34%) said they had
not; and 24 (12%) could not remember (Table 1). A comparison of
Consultation on Dataset for Protocol Registration
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responses to the second round questionnaire showed no significant
differences between those taking part in both rounds and those
only taking part in the second round.
There were no significant differences between role designations
(Table S1); areas of health interest (Table S2); review methods of
interest (Table S3); authorship of (Table S4), or involvement in
systematic reviews (Table S5); or proportion of work related to
research methodology (Table S6); between the first and second
round respondents.
There was little difference between the responses of those who
were members of The Cochrane Collaboration and those who
were not. There were three items in round one and two items in
round two where the differences were of statistical significance.
After Bonferroni adjustment for multiple comparisons, these were
no longer statistically significant (Table S7).
In the first round, 128 (66%) respondents said English was their
first language. In the second round, English was the first language
for 124 (65%) of respondents. Respondents to both the first and
second rounds were based in 34 countries, with an additional six
countries represented in the first round only, and a different five
countries represented in the second round only (Figure S1).
In the second round we specifically asked participants whether
they supported the principle of registration of ongoing systematic
reviews; 199 (95.2%) of participants said they did; three (1.4%) did
not and seven (3.3%) had no opinion.
Minimum dataset
Following review of the first round responses, it was decided that
the Anticipated publication date field would not be included in the
second round. This was because of the large number of comments
requesting that the list of items be kept as small as possible, and
158 (82%) respondents felt this field should be optional or was not
necessary. The field would be difficult for researchers to estimate
at the protocol stage and its inclusion in the register was not
integral to achieving the stated aims.
Likewise, 121 (63%) respondents felt it was ‘‘Desirable’’ or ‘‘Not
necessary’’ to include the Economic Evaluations field. As this
information could and should be included in the Review Question
field and elsewhere, it was not included in the second round
questionnaire.
Taking into account first round feedback on the need to keep
the dataset to the minimum and focus on information that would
contribute to reducing bias, it was proposed that although the
majority of respondents felt that the Context and Data extraction
fields should be required fields, they should be included as optional
fields. None of the fields in the first round had a majority in favour
of ‘Not needed’.
In the first round of questions, primary and secondary outcomes
were presented as separate items from effect measures in order to
find out if participants felt both were needed. As only 9% and 12%
of the respondents, (respectively for primary and secondary
outcomes), felt that effect measures were not necessary, these
fields were combined for the second round (Table 2). Time points
were added as a requirement in response to suggestions from
participants.
Informed by the responses to the Delphi exercise, the register
Advisory Group confirmed that all items with 70% or greater
agreement would be included as Required or Optional fields as
responses indicated.
In round one, there was $70% agreement on 14 of 40 items;
60–69% agreement on 7 items; 50–59% agreement on 8 items;
40–49% agreement on 10 items and 30–39% on one item.
After the second round, a 70% or greater agreement was
reached on whether 30 of 36 items should be required or optional.
There was 60–69% agreement on two and 50–59% agreement on
the remaining four items (Table 2).
The final PROSPERO dataset agreed by the register Advisory
Group consists of 40 items, 22 of which are required, and the
remainder are optional. Of the required fields, 12 are for details of
review methods, 10 are related to the review title, timescale and
review team (Table 3). In addition, the unique identification
number was designated as part of the dataset by the Advisory
Group as PROSPERO creates a unique number for each
accepted registration record.
Discussion
Although the drivers for trials registration differ in some respects
(e.g., legal ethical requirement [17]), systematic review protocol
registration faces the same potential barriers as trials registration.
In order to avoid the problems arising from the existence of
multiple trials registers [18,19] by providing a free, single,
comprehensive, open access register, a balance between level of
detail required and utility was sought. The proposed level of
information to be entered for each field was included in the survey
as the quality of data recorded in trials registers has been found to
vary considerably [20,21].
The aims of registering a systematic review include the
provision of sufficient information to (i) determine whether
reviews already in the pipeline might negate the need to initiate
a new review, (ii) enhance the transparency and completeness of
the plans for the systematic review, and (iii) make informed
judgements about potential risk of bias. The objective of this
Delphi process was to establish the minimum data set that will
achieve these three aims. The Delphi process did not seek to
capture the attributes of the wider information that should be
included in a full protocol for a systematic review, or to
determine all the variables that people might wish to record in
registers of systematic reviews that would be used for other
purposes.
The Delphi technique was chosen for its flexibility and
adaptability in gathering and analysing the necessary data, and
in particular for the utility of the process in garnering views and
opinions from a broad spectrum of people [8]. The commission-
ing, undertaking, publishing and use of systematic reviews involves
diverse disciplines, each with their own particular perspective, with
both inter- and intra-disciplinary differences of opinion. For the









First round 315 194 143 51 194 (100)
Second round 318 209 169 40 190 (91)
doi:10.1371/journal.pone.0027319.t001
Consultation on Dataset for Protocol Registration
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27319
Table 2. Registration dataset response rates for Delphi round one and two.














1 Review title 174 (90%) 17 (9%) 3 (2%) 189 (98%)* 4 (2%) 0 (0%) 0 (0%)
2 Named contact 186 (96%) 5 (3%) 3 (2%) 187 (97%)* 5 (3%) 0 (0%) 1 (1%)
3 Organisational affiliation of the review 136 (70%) 51 (26%) 7 (4%) 162 (84%)* 23 (12%) 1 (1%) 7 (4%)
4 Named contact address 74 (38%) 91 (47%) 29 (15%) 148 (77%) 30 (16%)* 9 (5%) 6 (3%)
5 Named contact phone number Item not included in first round 151 (78%) 13 (7%)* 21 (11%) 8 (4%)
6 Named contact email 166 (86%) 26 (13%) 2 (1%) 180 (93%)* 11 (6%) 0 (0%) 2 (1%)
7 Review team 76 (39%) 82 (42%) 36 (19%) 129 (67%) 49 (25%)* 10 (5%) 5 (3%)
8 Review team members’
rsorganisational affiliations
48 (25%) 104 (54%) 42 (22%) 146 (76%) 27(14%)* 12 (6%) 8 (4%)
9 Collaborators 35 (18%) 106 (55%) 53 (27%) 147 (76%) 18 (9%)* 19 (10%) 9 (5%)
10 Anticipated or actual start date 125 (64%) 57 (29%) 12 (6%) 170 (89%)* 18 (9%) 1 (1%) 3 (2%)
11 Anticipated completion date 91 (47%) 88 (45%) 15 (8%) 152 (79%)* 33 (17%) 3 (2%) 4 (2%)
12 Anticipated publication date 36 (19%) 109 (56%) 49 (25%) Item not included in second round
13 Funding sources/sponsors 155 (80%) 31 (16%) 8 (4%) 179 (93%)* 12 (6%) 1 (1%) 0 (0%)
14 Conflicts of interest 152 (78%) 31 (16%) 11 (6%) 173 (90%)* 14 (7%) 3 (2%) 2 (1%)
15 Other registration details Item not included in first round 134 (70%) 50 (26%)* 8 (4%) 0 (0%)
16 Organisation reference number 55 (28%) 88 (45%) 51 (26%) 139 (72%) 17 (9%)* 18 (9%) 18 (9%)
17 Language 110 (57%) 65 (34%) 19 (10%) 103 (54%) 72 (38%)* 10 (5%) 7 (4%)
18 Country 67 (35%) 83 (43%) 44 (23%) 136 (71%) 33 (17%)* 17 (9%) 6 (3%)
19 Key words 133 (69%) 47 (24%) 14 (7%) 114 (59%) 69 (36%)* 6 (3%) 3 (2%)
20 Any other information 30 (16%) 101 (52%) 63 (33%) 170 (89%) 6 (3%)* 8 (4%) 8 (4%)
21 Review question(s) 186 (96%) 6 (3%) 2 (1%) 186 (97%)* 4 (2%) 1 (1%) 0 (0%)
22 Economic Evaluations 73 (38%) 85 (44%) 36 (19%) Item not included in second round
23 Searches 131 (68%) 42 (22%) 21 (11%) 155 (81%)* 32 (17%) 3 (2%) 1 (1%)
24 URL to search strategy 51 (26%) 93 (48%) 50 (26%) 143 (75%) 28 (15%)* 14 (7%) 6 (3%)
25 Types of study to be included 167 (86%) 23 (12%) 4 (2%) 167 (87%) 21 (11%) 3 (2%) 0 (0%)
26 Condition or domain being studied 150 (77%) 35 (18%) 9 (5%) 177 (93%) 11 (6%) 3 (2%) 0 (0%)
27 Participants/population 176 (91%) 14 (7%) 4 (2%) 178 (93%) 12 (6%) 1 (1%) 0 (0%)
28 Intervention(s), exposure(s) 176 (91%) 15 (8%) 3 (2%) 184 (96%) 6 (3%) 1 (1%) 0 (0%)
29 Comparator(s)/control 168 (87%) 24 (12%) 2 (1%) 180 (94%) 9 (5%) 1 (1%) 1 (1%)
30 Contexta 99 (51%) 77 (40%) 18 (9%) 106 (56%) 77 (40%) 3 (2%) 5 (3%)
31 Primary outcome(s) 180 (93%) 13 (7%) 1 (1%) 177 (93%) 11 (6%) 3 (2%) 0 (0%)
32 Effect measures for primary outcome(s) 126 (65%) 51 (26%) 17 (9%) (Merged with item 31)
33 Secondary outcome(s) 130 (67%) 55 (28%) 9 (5%) 146 (76%) 38 (20%) 5 (3%) 2 (1%)
34 Effect measures for secondary outcome(s) 82 (42%) 88 (45%) 24 (12%) (Merged with item 33)
35 Data extraction, (selection and coding)a 100 (52%) 58 (30%) 36 (19%) 102(53%) 76 (40%) 11 (6%) 2 (1%)
36 Risk of bias (quality) assessment 118 (61%) 54 (28%) 22 (11%) 142 (74%) 35 (18%) 11 (6%) 3 (2%)
37 Strategy for data synthesis 131 (68%) 46 (24%) 17 (9%) 136 (71%) 41(22%) 10 (5%) 4 (2%)
38 Methods for exploring heterogeneity 1b 93 (48%) 67 (35%) 34 (18%) (Merged with 35 and 36 into item 37)
39 Methods for exploring heterogeneity 2c 78 (40%) 76 (40%) 40 (20%) (Merged with 34 and 36 into item 37)
40 Definition and rationale for use
of specific techniques
73 (38%) 71 (37%) 50 (26%) (Merged with 34 and 35 into item 37)
41 Analysis of subgroups or subsets (Presented in items 34, 35, 36 in first round)134 (70%) 42 (22%) 10 (5%) 5 (3%)
42 Dissemination plans 35 (18%) 98 (51%) 61 (31%) 151 (79%) 10 (5%) 24 (13%) 6 (3%)
43 Details of any existing review of the
same topic by the same authors
139 (72%) 39 (20%) 16 (8%) 124 (65%) 54 (28%) 8 (4%) 5 (3%)
aThe majority of respondents in round one selected this as ‘essential’.
bHow heterogeneity will be explored. Under what circumstances will a meta-analysis be considered appropriate.
cCovariates to be explored with method of analysis.
doi:10.1371/journal.pone.0027319.t002
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Table 3. PROSPERO dataset.
Review title and timescale
1 Review title* The working title of the review.
2 Original language title The working title in the language of the review where this is not English.
3 Anticipated or actual start date* The date when the systematic review commenced, or is expected to commence.
4 Anticipated completion date* The date by which the review is expected to be completed.
5 Stage of review at time of registration* The stage of progress of the review at the time of initial registration.
Review team details
6 Named contact* The named contact acts as the guarantor for the accuracy of the information presented
in the Register record.
7 Named contact email* The electronic mail address of the named contact.
8 Named contact address The full postal address for the named contact.
9 Named contact phone number The telephone number for the named contact, including international dialling code.
10 Review team members and their organisational affiliations Names of all members of the review team and their organisational affiliations.
11 Organisational affiliation of the review* Details of the organisational affiliations for this review.
12 Funding sources/sponsors* Details of the individuals, organizations, groups or other legal entities who take
responsibility for initiating, managing, sponsoring and/or financing the review.
13 Conflicts of interest* Any conditions that could lead to actual or perceived undue influence on judgements
concerning the main topic investigated in the review.
14 Collaborators The name, affiliation and role of any individuals or organisations who are working on
the review but who are not listed as review team members.
Review methods
15 Review question(s)* The question(s) to be addressed by the review.
16 Searches* Details of the sources to be searched, and any restrictions (e.g. language or publication
period).
17 URL to search strategy A link to the search strategy or an example of a search strategy for a specific database.
18 Condition or domain being studied* A short description of the disease, condition or healthcare domain being studied,
including health and wellbeing outcomes.
19 Participants/population* Summary criteria for the participants or populations being studied by the review. The
preferred format includes details of both inclusion and exclusion criteria.
20 Intervention(s)/exposure(s)* Full and clear descriptions of the nature of the interventions or the exposures to be
reviewed.
21 Comparator(s)/control* Details of the alternatives against which the main subject/topic of the review will be
compared.
22 Types of study to be included initially* Details of the study designs to be included in the review. If there are no restrictions on
the types of study design eligible for inclusion, this should be stated.
23 Context Summary details of the setting and other relevant characteristics which help define the
inclusion or exclusion criteria.
24 Primary outcome(s)* The most important outcomes, including information on timing and effect measures,
as appropriate.
25 Secondary outcomes* Any additional outcomes that will be addressed, including information on timing and
effect measures, as appropriate.
26 Data extraction (selection and coding) The procedure for selecting studies for the review and extracting data, including the
number of researchers involved and how discrepancies will be resolved.
27 Risk of bias (quality) assessment* Whether and how risk of bias will be assessed, how the quality of individual studies will
be assessed, and whether and how this will influence the planned synthesis.
28 Strategy for data synthesis* The planned general approach to be used, for example whether the data to be used
will be aggregate or at the level of individual participants, and whether a quantitative
or narrative (descriptive) synthesis is planned.
29 Analysis of subgroups or subsets* Any planned exploration of subgroups or subsets within the review. ‘None planned’ is a
valid response if no subgroup analyses are planned.
General information
30 Type of review The type of review.
31 Language The language(s) in which the review is being written and will be made available.
32 Country The country or countries in which the review is being carried out.
33 Other registration details Other places where the systematic review is registered (such as with The Cochrane
Collaboration, The Campbell Collaboration, or The Joanna Briggs Institute).
34 Reference and/or URL for published protocol The citation and link for the published protocol, if there is one.
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register to fulfil its aims and cater for all potential users it was
important to ensure that experts from all the relevant disciplines be
invited to contribute their opinions in order to reach a consensus.
It would not have been possible to arrange face to face meetings
with the number of participants achieved by this approach. The
Delphi approach allowed us to carry out the consultation with
complete anonymity and maintain a broad heterogeneity in
participants without any one discipline or individual having more
influence than another.
For pragmatic reasons we modified the standard Delphi
technique, and discuss here the limitations of the methods we used.
The notion of an ‘international expert’ in the defined areas is
largely subjective. We hoped to minimise any inadvertent bias in
the selection of the core panel by also issuing an open invitation to
participate. However, because of the option of sharing email
invitations, we cannot be sure that only core panel members
responded to the core panel collector. Nonetheless, a comparison
of the data from the two collectors showed little variation in
response between the two groups.
Ideally, the same participants should respond to each round of a
Delphi process. The pragmatic decision not to approach
participants in advance to confirm commitment to the whole
exercise, was balanced against the number being invited to take
part. Just over half the respondents participated in both rounds. A
comparison of second round responses between returning
respondents and new participants showed no significant differenc-
es. It is unlikely therefore that the approach taken introduced
additional bias.
Normally the first round of a Delphi would present open
questions such as ‘What items do you think should be included in the
registration of systematic reviews at the protocol stage?’ However, given that
the items that should be included in a systematic review protocol
are already well established and to reduce the burden on
participants, we invited the first round respondents to comment
on the utility of a pre-prepared list of candidate items.
Respondents also had the opportunity to suggest additional items.
The suggestions that were received and adopted were: the addition
of an optional field to record other registration details (e.g., on The
Cochrane Library); the requirement of time points to be included
in the primary and secondary outcomes fields; and an optional
field for telephone contact details.
Based on 315 invitations to participate in the first round, and
143 respondents, the response rate was 45%. In the second round
318 invitations were sent out and 169 responses received, making
the response rate 54%. However, the true response rates may be
lower as we cannot know how many individuals received a
cascaded invitation.
Our decision not to use a pre-determined list of participants for
the two rounds was based on the desire to ensure a range of
respondents, but could have led to an unrepresentative sample of
participants. In the event, responses were received from all key
groups and those people who labelled themselves as researchers/
reviewers were divided similarly in each round between members
(119 round one; 105 round two) and non-members (75 round one;
81 round two) of The Cochrane Collaboration.
We succeeded in gathering the opinions and judgments of a
large and diverse range of relevant experts. Given the heteroge-
neity of the respondents and their interests, we believe that the
degree of consensus achieved is acceptable, but we will keep the list
of data items under review and will revisit it after it has been in use
for a year, as part of a wider evaluation of the utility of
PROSPERO.
Conclusion
The consultation revealed widespread support for the principle
of registration of systematic reviews, and the Delphi exercise
established a dataset of 22 required items for the prospective
registration of systematic reviews, and 18 optional items. The
dataset captures the key attributes of review design, as well as the
administrative details necessary for registration. The findings were
also used to inform the development and implementation of the
technical and process elements of PROSPERO.
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Supporting Information for Establishing a Minimum Dataset for Prospective 
Registration of Systematic Reviews: An International Consultation 
 
 
Participant demographic information: Which country are you based in? 
 
Other countries are: Bahrain, Finland, Ireland, Republic of Korea, Mexico, Pakistan, 
Taiwan, (one response in first and second rounds). Columbia, Greece, Hong Kong, 
India, Israel, New Zealand, (one respondent in first round; none in second round). 
Argentina, France, Peru, Saudi Arabia, Thailand, (no respondents in first round; one 






Table S1. Professional information about respondents: role.  
 




Academic clinician 58 53 
Clinician 12 10 
Commissioner/funder of reviews 14 9 
Health economist 20 9 
Information specialist 15 27 
Journal Editor/board member/involved in publishing 35 44 
Researcher (but not a systematic reviewer) 37 25 
Statistician  20 12 
Systematic reviewer 110 106 
Other 19 21 
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 




Table S2. Professional information about respondents: health areas of interest.  
 




Blood and immune system 16 8 
Cancer  35 30 
Cardiovascular 22 25 
Care of the elderly 11 13 
Child health 27 28 
Complementary therapies 10 9 
Dental 7 5 
Digestive system  9 11 
Ear, nose and throat 9 12 
Endocrine and metabolic disorders 15 16 
Eye disorders 8 9 
Infections and infestations 24 19 
Mental health and behavioural conditions 31 25 
Musculoskeletal 25 18 
Neurological 19 16 
Obstetrics and gynaecology 22 17 
Oral health 5 8 
Perioperative care 7 6 
Public health (including social determinants of 
health) 75 69 
Respiratory disorders 18 20 
Service delivery 30 23 
Skin disorders 12 12 
Urological 11 11 
Wounds, injuries and accidents 11 13 
No specific health area of interest 53 61 
Other 36 17 
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 




Table S3. Professional information about respondents: review method of interest.  
 




Effects of health and social care interventions 
(including rehabilitation and prevention) 145 110 
Review methodology 135 132 
Reporting of reviews 78 75 
Reviews of reviews 64 73 
Diagnosis 66 62 
Adverse effects 71 58 
Qualitative research 38 43 
Scoping reviews 30 42 
Single technology appraisals 38 39 
Economic evaluation 61 39 
Prospective meta-analysis 39 36 
Screening 30 35 
Risk factors 39 32 
Prognosis 27 29 
Individual participant data 24 19 
Study level data 24 17 
Genetics 13 14 
Other 17 13 
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 






Table S4. Professional information about respondents: number of systematic reviews 
authored.  




0 24 24 
1-5 85 67 
6-10 30 32 
>10 55 67 
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 




Table S5. Professional information about respondents: number of systematic reviews 
involved with other than as an author. 
 




0 16 16 
1-5 41 44 
6-10 30 27 
>10 107 103 
(e.g., Peer review; searching; advisory panel). 
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 








Table S6. Professional information about respondents: proportion of work related to 
research methodology. 
 




0 10 8 
1-40% 98 110 
41-60% 48 40 
>60% 38 32 
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 
second round the question was optional: 190 responded, 19 skipped the question. 
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Table S7. Professional information about respondents: membership of relevant 
organisations.  
 




AHRQ Evidence-based Practice Centers (EPC) 
Network 5 12 
The Campbell Collaboration  27 21 
The Cochrane Collaboration 119 105 
Committee on Publication Ethics (COPE) 3 7 
Council of Science Editors 1 2 
Deutsches Netzwerk evidenzbasierte Medizin 1 7 
Evaluation of Genomic Applications in Practice and 
Prevention, U.S. Centers for Disease Control (A 
working group) 
1 1 
Guidelines International Network (G-I-N) 1 18 
Health Technology Assessment International 
(HTAi) 43 48 
International Committee of Medical Journal Editors 
(ICMJE) 2 3 
International Network of Agencies for Health 
Technology Assessment (INAHTA) 2 29 
International Clinical Epidemiology Network 
(INCLEN) TRUST 1 4 
International Society of Drug Bulletins (ISDB) 1 1 
International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) 6 9 
Partners in Health Technology Assessment 
(PiHTA) 1 1 
Society for Medical Decision Making 1 6 
Society for Research Synthesis Methodology 
(SRSM) 11 10 
World Association of Medical Editors (WAME) 4 11 
None of these 41 28 
Others from 1st round: National Institute for Health 
and Clinical Excellence (1) 
Others from 2nd round: The Joanna Briggs Institute 
(2); Agency for Healthcare Research and 
Quality/USPSTF program (1); CILIP (1); CRD 
advisory Board (1); GRADE member (1); HESG 
(1); HuGENet (1); Independent Meta-analysis 
Group (MRC) (1); International Society of 
Pharmacoepidemiology (1); METCARDIO 
(www.metcardio.org) (1); Saudi research group (1); 
Society for Social Medicine (1). 
  
 
N.B.  A response to this question was mandatory in the first round: 194 responded. In the 
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PROSPERO at one year: an evaluation of its utility
Alison Booth1*, Mike Clarke2, Gordon Dooley3, Davina Ghersi4, David Moher5,6, Mark Petticrew7 and Lesley Stewart1
Abstract
Background: PROSPERO, an international prospective register of systematic review protocols in health and social
care, was launched in February 2011. After one year of operation we describe access and use, explore user
experience and identify areas for future improvement.
Methods: We collated administrative data and web statistics and conducted an online survey of users’ experiences.
Results: On 21 February 2012, there were 1,076 registered users and 359 registration records published on
PROSPERO. The database usage statistics demonstrate the international interest in PROSPERO with high access
around the clock and around the world. Based on 232 responses from PROSPERO users (response rate 22%), almost
all respondents found joining and navigation was easy or very easy (99%); turn round time was good or excellent
(96%); and supporting materials provided were helpful or very helpful (80%). The registration fields were found by
80% to be relevant to their review; 99% rated their overall experience of registering with PROSPERO as good or
excellent. Most respondents (81%) had a written protocol before completing the registration form and 19% did not.
The majority, 136 (79%), indicated they completed the registration form in 60 minutes or less. Of those who
expressed an opinion, 167 (87%) considered the time taken to be about right.
Conclusions: The first year of PROSPERO has shown that registration of systematic review protocols is feasible and
not overly burdensome for those registering their reviews. The evaluation has demonstrated that, on the whole,
survey respondents are satisfied and the system allows registration of protocol details in a straightforward and
acceptable way. The findings have prompted some changes to improve user experience and identified some issues
for future consideration.
Keywords: Systematic review protocol, Register, Prospero, Evaluation
Background
PROSPERO, an international database of prospectively
registered systematic reviews in health and social care,
was launched in February 2011. The aim of the register is
to help reduce unplanned duplication of reviews, provide
transparency and to help minimise reporting bias by enab-
ling comparison of reported review findings with what
was planned in the protocol [1]. PROSPERO is funded
through the National Institute for Health Research in the
UK and is free to register and free to search.
Researchers provide key features from their review
protocol which are recorded and maintained as a perma-
nent record in PROSPERO. The registration form con-
tains 22 required fields and 18 optional fields, agreed
through international consultation [2]. ‘Required’ fields
contain ownership details and key protocol methods, such
as participants, outcomes and analyses; they must be
completed before a registration form can be submitted
[3]. ‘Optional’ fields provide more administrative informa-
tion, such as review team members and their affiliations
and dissemination plans.
PROSPERO was designed to collect and process regis-
tration details accurately while keeping the process of
registration as straight forward as possible in order to
minimise work for researchers registering their systematic
reviews.
After one year of operation, an evaluation of the regis-
tration process was undertaken to identify areas for im-
provement and further development. This paper outlines
the evaluation and findings and discusses issues raised.
Methods
Data relating to registered users, submitted registration
forms, the administration process and web statistics for
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access and usage were collated for the period 22 February
2011 to 21 February 2012. Feedback and suggestions for
future development were sought from those who had sub-
mitted registration requests within the same time frame
of interest using electronic questionnaires, which were
prepared in SurveyMonkeyW, Palo Alto, CA, USA. (www.
surveymonkey.com). The survey questions are listed in
Additional file 1.
Emails containing the link to the survey were sent out
to 1,076 registered users on 27 February 2012 with a re-
minder sent out 12 March 2012. The survey was closed
on 21 March 2012. There were 29 emails returned with
permanent failure to deliver messages. There were also
39 named individuals who had ‘joined’ more than once
using different email addresses and who accounted for
87 registered users. As all distinct email addresses were
included in the survey, some people will have received
invitations to participate at more than one email address.
However, SurveyMonkey was set to permit only one
response per computer to minimise multiple responses
from the same person. The number of individual regis-




On 21 February 2012, there were 359 published records
on PROSPERO. Of these, 339 were on-going, 15 had
been completed but not yet published and 3 had been
completed and published [4-6], subsequent to registra-
tion. Two were updates of existing reviews previously
registered.
In the same time period, a total of 89 submissions were
ineligible for inclusion in PROSPERO and not accepted
for registration (Table 1). Of these, 37 were already com-
pleted and 33 were too far advanced (progressed beyond
data extraction). Nine were methodological reviews with
no direct clinically related outcome; five did not have a
health intervention or health related outcome; four were
reviews of reviews and one was in Spanish.
For the period 1 March 2011 to 21 February 2012 the
average administrative turn round time for accepted sub-
missions was 1.0 working day.
Published records
On 21 February 2012, 359 systematic reviews were regis-
tered on PROSPERO. The reviews were being undertaken
in 33 different countries (Figure 1), many of them in col-
laboration between two or more countries. The 10 coun-
tries with the most registrations are listed in Table 2.
All the registrations were in English as other languages
are not accepted. All but one of the reviews will be writ-
ten in English; one will also be available in German, two
also in Norwegian and one in Spanish only.
The overall trend for submission of registrations
increased exponentially, but there were a number of peaks
in activity that may be explained by a variety of activities
(Figure 2):
1. 22 February 2011. Launch events in UK and Canada
and press releases sent to all relevant agencies and
organizations (for example, INAHTA, G-I-N);
2. 1 May 2011. NIHR piloted mandatory registration for
all HTA programme funded reviews, and contacted
all those already funded to register if still within
acceptance criteria.
3. 27 July 2011. Letters sent to all INAHTA member
organisations encouraging support for PROSPERO by
making registration part of the funding process.
4. 21 October 2011. Presentation on PROSPERO given
at the Cochrane Colloquium in Madrid.
5. 16 November 2011: Paper about the international
consultation to establish the minimum dataset
published in PLoS ONE [2].
6. Mid-end November 2011. NIHR rolled out
mandatory registration across all their other
Table 1 Eligibility criteria (February 2011 to March 2012)
Aspect Criteria
Scope PROSPERO will initially include systematic reviews of the effects of interventions and strategies to prevent, diagnose, treat,
and monitor health conditions, for which there is a health related outcome.
The long-term aim is to include details of all ongoing systematic reviews that have a health related outcome in the
broadest sense (for example, reviews of risk factors and genetic associations). Reviews of animal studies will not be included.
Review types excluded Scoping reviews, reviews of reviews, and reviews of methodological issues are not currently included in PROSPERO.
Timing Registration should take place once the systematic review protocol has been finalised, but ideally before screening studies
for inclusion begins. However, during the initial period of operation we will accept registration of reviews that are already
underway up to the point of completion of data extraction. Completed reviews should not be registered.
Cochrane Review
Protocols
An electronic upload of Cochrane Protocols from the Cochrane library is being developed. To avoid duplication of records,
Cochrane protocols should not be registered separately with PROSPERO.
Language Submissions must be in English.
If you are in any doubt about the eligibility of your review or the stage of progress please contact crd-register@york.ac.uk
for advice.
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programmes, and contacted all those already funded
to register if within acceptance criteria [7].
7. End of November 2011: Website ‘About’ pages
revised and expanded; training materials made
available to download [8].
8. January 2012: Paper promoting PROSPERO
published in prominent Chinese Medical Journal [9].
9. 9 February 2012: New BMC journal Systematic
Reviews published a thematic series on ‘The
importance of registering systematic reviews’,
including commentaries from Dame Sally Davies
(NIHR), Ian Graham (CIHR), the editors of the
journal and an article on the nuts and bolts of
PROSPERO [10].
The first record to be published on PROSPERO was for
a systematic review and multiple treatment meta-analysis
of drug-trials for hypertension carried out by the Norwe-
gian Knowledge Centre for the Health Services, which was
completed and published in April 2012 [11,12]. The last
record published before the first year cut-off was a Joanna
Briggs Institute review funded by the Australian Agency
for International Development. This review is looking at
demand-side financing measures to increase maternal
health service utilization and improve health outcomes in
low and middle income countries and is due for comple-
tion in September 2012 [13].
There were 171 Treatment, 46 Prevention, 40 Service
delivery, 36 Diagnostic, 31 Prognostic and 39 ‘Other’
reviews registered on the database (categories selected
from a drop-down menu). Funding sources included go-
vernment agencies (130), institutional (university/hospital)
(71), pharmaceutical company (10), miscellaneous other
funders (11) and no funding (137). Organisational affili-
ation included government agencies (4), hospital/medical
centers (56), research institutes (82), University/Medical
schools (169) and pharmaceutical companies (4). Forty-
four gave no organisational affiliation (providing this in-
formation is currently optional).
There were 435 registered users who had ‘joined’ but
never created a form and 266 who had created but never
submitted a form. This included users who had registered
more than once, using different email addresses. Those
who had never created or submitted a form were asked
why in the questionnaire. The reasons given included:
interest in seeing the form but not in a position to regis-
ter a review (for example, team member not lead;
Cochrane review; took part in formulating minimum
dataset); found their review did not meet the inclusion
criteria (for example, it was too far advanced); were con-
sidering registering but as yet undecided; were about to
submit their form.
Database usage
The total number of hits on the PROSPERO website be-
tween 22 February 2011 and 21 February 2012 was
Figure 1 Countries where registered reviews are being undertaken.








England 113 28 141





Australia 22 10 32
Brazil 16 3 19
Netherlands 8 11 19
Scotland 8 9 17
China 12 1 13
Denmark 7 6 13
Germany 9 4 13
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406,730; there were 829,766 page views by 13,607
visitors (Figure 3).
Users in 28 identified countries and territories around
the world accessed the database (Figure 3). The highest
use was from the UK, USA, Canada and China. The inter-
national nature of the register was further demonstrated
by around the clock access (Figure 4).
The five identifiable websites that referred most visitors
were: http://www.crd.york.ac.uk/; http://www.york.ac.uk/;
http://www.google.co.uk/; http://www.prisma-statement.
org/; http://www.google.com/. The search engines refer-
ring most visitors were Google, Bing and Yahoo. The top
five search phrases used to find PROSPERO were: pros-
pero; prospero crd; prospero systematic reviews; prospero
systematic review; and prospero York.
User experience
The survey link was sent to the active email accounts of
1,047 registered user accounts of which 48 were duplicate
accounts for the same named contact and as the question-
naire blocked more than one response per computer, we
anticipated a maximum return of 999. A total of 232
responses were received, giving a response rate of 23%.
None of the questions were compulsory so the number of
responses per question varied.
Overall, the feedback on functionality and ease of use
was positive. Brief details are given here with additional
information provided in Additional file 2. The joining
process and navigation around the registration form
were considered to be easy or very easy by 99% of users.






































New registrations by month 
1. Launch
















6. NIHR roll out 
mandatory 
registration
3. Letter sent to 
INAHTA
members
8. Article published 
in Chinese Medical 
Journal
7.  Training 
materials made 
available
*Includes numbers for the whole of Feb-12
Figure 2 Rate of new registrations.
Figure 3 Countries accessing PROSPERO: map.
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links to other resources, were found to be helpful or very
helpful by 67% of respondents; most people (177 (82%))
found all or most of the registration fields of relevance to
the systematic review protocols they had registered or
were likely to register.
The majority of respondents, 176 (81%) had a written
protocol for their systematic review before completing the
PROSPERO registration form. Of those who did not have
a protocol; 42 (19%) used their grant proposal or detailed
project description to complete the registration form. In
two cases, the protocol was designed using the headings
from PROSPERO. Others found that completing the
registration form helped improve their protocol by making
them formalise less detailed areas. One registrant had split
the protocol for a review looking at two different clinical
areas, funded by a single grant.
Completing the registration form
Most submissions took between 30 minutes and 1 hour
to complete; 136 (79%) indicated they completed the re-
gistration form in 60 minutes or less. The majority, 167
(87%), considered the time taken to be about right; 24
(12%) felt it took too long and 2 (1%) too short a time.
Comments received indicated that for those with a pre-
pared protocol, completion was quick. Where protocols
were in a different format completion took longer, but
there appeared to be a willingness to change to the
PROSPERO format. Some used the registration form as
a guide for ‘tidying up’ the protocol and some prepared
responses to each of the questions in a separate docu-
ment, and circulated it to colleagues to ensure it was
ready before cutting and pasting into the PROSPERO
form. Some felt the time taken depended on the subject
of the review, and that completion of the form would
become easier with familiarity.
A guideline developer with multiple reviews for each
guideline indicated that they were weighing the time/
resources involved against the benefits of registration.
Overall, there appeared to be recognition that for regis-
tration to be of good quality it needs an adequate amount
of time to be spent on it and the protocol, and that the
process helped.
Respondents reported that they were ‘impressed with
the turnaround time and the very friendly contact’ and
the majority rated the turn round time for a decision
(121 (97%)) and information provided in correspondence
(99 (79%)) as excellent or very good.
All seven respondents who had had a submission
rejected said the reason for rejection was made clear in
the email response. However, two said eligibility was not
clear in the information given in the form or on the
PROSPERO website; two did not look at the time; and
three said that on reflection the information was available
at the time. One commented that the inclusion criteria
could be more obvious to site users.
PROSPERO compared favourably with previous experi-
ences of trials registration, being ‘on a par’ with the
ANZCTR (Australian New Zealand Clinical Trials Registry)
and ‘much easier’ than clinicaltrials.gov. The absence of
registration fees was identified as helpful. Although a
number of respondents felt that PROSPERO was easier,
quicker and more flexible than registering a Cochrane
Review protocol, the majority acknowledged that the sys-
tems are different, particularly in the editorial process.
Overall, 189 (86%) respondents rated their experience of
registering their review protocol details on PROSPERO as
excellent or good; 21 (10%) as adequate and 9 (4%) as
poor. None of those who rated their experience as poor
had actually submitted a form, although eight said they are
likely to do so in the future and gave positive responses to
other questions in the survey. Thirty-two people had two
records published, five had three records published, two
had four records published, and one individual had seven
reviews registered.
Positive comments were made about the information
provided in correspondence, how useful the process











Figure 4 Visitors by time of day (GMT).
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systematic review, and satisfaction in knowing your work
is out in the public domain. The only negative comments
were about email enquiries made which had received no
response. This flagged a problem in the system which we
believe has subsequently been fixed.
Nearly all the respondents who had created a record or
previously submitted a registration form said they were
very likely or likely to register a systematic review protocol
in the future, 207 (94%). However, three (1%) said they
would only register if the commissioner of a review made
it a requirement. Comments were received from one per-
son who registered only because it was required, one who
was required to register but would have done so any way
and one who would do so if the commissioners/funders
allow it.
General feedback
Survey respondents were invited to make additional fur-
ther comments or suggestions. Some reiterated their sup-
port for the planned broadening of scope for inclusion of
systematic reviews beyond those of effects. Others asked
for more flexibility within the form while still acknowledg-
ing the good intent. Suggestions for improvements to the
search facility in the public interface were also given.
The majority of comments supported the principle of
protocol registration and PROSPERO. Comments ran-
ged from ‘A very useful tool for a not-very-experienced
reviewer. Thank you’ . to ‘the resources/references are
fantastic. the idea is fantastic and I will persevere, but
the form is initially daunting’ . Many said ‘Thank you’
and ‘Congratulations’.
Discussion and conclusions
A main aim of this evaluation exercise was to assess
the utility of the registration process, and its ‘fitness for
purpose’. Inevitably any survey is limited by the response
rate and we cannot make assumptions about the views of
non-responders. However, the response rate of 23% is ty-
pical for an electronic survey [14,15]. The feedback from
users about their experiences has provided reassurance
that on the whole the process is working well and has
prompted some changes and planned developments to
improve the user experience (Additional file 3). Requests
to include alternative review types were made in the
survey and by separate request; in particular, that reviews
of reviews and methodology reviews be accepted. The
PROSPERO Advisory Group have since agreed that re-
views with a methodological focus, which also include an
outcome of direct patient or clinical relevance, should be
included in PROSPERO. The advisory group also agreed
that systematic reviews of reviews should in future be
included in PROSPERO; all other inclusion/exclusion cri-
teria would still apply. One of the most encouraging find-
ings is the range of reviews being registered not only in
terms of countries, organisational affiliations and funding
but also in countries collaborating on reviews.
Database usage statistics demonstrate the international
interest in PROSPERO with high access around the clock
and across the week. We are aware that PROSPERO is
being routinely searched prior to new reviews being com-
missioned and, therefore, is already helping to avoid unin-
tended duplication of reviews.
Additional files
Additional file 1: Survey questions.
Additional file 2: Survey responses.
Additional file 3: Modifications made to PROSPERO in response to
user survey findings.
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Additional file 1  
Survey Questions 
1. How would you rate the ease of the 'Join' process, which allowed you to create a user 
account for PROSPERO?  
2. We are i e e ed i  h   ha e c le ed he J i  ce  f  PROSPERO b  d  
not currently appear to have submitted a registration form as Named Contact. (Please tick all 
that apply)  
x Took part in the Delphi consultation: interested in result 
x Curious to see registration process 
x Found my review was not eligible so did not submit 
x Will be registering in the near future 
x Another team member took responsibility for registration 
(N.B. Question only sent to emails of registered users who had not submitted a registration 
form.) 
3. How would you rate the ease of navigating around the registration form?  
x Very easy 
x Easy 
x Not easy 
x Difficult 
4. How useful did you find the following supporting materials?  
x Information about field content given in the form  
x Full information about field content accessed via the ? icon in the form 
x The 'About PROSPERO' pages on the website 
x The 'References and resources' provided on the website 
x The pdf of the Guidance notes for completing the registration form 
5. Please indicate the type of review you are likely to register/have submitted for registration 
x Type of review 
x Diagnostic 




x Other (please specify) 
6. In the registration form you were asked to indicate the stage of your systematic review as 
'started' or 'completed' for each of the options listed below. How relevant do you think these 
options are for indicating the stage of your systematic review from initial submission to 
completion of the review?  
x Preliminary searches 
x Piloting of the study selection process 
x Formal screening of search results against eligibility criteria 
x Data extraction 
x Risk of bias (quality) assessment 
x Data analysis 
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7. On a few submissions, registrants indicated they had started (but not completed) Data 
extraction, Risk of bias (quality) assessment, and Data analysis.  
We anticipated that data analysis would not begin until data extraction had been completed. 
To inform a review of the timing for acceptance of registrations, we would be interested to 
know the circumstances in which all these stages are active at the same time. Details of your 
experience of this and/or your comments are welcome. 
8. In general, how relevant were the registration fields to the systematic review protocol you 
were registering? / are likely to register? 
x All relevant 
x Mostly relevant 
x Mostly irrelevant 
x I cannot remember 
9. If you had any problems deciding what information to enter in which field, please describe 
the problems.  
10. How useful did you find the following technical facilities within the registration form? 
x Highlighting of Required fields 
x 'Save' button on each page 
x 'Validate this page' facility 
x Ability to print a copy of the form 
x Ability to upload pdf of search strategy 
x Ability to upload pdf of protocol 
11. How useful would you find it to be able to do the following?  
x Save a draft form as a pdf file 
x Save a draft form as a document that could be edited in word processing software 
x Save the submitted form as a pdf file 
x Save the submitted form as a document that could be edited in word processing 
software 
12. How long did it take you to complete the registration form?  
x Up to 30 minutes 
x 30 to 60 minutes 
x Over 60 minutes 
x I cannot remember 
13. Did you feel the time taken to complete the registration form was:  
x Response 
x Too long 
x About right 
x Too short 
x No opinion 
14. Did you have a written protocol for your systematic review before you completed the 
PROSPERO registration form? 
x Yes 
x No 
15. Following submission of your registration form, how would you rate the following?  
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x The turnaround time for a decision 
x The information provided in correspondence 
16. If your submission was rejected, was the reason for rejection made clear in the email 
response?  
x Options 
x Yes  
x No  
x Can  remember 
17. If your submission was rejected, on reflection, was the reason for rejection clear in the 
information given in the form or on the PROSPERO website?  
x No, not at the time of submission 
x Yes on checking, the information was available at the time 
x Did not look at the time 
x Can  remember 
x Information on eligibility was not clear at the time 
x Information currently provided is still not clear 
x Information is now provided and clear 
18. If you have experience of registering a systematic review protocol or any other piece of 
research anywhere else, we would be interested to hear your opinion of how PROSPERO 
compares with other registers. 






20. How likely are you to (return and) register a systematic review protocol in the future? 
x Very likely 
x Likely 
x Unlikely 
x Only if the commissioner or funders require it 






Additional file 2 
Survey responses 
Registering a review 
The joining process and navigation around the registration form was considered to be easy 
or very easy by 99% of registrants. 
Of those who had registered as users but not yet submitted a registration form, 39 (45%) 
said they would register their review in the near future; 26 (30%) found their review was not 
eligible and so did not submit; 24 (27%) were interested to see the process (three had taken 
part in the Delphi consultation); and 18 (21%) said another team member took responsibility 
for registering their review. 
Supporting materials such as brief and full guidance about field content, general information 
about PROSPERO and references and links to other resources are provided on the website 
and within the registration form. These supporting materials were found to be helpful or very 
helpful by 67% of respondents; 28% were unaware of them or aware but did not use them. 
Two respondents suggested that the eligibility criteria could be placed more prominently on 
the website. One person registering a slightly less conventional systematic review  did not 
find the guidance given really helped. Another person suggested providing a sample of a 
review protocol. 
Type of review 
Respondents were asked to indicate the type of review they had or were likely to register. Of 
the current options: 110 (56%) indicated a treatment review; 33 (17%) prevention; 24 (12%) 
service delivery; 19 (10%) diagnostic; and 12 (6%) a prognostic review. The numbers were 
very similar for those who had already submitted a review and those who planned to in the 
future. A list of 39 Other  types were given in the free text comments box; of these 20 were 
felt to fit existing categories. Three were methodology reviews and two reviews of reviews. 
Five referred to method to be use in conducting the review, e.g. meta analysis or IPD. The 
remaining nine were epidemiology related. 
Stage of progress 
Every submission and subsequent revision requires details of the stage of the systematic 
review by indicating whether key stages of the review have been 'started' or 'completed'. 
Respondents found these options to be very relevant: Preliminary searches 176 (81%); 
Piloting of the study selection process 147 (67%); Formal screening of search results against 
eligibility criteria 192 (88%); Data extraction 187 (86%); Risk of bias (quality) assessment 
170 (78%); Data analysis 186 (85%). 
A few submissions indicated that data extraction, risk of bias (quality) assessment, and data 
analysis had been started but not completed. When designing PROSPERO we anticipated 
that data analysis would not begin until data extraction had been completed. The 
questionnaire therefore asked for circumstances in which these stages might be active 
concurrently.  Responses included: none; the re-running of searches; delayed receipt of 
information for inclusion; different parts of a review or reviewers progressing at differing 
rates; entry of extracted data directly into analysis software; a characteristics table being 
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compiled during data extraction as part of the analysis; and for qualitative systematic reviews 
quality assessment, data extraction, and data analysis would be concurrent and iterative. 
Relevance of fields 
The majority of respondents (177 (82%)) found all or most of the registration fields relevant 
to the systematic review protocols they had registered or were likely to register. Three 
commented that they were not well tailored for reviews including qualitative studies and 
another asked for more flexibility in the information required in fields; specifically primary and 
secondary objectives. 
There were a few reported problems concerning decisions about what information to enter in 
which field. These related to non-intervention systematic reviews, qualitative systematic 
reviews and reviews done as part of a multiple strand project, but had not prevented 
completion and submission of a registration form. Some fields were felt to be a bit redundant 
(but not named). 
Functionality of the registration form 
The technical facilities within the registration form were felt to be useful or very useful by the 
majority of those who were aware of them. One hundred and sixty three (77%) found 
highlighting of required fields useful or very useful, 44 (20%) did not use or were unaware of 
the highlighting; one person commented that it could be clearer.  
The 'save' button on each page was useful or very useful for 175 (82%); 32 (15%) did not 
use or were unaware of the save button; a number commented that although the system 
automatically saves changes when the user exits a field, being able to manually save  gave 
good reassurance and the confidence to be able to complete the form in stages.  
The 'validate this page' facility, which highlights any required fields that have not yet had any 
information entered, was useful or very useful to 153 (72%) of respondents. 
The ability to print a copy of the form was useful or very useful to 150 (71%) of respondents.  
The option of being able to upload pdfs of the search strategy and/or protocol was 
considered to be very useful or useful by 135 (63%) and 138 (65%) respectively. 
The majority of respondents (86%) indicated that being able to save the draft and submitted 
form as either a pdf file or a document that could be edited in word processing software 
would be very useful or useful. Reasons given were around facilitating distribution amongst 
co authors to assist with joint formulation of submissions and subsequent updates/revisions 






Additional file 3 
Modifications made to PROSPERO in response to user survey findings 
The PROSPERO year one user survey findings reflected a positive experience for those 
who responded, but also identified some areas for improvement and some for consideration 
in the next phase of development. The actions taken and future considerations are outlined 
here. 
Scope for inclusion 
Inclusion criteria have been made more prominent on the PROSPERO website, and 
included in the full guidance notes. Future developments to accommodate the inclusion of 
other types of review will similarly be accompanied by relevant guidance. Examples of 
information required for each field are given in the full guidance notes and PROSPERO now 
contains numerous examples which all registrants can access. The PROSPERO Help ith 
registration: Incl sion criteria  page on the ebsite has also been re ised. 
[http://www.crd.york.ac.uk/PROSPERO/inclusion_criteria.asp]  
Support materials 
A few users commented that while supporting information was useful, it was not necessarily 
presented in the most accessible a . As a res lt separate tabs for Abo t PROSPERO , 
Help ith registration , and References and reso rces  ha e been created and the 
appropriate information placed under sub-headings into each of these pages. The full 
guidance is being prepared in alternative formats to suit a range of user preferences. 
 
Type of review 
Some respondents selected the other  categor  for type of review because the review fitted 
in more than one category; as from Nov 2011 it has been possible to make multiple 
selections. As a result of feedback, additional information about what is expected in each 
type of review will be added to the guidance. The option of Treatment has been amended to 
Intervention and the guidance notes revised.  
Some supplied an alternative descriptor to those listed, but the majority of these were found 
to fit ithin e isting options. This reflects a degree of conf sion o er the meaning of t pe  
seen in both submitted registrations and in the user survey. A few misunderstood and 
detailed the methods to be used, for example IPD; meta-analysis; qualitative. An alternative 
descriptor to t pe  has been so ght b t all alternati es had similar potential for 
misinterpretation. 
Responses also identified the potential need to include the addition of a term to cover 
epidemiological type reviews as an option. However there are a range of terms in use, for 
example epidemiological could be aetiological or observational; prevalence; risk. The most 
inclusive and widely understood and used term for this category of reviews is being 
considered before being added to the list. The categories will need to be reviewed regularly 
as scope for inclusion broadens. 
Stage of review at time of submission 
This field is important to users of the database as an indication of the stage the review is at 




record. As a result of feedback, an additional option of Started  Yes/No is being added to 
the field; and the option of Prospective Meta-Analysis removed. Consideration will be given 
to other changes when a review of the dataset is undertaken. 
Relevance of fields 
The dataset currently required was agreed for the initial inclusion of reviews of the effects of 
interventions, with the understanding that modifications or alternative templates would 
probably be required as the scope for inclusion expanded.  The majority of respondents 
found all or most of the registration fields of relevance to the systematic review protocols 
they had registered or were likely to register. A few respondents felt the fields were not well 
tailored for some reviews, for example when including qualitative studies. Given the range 
and variety of reviews now registered, the system would appear to have a good degree of 
flexibility, supported by a pragmatic approach to inclusion by the administration team.  
The terminolog  and separation of primar  and secondar  objecti es, as q estioned for 
being related to trials rather than systematic reviews. However, as this is the language used 
by The Cochrane Collaboration, in the PRISMA statement and agreed through international 
consultation, it was not felt necessary to change at this time. The advisory group also felt the 
separation of the terms is appropriate for the current inclusion criteria, as it requires the 
focus of the review to be clearly stated a priori, with the option of including secondary 
objectives if required.  
A full evaluation of the required dataset will be undertaken in the future and relevance of 
fields considered during the stepped approach to expansion of the scope for inclusion. 
Functionality of the registration form 
Enabling a copy of the draft and submitted form to be saved as a pdf file and a word 
processing document to facilitate editing by multiple authors is a feature that will be added to 
the registrant interface as soon as this can be technically achieved. (In the meantime, 
clicking on the Print review button, then viewing the list of printer options should identify a 
way of saving the form as a pdf.) 
General issues 
Five respondents commented that they had not received a response to an email enquiry. 
None supplied contact details so we are unable to follow them up individually. However, all 
enquiries received at CRD-register@york.ac.uk (and at alison.booth@york.ac.uk) have been 
responded to. Response time is generally same or next day. A note has been added to the 
PROSPERO contact page sa ing: We aim to respond to all enquiries within 5 working days. 
We have recently experienced some problems receiving emails, so if after 5 days you have 
not heard from us, please try emailing crd@york.ac.uk, call, fax or write to us.  
Finally, a number or respondents commented that they could not remember specific aspects 
of the registration process well enough to comment on the experience. However many also 
said they would be willing to give feedback at the time of registration if this option was made 
available. All registrants are now invited to take part in a short on-line survey via a link in the 
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Abstract
Systematic reviews should build on a protocol that describes the rationale, hypothesis, and planned methods of the
review; few reviews report whether a protocol exists. Detailed, well-described protocols can facilitate the understanding
and appraisal of the review methods, as well as the detection of modifications to methods and selective reporting in
completed reviews. We describe the development of a reporting guideline, the Preferred Reporting Items for
Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015). PRISMA-P consists of a 17-item checklist
intended to facilitate the preparation and reporting of a robust protocol for the systematic review. Funders and those
commissioning reviews might consider mandating the use of the checklist to facilitate the submission of relevant
protocol information in funding applications. Similarly, peer reviewers and editors can use the guidance to gauge the
completeness and transparency of a systematic review protocol submitted for publication in a journal or other
medium.
Background
Systematic reviews are the reference standard for syn-
thesizing evidence in health care because of their meth-
odological rigor. They are used to support the
development of clinical practice guidelines and inform
clinical decision-making. They are becoming increas-
ingly common; in 2010, 11 new reviews were estimated
to be published daily [1]. Ideally, systematic reviews are
based on pre-defined eligibility criteria and conducted
according to a pre-defined methodological approach as
outlined in an associated protocol.
The preparation of a protocol is an essential compo-
nent of the systematic review process; it ensures that a
systematic review is carefully planned and that what is
planned is explicitly documented before the review
starts, thus promoting consistent conduct by the review
team, accountability, research integrity, and transparency
of the eventual completed review. A protocol may also
reduce arbitrariness in decision-making when extracting
and using data from primary research, since planning
provides an opportunity for the review team to antici-
pate potential problems. When clearly reported proto-
cols are made available, they enable readers to identify
deviations from planned methods in completed reviews
and whether they bias the interpretation of a review re-
sults and conclusions. Bias related to the selective
reporting of outcomes has been characterized as a ser-
ious problem in clinical research, including systematic
reviews [2-7].
Until recently, systematic review protocols were gener-
ally available only through select organizations, such as
The Cochrane [8] and Campbell Collaborations and the
Joanna Briggs Institute, for which the preparation of a
protocol is mandatory. Outside of these organizations,
the existence of a protocol is infrequently reported in
completed reviews [9,10]. Fewer than half of 300 system-
atic reviews indexed on MEDLINE in November 2004
(most recent generalizable sample; 2014 update under-
way) report working from a protocol [10], 80% of which
are non-Cochrane affiliated. Of the non-Cochrane thera-
peutic reviews, only 11% mentioned the existence of a
protocol [10]. The majority of reviews in health care are
* Correspondence: dmoher@ohri.ca
ˆDeceased
1Ottawa Hospital Research Institute and University of Ottawa, Ottawa,
Canada
Full list of author information is available at the end of the article
© 2015 Moher et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Moher et al. Systematic Reviews 2015, 4:1
http://www.systematicreviewsjournal.com/content/4/1/1
conducted and published outside of Cochrane, however
[10]. The paucity of protocols may be due, in part, to the
authors’ lack of knowledge about how to write them and
what to include. Currently, little succinct guidance is
available for those preparing systematic review protocols,
although the recent Standards for Systematic Reviews
prepared by the Institute of Medicine (IOM) provide
some guidance toward addressing this gap [11].
Many groups have called for the widespread preparation
and registration of systematic review protocols in order
to increase the availability and accessibility of a priori
methods for systematic reviews [12-14]. Such an effort
may reduce the duplication of effort [15] and reduce
the publication bias of systematic reviews. This chal-
lenge has been taken up by the Centre for Reviews and
Dissemination, University of York, which has spearheaded
the establishment of an international register—PROS-
PERO (International Prospective Register of Ongoing
Systematic Reviews, http://www.crd.york.ac.uk/prospero)
[16,17]. The register, which enables the permanent docu-
mentation of 22 mandatory (and 18 optional) items about
the a priori design and conduct of a review, was launched
in February 2011. At the time of writing, >5,000 system-
atic review protocols from over 70 countries have been
registered since its inception. Starting in October 2013,
new Cochrane protocols were and continue to be auto-
matically added to PROSPERO.
Along with the improved accessibility of protocols
through registration comes the need for strengthened
transparency, accuracy, and completeness of the reports
of protocols intended for dissemination. A template to
aid in the preparation of systematic review protocols,
such as a reporting guideline, may help achieve this. Fur-
thermore, such guidance will enable authors to create a
clear and complete document of their a priori methods,
which may facilitate the registration of key information
into the PROSPERO database. Building on an estab-
lished guideline for systematic reviews and meta-
analyses of studies evaluating health care interventions
—the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA, www.prisma-statement.
org) [12,13]—we have developed PRISMA for Protocols
(PRISMA-P) 2014. Table 1 summarizes the difference
in intentions between PRISMA-P and PROSPERO.
The aim of PRISMA-P 2015 is to improve the quality
of systematic review protocols, similar to the impact
achieved by other reporting guidelines [18-20]. By help-
ing authors document an a priori road map of their sys-
tematic review, PRISMA-P also has the potential to
improve the conduct of systematic reviews, as has been
suggested of other reporting guidelines [21]. This State-
ment paper summarizes the development of the guide-
line and presents the PRISMA-P checklist.
Terminology
There is no standard definition for a systematic review
and meta-analysis protocol, and we note that some ter-
minology contained within these definitions may carry
different meanings for different readers (i.e., ‘systematic
search’). The terms ‘systematic review’ , ‘meta-analysis,’
and ‘protocol’ are defined in Table 2. The former two
terms are in accordance with the definitions reported in
the PRISMA Statement [13] and are in line with those
used by the Agency for Healthcare Research and Qual-
ity’s Evidence-based Practice Center (EPC) program [22],
The Cochrane Collaboration [23], and the 2011 guidance
from the Institute of Medicine [11]. The definition pro-
vided is a culmination of the terminology used by the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 initiative [24], the PROS-
PERO register, and the IOM Standards (Table 2).
Scope
The PRISMA-P checklist is intended primarily for the
preparation of protocols of systematic reviews and meta-
analyses that summarize aggregate data from studies,
Table 1 PROSPERO and PRISMA-P
Definition and objective
PROSPERO: International Prospective
Register of Systematic Reviews
An online portal through which to register the intention to conduct a systematic review, with health-related
outcomes, before it is initiated [16]. One of the main goals of PROSPERO is to make the intent of systematic
reviews known before they are conducted in order to reduce the unplanned duplication of systematic
reviews [15]. In addition, by requiring the documentation of a priori methods, the register facilitates
increased transparency in the review process by allowing readers of systematic reviews to compare
methods, outcomes, and analyses carried out with those planned in advance and judge whether such
changes impact the results of a review.
PRISMA-P: Preferred Reporting Items for
Systematic Review and Meta-Analysis
Protocols
A guideline to help authors prepare protocols for planned systematic reviews and meta-analyses that
provides them with a minimum set of items to be included in the protocol. A protocol is intended to
provide the rationale for the review and pre-planned methodological and analytic approach, prior to
embarking on a review. Investigators should prepare a review protocol in advance of registering it in
PROSPERO so that details requiring further consideration may be thought through in advance, avoiding
the need for multiple amendments to registration information. PRISMA-P items have been derived largely
from the PRISMA checklist and items of the PROSPERO register, in order to facilitate seamless registration.
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particularly the evaluations of the effects of interven-
tions. There are many review types that are outside of
this scope. As such, given the general lack of protocol
guidance for other types of reviews, we encourage re-
viewers preparing any type of review protocol to make
use of PRISMA-P as applicable. Readers can also use the
checklist to assess the completeness of the reporting of
published protocols. However, it is not recommended to
use the checklist as an assessment tool to gauge the ap-
propriateness of the methods of a systematic review
protocol; it has not been validated for that purpose.
Development of PRISMA-P 2015
An international steering committee (MC, DG, AL, DM,
MP, PS, and LAS) comprising members with wide-ranging
experience in systematic review methodology, protocol
registry development, and reporting guideline development
led the development of PRISMA-P, coordinated by LS. The
process proposed by the Enhancing the Quality and Trans-
parency of Health Research (EQUATOR) Network was
used to guide PRISMA-P development [27]. The process
has 18 step-by-step recommendations grouped into five
main stages:
1. Initial steps (determine the need for a reporting
guideline);
2. Pre-meeting activities (identify contributors, conduct
Delphi exercise, generate a list of potential items,
and prepare for face-to-face meeting);
3. Face-to-face consensus meeting (present results of
pre-meeting activities and relevant evidence);
4. Post-meeting activities (develop guidance Statement,
Explanation and Elaboration document, and a
publication strategy);
5. Post-publication activities (encourage uptake of
guideline).
The first stage, ‘Initial steps,’ was described above; de-
tails of the remaining four steps are below.
Pre-meeting activities
In developing the PRISMA-P checklist, the steering
committee compiled a list of items from various tools
relating to the preparation of systematic review proto-
cols for discussion at a consensus meeting of experts.
Specifically, we mapped items from a Delphi exercise
carried out during the development of PROSPERO [28],
PROSPERO register items, PRISMA checklist items [13],
SPIRIT 2013 checklist items [29], and items of IOM
Standard 2.6 [11] against each other to identify unique
and overlapping concepts. Lessons learned from the de-
velopment of the SPIRIT checklist with respect to the
concept and content of research protocols were used to
guide discussion and debate at the meeting.
PRISMA-P consensus meeting
Twenty-three international experts attended the
PRISMA-P consensus meeting on June 23–24, 2011, in
Rockville, MD, USA to gain consensus on and reduce
the number of potential PRISMA-P items. Delegates in-
cluded journal editors, systematic review methodologists
(including directors and representatives from inter-
national Cochrane Centres, Agency for Healthcare Re-
search and Quality’s (AHRQ’s) Evidence-based Practice
Centres, and the UK National Institute for Health Re-
search), reporting guideline developers, information spe-
cialists, biostatisticians, and health research funders.
Through group discussion at the meeting, 38 potential
checklist items were reduced to 22.
Post-meeting activities
Following the meeting, the steering committee revised
the draft 22-item checklist and refined their wording
such that they accurately reflected meeting discussions.
The draft checklist was also presented to the PROS-
PERO group, at a scientific meeting of the Cochrane
Collaboration, for input and feedback and to AHRQ’s
Learning Network. After each of these reviews, the steer-
ing committee made minor amendments to the items.




A systematic review attempts to collate all relevant evidences that fits pre-specified eligibility criteria to answer a specific research
question. It uses explicit, systematic methods to minimize bias in the identification, selection, synthesis, and summary of studies.
When done well, this provides reliable findings from which conclusions can be drawn and decisions made [25,26]. The key
characteristics of a systematic review are (a) a clearly stated set of objectives with an explicit, reproducible methodology; (b) a
systematic search that attempts to identify all studies that would meet the eligibility criteria; (c) an assessment of the validity of the
findings of the included studies (e.g., assessment of risk of bias and confidence in cumulative estimates); and (d) systematic
presentation, and synthesis, of the characteristics and findings of the included studies
Meta-analysis Meta-analysis is the use of statistical techniques to combine and summarize the results of multiple studies; they may or may be
contained within a systematic review. By combining data from several studies, meta-analyses can provide more precise estimates
of the effects of health care than those derived from the individual studies
Protocol In the context of systematic reviews and meta-analyses, a protocol is a document that presents an explicit plan for a systematic
review. The protocol details the rationale and a priori methodological and analytical approach of the review
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The checklist was then circulated to all meeting invitees
for critical input.
The PRISMA-P 2015 checklist
The final PRISMA-P 2015 checklist contains 17 numbered
items (26 including sub-items) Items are categorized into
three main sections: administrative information, introduc-
tion, and methods (Table 3).
We made a conscious effort to harmonize the PRISMA-
P checklist items with the items of the PRISMA checklist
to facilitate authors in transitioning their protocol into
a report of a systematic review. Thirteen PRISMA-P
sub-items have existing PRISMA counterparts. Where
PRISMA wording or content did not sufficiently ad-
dress protocol reporting, checklist items were modified.
Readers familiar with PRISMA will notice that PRISMA-
P does not contain a flow diagram documenting the flow
of studies throughout the systematic review process. Such
documentation is possible only after a review has been car-
ried out and remains an essential component to include in
the report of a completed systematic review or meta-
analysis; for further guidance, see the PRISMA Explanation
and Elaboration document [12].
We strongly recommend that the present document
and the accompanying PRISMA-P 2015 Explanation and
Elaboration document [30], which includes examples of
good reporting, rationale, and evidence (where available),
be read together with the PRISMA-P 2015 checklist.
PRISMA-P 2015 explanation and elaboration
Once the steering committee prepared the PRISMA-P
2015 Statement and checklist, they drafted the content
of an Explanation and Elaboration document, with as-
sistance from the larger PRISMA-P group. The explana-
tory text was derived largely from discussions at the
PRISMA-P meeting (recorded at the time) as well as the
PRISMA Explanation and Elaboration document [12].
Examples of well-reported PRISMA-P items came from
protocols registered in the PROSPERO database,
AHRQ’s EPC Program, and the Cochrane Database of
Systematic Reviews or those published elsewhere. After
the entire group had an opportunity to suggest addi-
tions, deletions, and changes, the steering committee
combined all amendments to create the PRISMA-P 2014
Explanation and Elaboration document [30].
Post-publication activities
The post-publication activities recommended by EQUA-
TOR include seeking and responding to criticism, encour-
aging the endorsement of and adherence to the guideline
from various stakeholders, translating the guideline into
other languages, evaluating its impact, ensuring website
development, and updating of the guideline. The
PRISMA-P 2015 checklist and related publications are
freely available on the websites of the PRISMA Group
(www.prisma-statement.org) and EQUATOR Network
(www.equator-network.org). The PROSPERO register
also contains a link to the guidance to encourage regis-
trants to prepare a complete documentation of their
protocol if they have not done so already.
We plan to develop an educational webinar about the
rationale, usefulness, and potential impact of PRISMA-P,
similar to what was done for PRISMA [31]. In addition,
the potential for PRISMA-P 2015 to be used as an educa-
tional tool for authors, peer reviewers, and editors will be
explored. Targeted implementation activities for PRISMA-
P will be developed in a systematic manner together with
experts in knowledge translation. The PRISMA website
and social media (@PRISMAStatement, www.twitter.
com/PRISMAStatement) will be used to make an-
nouncements about the launch of PRISMA-P and edu-
cational initiatives.
Endorsement
We encourage journals publishing systematic review prod-
ucts to modify their ‘Instructions for Authors’ section to
endorse PRISMA-P 2015 and to consider publishing sys-
tematic review protocols, if they do not do so already. We
plan to communicate with known endorsers of PRISMA
(http://prisma-statement.org/endorsers.htm) as well as to
other, relevant non-endorsing journals, to ask them to
consider extending their support to PRISMA-P.
To help ensure optimal uptake by systematic reviewers,
we propose a uniform endorsement policy across organi-
zations and journals involved in the development and
publication of systematic review protocols, demonstrated
by the adoption of the following statement:
‘[this organization/journal] requires a completed
PRISMA-P 2015 checklist as a condition of submission
of systematic review protocols. We recommend that,
while completing the PRISMA-P 2015 checklist, you
ensure your protocol addresses all items. Taking the
time to ensure that your protocol adheres to these
basic reporting elements will improve your manuscript
and potentially enhance its chances of eventual
acceptance.’
Such a statement could be included in a journal’s ‘In-
structions to Authors,’ or for funding agencies and those
commissioning systematic reviews, in their Application
Guidelines, recommending that applicants developing
the proposals of systematic reviews for funding use
PRISMA-P 2014. Peer reviewers and scientific commit-
tees can also use the checklist to gauge the extent to
which protocols include necessary information.
As has been done for previous reporting guidelines
[18,32] we plan to evaluate whether and to what degree
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Table 3 PRISMA-P 2015 checklist: recommended items to include in a systematic review protocola
Section/topic Item # Checklist item
ADMINISTRATIVE INFORMATION
Title
Identification 1a Identify the report as a protocol of a systematic review
Update 1b If the protocol is for an update of a previous systematic review, identify as such
Registration 2 If registered, provide the name of the registry (e.g., PROSPERO) and registration number
Authors
Contact 3a Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical
mailing address of corresponding author
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol,
identify as such and list changes; otherwise, state plan for documenting important protocol
amendments
Support
Sources 5a Indicate sources of financial or other support for the review
Sponsor 5b Provide name for the review funder and/or sponsor
Role of sponsor/
funder
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION
Rationale 6 Describe the rationale for the review in the context of what is already known
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants,
interventions, comparators, and outcomes (PICO)
METHODS
Eligibility criteria 8 Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics
(e.g., years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources 9 Describe all intended information sources (e.g., electronic databases, contact with study authors,
trial registers, or other grey literature sources) with planned dates of coverage
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned
limits, such that it could be repeated
Study records
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review
Selection process 11b State the process that will be used for selecting studies (e.g., two independent reviewers) through each
phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)
Data collection process 11c Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in
duplicate), any processes for obtaining and confirming data from investigators
Data items 12 List and define all variables for which data will be sought (e.g., PICO items, funding sources), any
pre-planned data assumptions and simplifications
Outcomes and
prioritization
13 List and define all outcomes for which data will be sought, including prioritization of main and
additional outcomes, with rationale
Risk of bias in
individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will
be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data
Synthesis 15a Describe criteria under which study data will be quantitatively synthesized
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of
handling data, and methods of combining data from studies, including any planned exploration of
consistency (e.g., I2, Kendall’s tau)
15c Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)
15d If quantitative synthesis is not appropriate, describe the type of summary planned
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endorsement of PRISMA-P 2015 by journals (and poten-
tially by other organizations) influences the complete-
ness of reported protocols. Such an evaluation will be
planned after allowing sufficient time for the wide dis-
semination of PRISMA-P 2015.
Implementation
The current system of implementing reporting guide-
lines is not optimal. At present, their primary mechan-
ism of uptake is through endorsement by journals at
their discretion, if at all. In journals that do endorse
Table 3 PRISMA-P 2015 checklist: recommended items to include in a systematic review protocola (Continued)




17 Describe how the strength of the body of evidence will be assessed (e.g., GRADE)
PRISMA-P Preferred Reporting Items for Systematic review and Meta-Analysis Protocols.
aIt is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration [30] for important clarification on the items.
Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed
under a Creative Commons Attribution License 4.0.
Table 4 Proposed stakeholders, actions, and potential benefits for supporting adherence to PRISMA-P
Stakeholder Proposed action Potential benefits
Funders Promote or mandate adherence to PRISMA-P or use PRISMA-P as
a template for systematic review proposals for grant applications
Improved quality, completeness, and consistency
of systematic review proposal submissions
Standardized protocol content will improve peer




Use/adhere to PRISMA-P during protocol development Improved quality, completeness, and consistency
of protocol content
Enables reviewers to anticipate and avoid future
changes to review methods (i.e., outcomes)
Increased awareness of minimum content for
protocol reporting




Encourage the development of PRISMA-P-based protocols Improved quality of registry entries
Improved consistency across registry entries,
protocols, and systematic reviews
Practice guideline
developers
Use PRISMA-P to gauge the completeness of protocols and
facilitate detection of selective reporting when considering
reviews for guideline inclusion
Enables easy comparison across protocols, registry
entries, and completed systematic reviews
Policymakers Advocate use of PRISMA-P by those funding and carrying
out systematic reviews
May yield better quality, more complete, and more
consistent reviews to inform decision-making
Journal editors Encourage compliance to PRISMA-P for authors submitting
protocols for publication
Improved quality, completeness, and consistency
of protocols over those published in journals not
endorsing PRISMA-P
Offer PRISMA-P as a template to assist in protocol
writing for publication
Increased efficiency in protocol peer and
author understanding of journal requirements
Improved transparency and interpretation
of reviews by readers
Educators Use PRISMA-P as a training tool Simplified teaching and grading of protocols
Encourage adherence in students submitting protocols
for coursework
Improved quality, completeness, and
consistency of protocol content
Students Develop protocols for coursework or research using PRISMA-P Improved understanding of the minimum
protocol content
Well-trained systematic reviewer going
into the workforce
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guidelines, language describing their support is often
vague, leaving authors unclear on what they are sup-
posed to do with a given reporting guideline during the
submission process [33]. Furthermore, policies around
how journal editors and peer reviewers should ensure
and/or enforce adherence to reporting checklists are
even less clear, if they exist at all [34]. Other barriers to
implementation may include a lack of awareness of the
guideline and perceived burden of using a reporting
guideline checklist during the editorial process [35].
Some well-known checklists, such as PRISMA, include
a column to the right of the main checklists in which
users report the page number on which a specific item is
reported. This was initially intended to help authors en-
sure each checklist item is addressed and to aid peer re-
viewers in locating reported text for each item within a
document. However, this system is not optimal. One
major problem is that peer reviewers still have to search
within a considerable body of text to locate the exact
text describing a checklist item. When multiple items
are listed separately but reported together or vice versa,
this problem is compounded, because exactly which
content pertains to each item may remain unclear.
The lack of implementation and adherence to report-
ing guidelines is systemic; additional authorities encoun-
tered early in the research process should promote a
clearer message about author adherence to reporting
standards if improvements in reporting are to be made.
In targeting protocols of systematic reviews, PRISMA-P
has a unique opportunity to not only affect the way in
which protocols are reported but to also impact the way
in which reviews are eventually conducted, perhaps
allowing for a more seamless transition into a com-
pletely reported systematic review.
To overcome known challenges with reporting guideline
uptake [36,37], we are developing a prospective imple-
mentation strategy for PRISMA-P 2015 using knowledge
translation principles involving theoretically derived inter-
ventions [37] which have demonstrated effectiveness in
the development of implementation interventions for clin-
ical practice guidelines [38,39]. An initial list of proposed
stakeholders who can assist in the implementation of
PRISMA-P, along with proposed actions and benefits, is
provided in Table 4.
Discussion
Studies comparing trial protocols to final reports have
widely documented both the presence and the extent of
reporting biases in publications of randomized trials
[2,40]. Protocols for systematic reviews are rarely available
for such comparisons, with the exception of select organi-
zations. Of 288 reviews with available protocols in a 2006/
2007 cohort, 64 (22%) were observed to have at least one
discrepant outcome with their completed reviews; only 4
described reasons for the change in the completed review
[3]. Discrepant outcomes added or upgraded from second-
ary to primary at the review stage were more likely to be
statistically significant than those outcomes that had not
changed. This practice (i.e., including, excluding, or chan-
ging outcomes in association with the strength or direc-
tion of findings) has the potential to bias the findings of
any meta-analysis and the review’s conclusions. As review
protocols are expected to become increasingly available
with the advent of PROSPERO, clear reporting will be-
come essential to facilitate the identification of discrepan-
cies between protocol and review by readers and help
them determine whether they need to be cautious in inter-
preting findings.
Reporting and publishing protocols is an important step
in increasing the transparency of the research process and
reliability of published papers. For example, some journals
require a copy of the protocol as part of the peer review
process of randomized trials. As of 1 March 2014, BioMed
Central has published 4,158 trial protocols across 66 of its
258 open-access journals, including 1,026 in Trials. Sys-
tematic Reviews, a BioMed Central journal launched in
February 2012, is committed to publishing systematic re-
view products, including protocols [41], and has published
142 protocols since inception (to 8 June 2014).
Journals, granting agencies, and systematic review or-
ganizations are encouraged to endorse PRISMA-P 2015
in their ‘Instructions to Authors’ and guidance for appli-
cants and to implement its use during their peer review
process of systematic review proposals. Reviewers are
encouraged to use the PRISMA-P checklist and Explan-
ation and Elaboration [30] document to guide them
through the documentation of a protocol. Doing so will
enhance the completeness of reporting of review proto-
cols, facilitate the assessment of potential in systematic
reviews, and hopefully strengthen the methodological
quality and reliability of completed systematic reviews.
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Abstract
Objectives: To examine outcome reporting bias of systematic reviews registered in PROSPERO.
Study Design and Setting: Retrospective cohort study. The primary outcomes from systematic review publications were compared
with those reported in the corresponding PROSPERO records; discrepancies in the primary outcomes were assessed as upgrades, additions,
omissions, or downgrades. Relative risks (RRs) and 95% confidence intervals (CI) were calculated to determine the likelihood of having a
change in primary outcome when the meta-analysis result was favorable and statistically significant.
Results: Ninety-six systematic reviews were published. A discrepancy in the primary outcome occurred in 32% of the included reviews and
39%of the reviews did not explicitly specify a primary outcome(s); 6% of the primary outcomeswere omitted. Therewas no significant increased
risk of adding/upgrading (RR, 2.14; 95% CI: 0.53, 8.63) or decreased risk of downgrading (RR, 0.76; 95% CI: 0.27, 2.17) an outcome when the
meta-analysis resultwas favorable and statistically significant.Aswell, therewas no significant increased riskof adding/upgrading (RR,0.89; 95%
CI: 0.31, 2.53) or decreased risk of downgrading (RR, 0.56; 95% CI: 0.29, 1.08) an outcome when the conclusion was positive.
Conclusions: We recommend review authors carefully consider primary outcome selection, and journals are encouraged to focus
acceptance on registered systematic reviews. ! 2016 Elsevier Inc. All rights reserved.
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1. Introduction
The Cochrane Handbook for Systematic Reviews of In-
terventions [1] states that systematic reviewers should
prepare a systematic review protocol before their review
conduct, to encourage transparency of reporting hypotheses
and methods (including outcomes) and avoid outcome
reporting bias. This is consistent with the Institute of Med-
icine Standards for Systematic Reviews [2]. As well, the
Cochrane Handbook [1] and Preferred Reporting Items
for Systematic reviews and Meta-Analyses Statement [3]
state that any changes to the protocol should be fully docu-
mented and explained in the systematic review publication.
Despite this guidance, research consistently has found that
more than one-third of published systematic reviews have
an undisclosed discrepancy between the outcomes reported
in the protocol vs. final review [4e7].
In the most simplistic definition, outcome reporting bias
‘‘occurs when a study in which multiple outcomes were
measured reports only those that are (statistically) significant’’
[8]. Previous studies have compared final Cochrane review
methods to those reported in the review protocols [4e7],
including a recent Cochranemethodology review on outcome
reporting bias [9]. One of these studies found evidence of
outcome reporting bias, in which statistically significant out-
comes were more likely to be upgraded (i.e., promoted from
secondary to primary) or added in the final publication
compared to the protocol [5]. All these studies included a sam-
ple of systematic reviews published in the Cochrane Database
of Systematic Reviews before the year 2009.
The International Prospective Register of Systematic
Reviews (PROSPERO) was established in 2011 [10] and
is the only open-access online facility to prospectively reg-
ister non-Cochrane systematic reviews. Because most pub-
lished systematic reviews are not Cochrane reviews [11],
this register of review protocol details is likely a more
representative sample of systematic reviews in the litera-
ture. No previous study has explored outcome reporting
bias of systematic reviews registered in PROSPERO. As
such, we aimed to (1) examine whether outcome reporting
bias exists, and to what extent, in published systematic re-
views registered in PROSPERO and (2) assess the method-




Before conducting this retrospective cohort study, we
created a project plan, which outlined our study methods.
Our protocol was revised after receiving feedback from
all authors. The final protocol can be found in Appendix
A at www.jclinepi.com. Because this study was not a sys-
tematic review, it was not eligible to be registered with
the PROSPERO repository.
2.2. Sample of systematic reviews
We aimed to identify all completed systematic reviews
of interventions that were registered in PROSPERO. On
November 29, 2013, all records from the PROSPERO data-
base identified as ‘‘completed and published’’ were down-
loaded. These records also include the citation/link to the
final publication. PROSPERO includes an audit trail for
protocol amendments and progress reports. In this study,
the protocol record used was the version immediately
before the version where the Named Contact updated the
record to report that the review had been completed. Our
scope was limited to systematic reviews of interventions
to allow the comparison of statistically significant meta-
analysis results, which would not be feasible for other re-
view products (e.g., diagnostic reviews, prognostic reviews,
prevalence reviews). Only non-Cochrane reviews were
included. Completed reviews not published in English were
also excluded, due to resource limitations.
2.3. Data abstraction process
A data abstraction form with an explanation guide was
developed (Appendix Table A at www.jclinepi.com) and
calibrated through a team exercise. Specifically, the team
independently pilot tested the forms using a random sample
of 10 included systematic reviews. Data abstraction did not
commence until high agreement (O90%) was achieved.
Subsequently, three pairs of reviewers abstracted each of
the systematic review publications, independently. To
ensure consistency across the team regarding the classifica-
tion of outcomes, one team member verified all the data
(E.C.) and resolved discrepancies.
2.4. Data items
The data items were abstracted from both the protocol
details and the publication and included study characteris-
tics (e.g., year of publication, number of studies included,
type of studies included, whether meta-analysis was con-
ducted, source of funding), number of primary outcomes,
changes in primary outcomes from the PROSPERO record
to review publication, reasons for changes in primary out-
comes (if reported), meta-analysis results, and conclusions.
The reason we focused on primary outcomes is because this
is the outcome of greatest interest and importance. Similar
research on outcome reporting bias has used this approach
[4e7].
If the primary outcome(s) was not explicitly stated in
the publication (i.e., not specifically called a ‘‘primary’’
outcome), the following decision-tree approach [12,13]
was used to ‘‘derive’’ the primary outcome(s), by select-
ing the outcome that met the first of the following
criteria: (1) the outcome(s) listed in the title; (2) the out-
come(s) listed in the objectives; and (3) the most serious
outcome (e.g., mortality). To facilitate comparison across
studies, all changes in primary outcomes from the
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What is new?
Key finding
! Many systematic reviews that are registered in
PROSPERO have discrepancies in primary out-
comes between their record and review
publication.
What this study adds to what was known?
! This is the first study to examine outcome report-
ing bias using the PROSPERO register, a database
for prospectively registering systematic reviews
that was established in 2011.
! Previous studies have compared outcomes reported
in Cochrane reviews to those reported in the corre-
sponding review protocols. These studies found
that more than one-third of published systematic
reviews had a discrepancy between the outcomes
reported in the protocol vs. final publication. One
study found evidence of outcome reporting bias,
in which statistically significant outcomes were
more likely to be upgraded (i.e., promoted from
secondary to primary) or added in the final publica-
tion compared to the protocol.
! We found that approximately one-third of pub-
lished systematic reviews had a discrepancy be-
tween the outcomes reported in the PROSPERO
record vs. the review publication. However, evi-
dence of outcome reporting bias was not observed.
What is the implication and what should change
now?
! Our study suggests that non-Cochrane review au-
thors have similar outcome reporting behaviors to
Cochrane review authors. We recommend that all
non-Cochrane reviews are registered with
PROSPERO, review authors carefully consider
the selection of primary outcomes, peer reviewers
should check PROSPERO to see if there are any
discrepancies between the record and review pub-
lication, and journals are encouraged to focus
acceptance on registered systematic reviews.
PROSPERO record to the systematic review publication
were coded using the same classification scheme used in
the Parmelli et al. [7] and Kirkham et al. [5] studies. These
categories were new inclusion of outcomes (or additions),
exclusion, upgrade, and downgrade of outcomes (Box 1).
The meta-analysis results were categorized using a previous
approach [13], including favorable and statistically signifi-
cant, favorable and not statistically significant, neutral,
unfavorable and not statistically significant, and unfavor-
able and statistically significant (Box 1, Appendix Fig. A
at www.jclinepi.com). The conclusions were obtained from
the abstract and discussion sections from the systematic re-
views and were categorized using a previous approach [13],
including positive, neutral, negative, and indeterminate
(Box 1).
We used the same hierarchy reported by Kirkham et al.
[5] to select meta-analyses from systematic reviews with
multiple treatment group comparisons. Specifically, we
selected the first intervention comparison which met the
following criteria: ‘‘(1) an intervention comparison
described in the protocol as the primary review comparison;
(2) the first intervention comparison mentioned in the title
of the protocol; (3) an intervention comparison described
in the review as the primary review comparison; (4) the first
intervention comparison mentioned in the objectives of the
review; and (5) the intervention comparison used in the first
meta-analysis presented in the review.’’
Box 1 Classification: primary outcomes, meta-
analysis results, and conclusion statements
Classification of changes to primary outcomes:
! New (inclusion or addition): the addition of a completely new
primary outcome;
! Exclusion: the omission of a primary outcome in the
publication;
! Upgrade: when a secondary outcome in the protocol was
changed to a primary outcome in the publication;
! Downgrade: when a primary outcome in the protocol was
changed to a secondary or undefined outcome in the
publication.
Classification of meta-analysis results:
! Favorable, statistically significant (i.e., effect in favor of the
intervention with P " 0.05);
! Favorable, nonstatistically significant;
! Neutral (effect size between 0.95 and 1.05 and the confi-
dence interval crosses 1);
! Unfavorable, statistically significant (i.e., effect in favor of
the nonintervention comparator with P " 0.05);
! Unfavorable, nonstatistically significant.
Categorization of conclusion statements
! Positive (authors stated that there is evidence of
effectiveness);
! Neutral (no evidence of effectiveness or they reported no
opinion);
! Negative (authors advised against the use of the intervention
or it was not recommended); or
! Indeterminate (authors stated that there is insufficient evi-
dence or that more research is required).
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2.5. Methodological quality appraisal
The overall methodological quality of the systematic re-
views was assessed using the Assessment of Multiple
SysTemAtic Reviews (AMSTAR) tool (Appendix Table B
at www.jclinepi.com) [14]. The scores range from 0 to
11, with higher scores indicating superior quality. For our
study, a score of 8 or higher was considered higher quality.
This assessment was conducted to ascertain the overall
quality of completed and published systematic reviews that
were registered in PROSPERO.
2.6. Analysis
We explored the association between statistical signif-
icance of meta-analysis results and adding, upgrading, or
downgrading of outcomes compared to no discrepancies,
by calculating a relative risk (RR) and 95% confidence
interval (CI), where the meta-analysis results were dichot-
omized into favorable and statistically significant vs. any
of the other four categories. The formula is
RR5#a=$a % b&'O#c=$c % d&', where a is the number
of meta-analysis outcomes that are discrepant and have
a favorable and statistically significant result, b is the
number of meta-analysis outcomes that are not discrepant
and have a favorable and statistically significant result, c
is the number of meta-analysis outcomes that are
discrepant and do not have a favorable and statistically
significant result, and d is the number of meta-analysis
outcomes that are not discrepant and do not have favor-
able and statistically significant result. This analysis was
similar to those conducted by Page et al. [9] in their Co-
chrane review of outcome reporting bias. The RR and
95% CI were calculated for outcomes that were explicitly
reported as primary outcomes, as well as including those
that were derived using the classification scheme reported
above. Our hypotheses were that when the meta-analysis
result was favorable and statistically significant, adding/
upgrading of outcomes would be more likely, whereas
downgrading of outcomes would be less likely. A sensi-
tivity analysis was also conducted consistent with the
analysis method used by Kirkham et al. [5], to allow
comparability of results. For this analysis, the meta-
analysis results were dichotomized into statistically sig-
nificant vs. not statistically significant, and the hypotheses
were that new/upgraded outcomes would be more likely to
have statistically significant meta-analysis results,
whereas downgraded outcomes would be less likely, than
if there was no discrepancy.
We also conducted a post hoc analysis for systematic re-
views that were funded. Similar to our primary analysis, we
explored the association between statistical significance of
meta-analysis results and adding, upgrading, or downgrad-
ing of outcomes compared to no discrepancies by calcu-
lating an RR and 95% CI, where the meta-analysis results
were dichotomized into favorable and statistically
significant vs. any of the other four categories. This anal-
ysis was repeated for systematic reviews that did not have
funding. Sensitivity analyses were also conducted using
the Kirkham et al. [5] approach.
The RR and 95% CI were calculated for obtaining a pos-
itive conclusion for new primary outcomes or upgrades, and
downgrades compared to no discrepancies (where conclu-
sions were categorized as positive vs. all other conclusion
types). Our hypotheses were that when the conclusion
was positive, adding/upgrading of outcomes would be more
likely, whereas downgrading of outcomes would be less
likely. A sensitivity analysis was also conducted to calcu-
late the RR and 95% CI using a similar approach as to
Kirkham et al. [5]. For this sensitivity analysis, our hypoth-
esis was that when outcomes were added or upgraded, a
positive conclusion would be more likely, whereas when
outcomes were downgraded, a positive conclusion would
be less likely.
3. Results
3.1. Sample of PROSPERO records
In November 2013, 2,426 protocol records were regis-
tered with PROSPERO and 343 were completed systematic
reviews (Fig. 1). Of the completed reviews, 140 were
potentially relevant (i.e., published or in press), and of
these, 44 were excluded because they were not systematic
reviews of interventions or the final review was not written
in English (Appendix Table C at www.jclinepi.com).
Ninety-six systematic reviews fulfilled the eligibility
criteria and were subsequently included (Appendix Table
C at www.jclinepi.com).
3.2. Systematic review characteristics
Eighty-nine (92.7%) of the systematic reviews were
published between 2012 and 2013, and 4 (4.2%) were pub-
lished in 2014, as they were in press at the time we down-
loaded their PROSPERO records. Eighty-one (84.3%)
included 2 to 30 studies, 56 (58.3%) limited inclusion to
randomized controlled trials, and 67 (68.8%) conducted a
meta-analysis (Table 1). In addition, 36 (37.5%) reported
no source of funding, 45 (46.9%) were conducted in the
United Kingdom or North America, and 5 (5.2%) published
their protocol in a journal.
3.3. Methodological quality
Eight of the 11 AMSTAR items were adequately ad-
dressed by more than 72 (75%) of the systematic reviews
(Fig. 2, Appendix Table D at www.jclinepi.com). Howev-
er, 72 (75%) of the reviews did not state conflicts of inter-
est for included studies and review authors, 63 (66%) did
not provide a list of excluded studies, 39 (41%) did not
assess publication bias where it would have been
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appropriate to do so, and 14 (15%) did not consider meth-
odological quality or risk of bias results in their conclu-
sion statements.
3.4. Outcome reporting
Although the primary outcome was indicated in PROS-
PERO, which is structured to separate primary and second-
ary outcomes, it was not explicitly reported for 37 (38.5%)
of the completed systematic reviews, so was derived in this
study (Table 2). The primary outcomes were derived using
the title (35.2%), objectives (24.3%), or were the most
serious outcomes (40.5%). Thirty-one (32.3%) of the
systematic reviews had a discrepancy between the primary
outcomes reported in the PROSPERO record and final pub-
lication, whereas 65 (67.7%) had no discrepancies
(Table 3). Of the reviews with discrepancies, 6 (5.9%)
had a new primary outcome, 6 (5.9%) excluded a primary
outcome, 6 (5.9%) upgraded an outcome, and 22 (21.8%)
downgraded a primary outcome. One (1.0%) of the system-
atic reviews reported a reason for changing their primary
outcome. Six (5.9%) systematic reviews reported a change
in their primary outcome definition, and 1 (1.0%) changed
the measurement method for the primary outcome.
3.5. Meta-analysis results
The results of 139 meta-analyses in 67 systematic re-
views are presented in Appendix Table E at www.jclinepi.
com. There was no significant increased risk of adding or
upgrading an outcome when the meta-analysis result was
favorable and statistically significant (RR, 2.14; 95% CI:
0.53, 8.63), which was the same result as found in our
sensitivity analysis (Appendix Table F at www.jclinepi.
com). This result was unchanged when only the primary
outcomes that were explicitly reported were included in
our analysis (RR, 2.02; 95%: CI 0.35, 11.56; Appendix
Table G at www.jclinepi.com). Furthermore, there was no
significant decreased risk of downgrading an outcome when
the meta-analysis result was favorable and statistically sig-
nificant (RR, 0.76; 95% CI: 0.27, 2.17), and the same result
was observed in our sensitivity analysis. Similarly, when
only the primary outcomes that were explicitly reported
were included in our analysis, no statistically significant re-
sults were observed for downgrades (RR, 1.37; 95% CI:
0.20, 9.42). Calculations were not possible for excluded
primary outcomes because they were absent from the pub-
lications (by definition).
A post hoc analysis was conducted for systematic
reviews with funding and without funding (Appendix
2,426 registered systematic 
reviews of which 343 were 
completed systematic reviews
203 excluded records because 
systematic review was not published
140 potentially 
relevant records 
(completed and published 
systematic reviews)
96 included systematic review 
PROSPERO records
44 excluded records:
• 43 were not a systematic review 
of an intervention
• 1 final report was not published 
in English
Fig. 1. Flow of systematic reviews through the study.
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Tables HeJ at www.jclinepi.com). No statistically signifi-
cant results were observed in our overall analysis or sensi-
tivity analyses.
3.6. Conclusion statements
The categorization of conclusions for all included sys-
tematic reviews is presented in Appendix Table K at
www.jclinepi.com. There was no significant increased risk
of adding or upgrading outcomes when the conclusion
was positive (RR, 0.89; 95% CI: 0.31, 2.53). Furthermore,
there was no significant decreased risk of downgrading an
outcome when the conclusion was positive (RR, 0.56;
95% CI: 0.29, 1.08). Our sensitivity analyses also found
no significant risk of a positive conclusion when the out-
comes were added/upgraded or downgraded (Appendix
Table L at www.jclinepi.com).
4. Discussion
One-third of published systematic reviews that were
registered with PROSPERO had a discrepancy between
the primary outcome reported in their record and the pri-
mary outcome reported in the review publication. Of the
discrepancies, downgrading of primary outcomes was most
common (22%), and 6% of reviews omitted a protocol-
specified primary outcome from the review. In addition,
39% of reviews did not explicitly specify a primary out-
come(s) in the review. Although a lot of discrepancies were
observed, we did not find statistically significant associa-
tions between discrepant outcome reporting and having a
favorable and statistically significant meta-analysis result
or positive conclusion. However, the small number of re-
views within each subgroup of discrepancy classification
likely limited the statistical power to detect statistically sig-
nificant results. PROSPERO has now passed 10,000 re-
cords, and repeating this study is likely to yield a larger
number of published systematic reviews to examine.
Our study is the first to measure outcome reporting bias of
systematic reviews that were registered in PROSPERO. To




















Not reported 31 (32.3)
Study designs included
All randomized controlled trials 56 (58.3)
Mixed study designsa 35 (36.5)





Stated no funding received 36 (37.5)
Public funder (e.g., academia,
government)
56 (58.4)
Commercial organization 4 (4.2)
Geographic regionc
Europe 47 (49)
North America 20 (20.9)
South America 11 (11.4)
Eastern Asia 9 (9.3)
Australia 5 (5.2)
Southern Asia 2 (2.1)
Southern Africa 2 (2.1)
Published protocol in a journal
Yes 5 (5.2)
No 91 (94.8)
Participant population in publicationd
Healthy or presumed healthy 14 (14.6)
Mixed conditions 11 (11.5)
Musculoskeletal conditions 10 (10.4)
Infectious diseases 9 (9.4)




Psychiatric/mental health conditions 7 (7.3)
Cardiovascular conditions 6 (6.3)
Respiratory conditions 6 (6.3)








Oral-related conditions 2 (2.1)
Urinary conditions 2 (2.1)







Type 2 diabetes 1 (1.0)
Abbreviation: RCT, randomized controlled trial.
a Mixed could indicate, for example, RCT and quasi-RCT (not
necessarily mixed with observational studies).
b Source: Cochrane EPOC Group. Available at: http://epoc.
cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionche
cklist.pdf.
c If more than one country was listed (n 5 8), only the first coun-
try’s geographic region is listed here.
d As reported by the review authors.
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examine this issue, we systematically searched for 96 sys-
tematic reviews published between 2011 and 2014. We
abstracted data in duplicate, which were triple checked by
a third reviewer, and appraised the included reviews using
the AMSTAR tool. The included systematic reviews were
of high methodological quality, on average. Areas for
improvement included providing a list of excluded studies,
assessing publication bias when appropriate (as per the
AMSTAR criterion), and reporting conflicts of interest for
the systematic review authors, as well as for the included
studies.
Our results are only generalizable to intervention reviews,
as the risk of outcome reporting bias in other types of reviews
(e.g., diagnostic reviews) remains unknown.Aswell, we only
included non-Cochrane reviews. We considered only pri-
mary outcomes, which may have underestimated the occur-
rence of outcome reporting bias for all types of outcomes.
Fig. 2. AMSTAR methodological quality results. Items: 1. a priori design, 2. duplicate selection/DA, 3. literature search, 4. publication status, 5.
list of studies, 6. study characteristics, 7. quality assessed, 8. quality used, 9. methods appropriate, 10. publication bias assessed, and 11. con-
flicts stated. AMSTAR, Assessment of Multiple SysTemAtic Reviews; NA, not applicable.
Table 2. Number of primary outcomes in the publications
Outcome details # of systematic reviews (%)










Number derived per review








NA (were explicit) 59 (61.5)
Method 1dfrom title 13 (13.5)
Method 2dfrom objectives 9 (9.4)
Method 3dmost serious 15 (15.6)
Abbreviation: NA, not applicable.





New primary outcome(s) 6 (5.9)
Exclusion of primary outcome(s) 6 (5.9)
Upgrade of primary outcome(s) 6 (5.9)
Downgrade of primary outcome(s) 22 (21.8)
Change in primary outcome definition 6 (5.9)
Change in primary outcome measure 1 (1.0)
No discrepancies 65 (67.7)
a Does not add up to 100% because some systematic reviews
included more than one primary outcome.
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However, this is the same approach to other studies exam-
ining outcome reporting bias [4e7]. Limited resources
meant that we were unable to contact authors of the
discrepant systematic reviews to determine the reason for
these inconsistencies. Only one review reported a rationale
for changing the outcome, whichmakes it difficult to provide
definitive conclusions as to why these changes may occur
[15]. The reason that was reported by the authors was that
the clinical experts on their team selected the most clinically
important outcomes, which did not align with what was re-
ported in their PROSPERO record. We were unable to
include a larger sample of published and completed system-
atic reviews, due to resource restraints. Because of the small
number of included reviews in our analyses, we were unable
to examine possible sources of heterogeneity that may have
confounded our results or conduct subgroup analysis for
outcome reporting bias for systematic reviews with active
comparators vs. placebo, ‘‘high’’ vs. ‘‘low’’ quality as per
the AMSTAR tool, and randomized trials vs. nonrandomized
studies. As well, there is a chance that there were more
completed systematic reviews that were published, but the
authors of the review failed to update their PROSPERO re-
cord (although they are sent three autoreminders to update
their information in PROSPERO). We were only able to
include the systematic reviews withmeta-analyses in our sta-
tistical analysis of outcome reporting bias, which is consis-
tent with previous studies [4e7]. Finally, we calculated risk
ratios instead of odds ratios to compare our study with previ-
ous studies conducted in this area.
A recent Cochrane review [9] included four previous
studies that examined discrepancies in outcome reporting
between systematic review protocols and published system-
atic reviews [4e7]. All these studies included Cochrane re-
views that were published between 2000 and 2009, and
none appraised the methodological quality of included sys-
tematic reviews using the AMSTAR tool. A total of 485
Cochrane reviews were included, and discrepancies were
identified in 38% of these. A meta-analysis of two of the
studies was conducted, and no statistically significant asso-
ciation between statistical significance of meta-analysis re-
sults and discrepant outcome reporting (adding, upgrading,
or downgrading) was found. These results are consistent
with those observed in our study.
Our results suggest that authors of non-Cochrane re-
views are similar to Cochrane review authors in their
outcome reporting behaviors. It is possible that systematic
review authors are not focused on identifying primary out-
comes of interest at the protocol stage and are instead just
completing the PROSPERO form. Furthermore, as registra-
tion in PROSPERO is voluntary (and is relatively new), it is
possible that our sample (as well as studies using samples
of Cochrane reviews) underestimated the overall number
of primary outcome discrepancies in systematic reviews
in general.
Using pre-established methods [16], we estimate that
17,399 systematic reviews were published in 2013. During
this time, 1,612 Cochrane reviews were registered and
1,526 non-Cochrane reviews were registered with
PROSPERO. This means that only 18% of published sys-
tematic review authors registered their protocol. As such,
we recommend that all non-Cochrane reviews are regis-
tered with PROSPERO. Furthermore, review authors are
advised to consider the selection of primary outcomes care-
fully and report the explanations for protocol modifications
in the final review publication. Review authors should think
about the importance of outcomes before embarking on
their review and limit the number of outcomes to ensure
that those selected are both necessary and meaningful. Core
outcome sets have been recommended for trials (COMET
initiative, http://www.comet-initiative.org/), and it is rec-
ommended that systematic review authors are familiar with
this guidance when selecting outcomes for inclusion in
their review. Peer reviewers should check PROSPERO to
see if there are any discrepancies between the record and
review publication and ensure that the author explains
these. Finally, journals are encouraged to focus acceptance
on registered systematic reviews, as we found that these are
likely to be of high methodological quality.
Few studies have examined outcome reporting bias in sys-
tematic reviews [9]. There has been no study of systematic re-
views that are not registeredwith the CochraneCollaboration
or PROSPERO. This could be done by contacting review au-
thors to obtain their unpublished protocol, if one exists.
Future research should examine a larger sample of PROS-
PERO records as this database matures and examine the dis-
crepancies in primary outcomes reported in the abstract and
full text of the published systematic reviews.
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Appendix A. Study protocol  
Team: Andrea C. Tricco, Elise Cogo, Alison Booth, David Moher, Sharon E. Straus, Julie 
Polisena, Tammy Clifford, Lesley Stewart, Kerry Dwan, Matthew Page. 
 
Background and rationale: 
A study protocol helps reduce the risk of bias in a systematic review by specifying a priori 
hypotheses and methods. Outcome reporting bias is a recognized problem in clinical trials but 
has been less studied in systematic reviews. We plan to conduct the first study using the 
International Prospective Register of Systematic Reviews (PROSERO) to compare systematic 
review publications to their protocol details. Four similar studies focused their research on 
Cochrane reviews [4-7] and found a substantial number of changes in outcomes between the 
protocol and completed reviews. The PROSPERO database is another source of systematic 
review protocol details, which might be a more generalizable sample of systematic reviews 
versus those from the Cochrane Collaboration. 
 
As of October 9, 2013, there are 95 completed publications of systematic review protocol details 
that were registered with the PROSPERO database. We will compare the results generated by 
this sample of systematic reviews with the previous studies [4-7,17]. If similar results are found, 
we will submit a paper for publication. However, if we obtain different results, we will use the 
data to apply for a CIHR open operating grant targeting the spring 2014 competition. The grant 
will propose to examine the risk of outcome reporting bias using the entire sample of systematic 
reviews that were registered in the PROSPERO register. 
 
Objectives: 
1. To assess whether outcome reporting bias exists, and to what extent, in published systematic 
reviews registered in PROSPERO.  
2. To assess the methodological quality overall in published systematic reviews that are 
registered in PROSPERO.   
 
Methods: 
We will identify all published, completed systematic reviews whose protocol details are 
registered in the PROSPERO register. We will compare the primary outcomes reported in the 
published systematic reviews to those reported in the PROSPERO protocol registrations. We will 
also compare these outcomes with any protocols published in other sources, such as the 
Systematic Reviews journal.  
 
Changes from PROSPERO record to publication will be coded using the following classification 
scheme, similar to that used by Parmelli et al. 2007 [7] and Kirkham et al. 2010 [5]: Inclusion of 
a new primary outcome, exclusion of a primary outcome, or change in type of outcome. The 
latter ('change') will be further classified as either an upgrade (when a secondary outcome was 
changed to a primary outcome or when not defined in protocol became primary in the systematic 
review) or a downgrade (vice-versa). If the primary outcome is not stated (e.g., in the title or 
objectives), a decision-tree approach will be used and the most serious outcome will be chosen 
[12, 13]. The overall methodological quality of the systematic reviews will be assessed using the 




Prior to embarking on data abstraction, the teams will pilot-test the data abstraction form using a 
random sample of 10 of the included systematic reviews. Data abstraction will only commence 
when high agreement has been achieved (e.g., percent agreement >80%). Subsequently, two 
members of the research team will abstract each of the systematic reviews and appraise their 
methodological quality, independently. In addition, if reasons for the changes to primary 
outcomes from protocol to publication are not indicated in the publication, the corresponding 
author of the review will be contacted twice, separated by two weeks. All conflicts will be 





Appendix Table A. Data abstraction explanation and elaboration document  
NB:  
For all items if either not applicable or not reported, enter NA or NR.  
Please do not leave blank spaces. 
Please do not abstract non-English publications. 
We will only include intervention systematic reviews. 
 
Items in white will be data abstracted manually. 





Excel Column Description 
CRD no. Enter the number in the first column from the PROSPERO download 
file (registration number). 
DA 1 Enter your initials here. 
DA 2 (Leave blank). 
Publication author List the last name of the first author of the publication. 
Publication year List the year of the publication. 
Contact Contact author named in the PROSPERO record. 
Publication citation Citation information of the systematic review publication. 
(Note that scoping reviews are not included). 
Registration date Latest date when protocol details were registered before status changed 
to Completed. This is the PROSPERO record version that will be used 
for data abstraction and comparison below. 
Other protocol URL for the PDF or citation information of the full protocol 
publication. If not applicable, enter NA. 
Country of conduct Country in which the systematic review was conducted (if this is 
unclear then use the country of origin of the first author). 
Funding  Data from PROSPERO record will be categorized for funding source 
into the following options: 
- No funding; 
- Governmental organisation; 
- Commercial organisation; 
- Health-care provider organisation; 
- Voluntary body (e.g., American Medical Association); 
- Charitable trust; 









[Source: Cochrane EPOC Group. Available at: 
http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacolle
ctionchecklist.pdf]. 
No. of studies Total number of studies included in the systematic review. 
Study design Select from the drop-down menu options below the study designs 
included in the systematic review: 
- all RCTs; 
- all observational; 
- mixed. 
Sample size Total number of participants captured in the systematic review. If this 












Brief description of the systematic review intervention(s) in the 
protocol details. If it is not a therapy review, describe the experimental 
procedure or exposure that was studied (e.g., diagnostic test, risk 
factor, etc.). 
Intervention in  
publication 
Brief description of the systematic review intervention(s) in the 
abstract and publication. 
Comparator in 
protocol details 
Brief description of the systematic review comparator(s) in the protocol 
details. 
Comparator in  
publication 
Brief description of the systematic review comparator(s) in the abstract 
and publication. 
Excel Column Description 
CRD no. Enter the number in the first column from the PROSPERO download 
file (registration number). 
No. of 1ooutcomes 
in protocol details 
Data from PROSPERO record will be used to record the number of 
primary outcomes. (This is a mandatory field in PROSPERO). 
No. of 1ooutcomes 
in publication- 
Explicit 
Number of primary outcomes in systematic review publication that are 
 a  a   
NB- use the overall domain of the outcome instead of the specific 
outcome measures.  
 
Example: 
-Ma  a    a     a   a    





Name(s)- Explicit Enter the names of the explicit primary outcome(s). 
No. of 1ooutcomes 
in publication- 
Derived 
Number of primary outcomes in systematic review publication that are 
derived. 
 
If zero was entered above (i.e. no explicit 1o outcome), then use the 
following order to select the primary outcome for the purpose of 
comparison with the PROSPERO record: 
1) the outcome listed in the title; 
2) the outcome listed in the objectives; 
3) the most serious outcome (e.g., death); 
 
If this row is not applicable, enter NA. 
Name(s)- Derived Enter the name(s) of the derived primary outcome(s). 
Derived method Enter the method used above to derive the primary outcome.  If this row 
is not applicable, enter NA. 
2ooutcomes in 
protocol details 
Data from PROSPERO record on secondary outcomes. This will only be 
used for the primary outcome change categorizations below. (This is a 
mandatory field in PROSPERO). 
Change  New 1o 
outcome 
For a change in the type of primary outcome from the protocol details to 
the publication that is the addition of a completely new primary 
outcome, enter the number of new primary outcomes added. 
 
N :     a a ,  0  .  
Name(s)- New Enter the names of the new primary outcome(s). 
Change  Exclusion 
of1o outcome 
For a change in the type of primary outcome from the protocol details to 
the publication that is the omission of a primary outcome in the 
publication, enter the number of excluded primary outcomes. 
 
N :     a a ,  0  . 
Name(s)- Exclusion Enter the names of the excluded primary outcome(s). 
Change  Upgrade 
of 1o outcome 
For a change in the type of primary outcome from the protocol details to 
the publication that is an upgrade (i.e. when a secondary or undefined 
outcome in the protocol details was changed to a primary outcome in 
the publication), enter the number of upgraded primary outcomes. 
 
N :     a a ,  0  .  
Name(s)- Upgrade Enter the names of the upgraded primary outcome(s). 
Change   
Downgrade of 1o 
outcome 
For a change in the type of primary outcome from the protocol details to 
the publication that is a downgrade (i.e. when a primary outcome in the 
protocol details was changed to a secondary or undefined outcome in 
publication), enter the number of downgraded primary outcomes. 
 
N :     a a ,  0  . 
Name(s)- 
Downgrade 
Enter the names of the downgraded primary outcome(s). 
Change in 1o If there was a change in primary outcome definition between the 
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outcome definition protocol details and publication, enter the name of the outcome that was 
changed. 
If not applicable, enter NA. 
The row above will be repeated for up to 10 changes. 
Change in 1o 
outcome measure 
If there was a change in primary outcome measure between the protocol 
details and publication, enter the name of the outcome that was changed. 
If not applicable, enter NA. 
The row above will be repeated for up to 10 changes. 
Rationale for 
change  of 1o 
outcome 
If the authors provide a reason for a change in primary outcome in the 
publication, enter the text here including which outcome(s) they are 
referring. 
If none was provided, enter NR here.  
If not applicable, enter NA. 
The row above will be repeated for up to 10 reasons. 




Was a meta-analysis conducted for the primary outcome in the 





Enter the direction of the results from the following drop-down options 
(see Fig. 1* below): 
- Favourable, statistically significant (i.e. effect in favour of the 
   0.05); 
- Favourable, non-statistically significant; 
- Neutral (effect size between 0.95-1.05 and the confidence interval 
crosses 1); 
- Unfavourable, statistically significant (i.e. effect in favour of the 
 a a    0.05);  
- Unfavourable, non-statistically significant; 
- Non-comparative (e.g., review of prevalence); 
- NA. 
Name- MA Enter a description of the corresponding meta-analysis above. 
 
Examples: 
- intervention vs. control for pain 
- Tx gp 2 vs. placebo for nausea 
The 2 rows above will be repeated for up to 10 results. 
Conclusions For all the systematic reviews (with or without meta-analysis),choose 
the categorization of the conclusions (from the Abstract &Discussion 
sections) from the following drop-down options: 
- Positive (authors stated that there is evidence of effectiveness); 
- Neutral (no evidence of effectiveness or they reported no opinion); 
- Negative (authors advised against the use of the intervention or it was 
not recommended); 









Name- Conclusion Enter a description of the corresponding conclusion above. 
 
Examples: 
- intervention vs. control for pain 
- Tx gp 2 vs. placebo for nausea 
The 2 rows above will be repeated for up to 10 conclusions. 
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Appendix Figure A. Non Cochrane vs. Cochrane Re ie s  Concl sion Statements 
 
N : U a a   a    a     a  ,  
a a   a    a     . 
 
*From Tricco AC, Tetzlaff J, Pham B, Brehaut J, Moher D. Non-Cochrane vs. Cochrane reviews were twice as 





Appendix Table B. Quality Assessment using AMSTAR* 
Choose YES , NO , UNCLEAR , or NOT APPLICABLE (NA)  for each question belo : 
 
Excel Column Description 
1. A priori design Was an 'a priori' design provided? 
T  a   a   a   a   
    .  
 
This means that the authors must mention that they worked from a 
protocol or that they registered their review protocol or that they published 
their review protocol.  
All our included reviews will automatically have a YES here. 
2. Duplicate 
selection 
Was there duplicate study selection and data extraction? 
T    a  a    a a a  a  a consensus 
  a     a . 
 
Since this item lumps 2 questions into 1, data can be screened in duplicate 
and data abstraction verified or vice versa. 
Note: 2 people do study selection, 2 people do data extraction, consensus 
p        . 
3. Literature 
search 
Was a comprehensive literature search performed? 
A  a       a . T    
include years and databases used (e.g., Central, EMBASE, and 
MEDLINE). Key words and/or MESH terms must be stated and where 
feasible the search strategy should be provided. All searches should be 
supplemented by consulting current contents, reviews, textbooks, 
specialized registers, or experts in the particular field of study, and by 
      . 
 
In order to score a YES, at least two electronic sources should be searched. 
N : I  a  a  2  +  a  a  ,   
(Cochrane register/Central counts as 2 sources; a grey literature search 
counts as supplementary). 
4. Publication 
status 
Was the status of publication (i.e. grey literature) used as an inclusion 
criterion? 
T  a   a  a   a    a    
publication type. The authors should state whether or not they excluded 
any reports (from the systematic review) based on their publication status, 
a a , .  
 
In order to score a YES, they should include unpublished data. If they only 
included peer reviewed material, a  N  . 
N : I   a  a   a  a a    a   
 a ,  a  .  SINGLE a a a , a , 
conference proceedings, and trial registries are all considered grey for this 
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purpose. If searching a source that contains both grey and non-grey, must 
specify that they were searching for grey/unpublished lit.    
5. List of studies Was a list of studies (included and excluded) provided? 
A    a      . 
 
To score a YES, all included AND excluded studies should be provided. 
Note: Acceptable if the excluded studies are referenced. If there is an 
         a ,  .  
6. Study 
characteristics 
Were the characteristics of the included studies provided? 
I  a  a a    a  a a , a a   a   
should be provided on the participants, interventions and outcomes. The 
ranges of characteristics in all the studies analyzed (e.g., age, race, sex, 
relevant socioeconomic data, disease status, duration, severity, or other 
a )   .  
 
To score a YES, they must at least report one each of participants, 
interventions and outcomes. 




Was the scientific quality of the included studies assessed and 
documented? 
'A '   a     ( . .,  
effectiveness studies if the author(s) chose to include only 
randomized, double-blind, placebo controlled studies, or allocation 
concealment as inclusion criteria); for other types of studies alternative 
   a . 
 
To score a YES, they must appraise risk of bias or methodological quality 
(i.e. assessed quality but detailed reporting of these findings not required 
here). 
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad 
scale, risk of bias, sensitivity analysis, etc., or a description of quality 
items, with some kind of res   EACH  (     , 
a   a    a      a    ; 
a summary score/range for all studies is not acceptable). 
8. Quality used Was the scientific quality of the included studies used appropriately in 
formulating conclusions? 
T     a   a   a    
considered in the analysis and the conclusions of the review, and explicitly 
a   a  a . 
 
If quality/risk of bias was not assessed, then this is NA. 
N : M  a    a        
a     a    .  Ca     
       7. 
9. Methods Were the methods used to combine the findings of studies appropriate? 
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*Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter 
LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic 





appropriate F    , a          
combinable, to assess their homogeneity (i.e. Chi-squared test for 
homogeneity, I2). If heterogeneity exists, a random effects model should be 
used and/or the clinical appropriateness of combining should be taken into 
a  ( . .     ?) . 
 
For reviews that do not conduct a meta-analysis, authors should provide a 
rationale for this (e.g., the results were too heterogeneous so the results 
were described narratively).  
Reviews that do not describe their synthesis process should be scored as a 
NO. 
N : I a        , . .,   




Was the likelihood of publication bias assessed? 
A  a   a  a    a a   
graphical aids (e.g., funnel plot, other available tests) and/or statistical tests 
(e.g., Egger regression test, Hedges-O ) . 
 
If a meta-analysis was not conducted, then the possibility of publication 
bias should be at least mentioned in the discussion section. 
Note: If no test values or funnel  ,  . S    
mentions that publication bias could not be assessed because there were 
fewer than 10 included studies. 
11. Conflicts 
stated 
Was the conflict of interest stated? 
P a       a  a nowledged in both the 
a   a    . 
 
Score as a YES even if a conflict of interest exists but it is stated. This item 
is asking whether it was reported (not whether conflicts of interest exist).  
N : T   a ,   dicate source of funding or support for the 
systematic review AND for each of the included studies. 
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Appendix Table E. Meta-analysis results 
  Direction & Significance of Meta-analysis Result 
Type of Discrepancy Favourable 




Favourable         
Non-
significant 

















New Primary Outcome (all) 2 (2) 2 (2) 0 0 0 
T  N  P a  O  1 (1) 1 (1) 0 0 0 
Upgrade of Primary Outcome (all) 3 (3) 1 (1) 0 0 0 
T  Upgrade of Primary 
Outcome 2 (2) 1 (1) 0 0 0 
Downgrade of Primary Outcome 
(all) 5 (3) 3 (2) 5 (3) 1 (1) 0 
T  Downgrade of Primary 
Outcome 2 (1) 0 1 (1) 1 (1) 0 
No Discrepancy (all) 62 (40) 39 (27) 23 (17) 10 (8) 11 (6) 
T  No Discrepancy  49 (31) 33 (23) 20 (14) 10 (8) 5 (3) 
Notes: *Parentheses indicate the number of systematic reviews affected, which do not add up to 67 because some 
systematic reviews had multiple meta-a a , T  a   a  a    a   





Appendix Table F. Sensitivity analyses results, meta-analysis results by overall statistical 
significance: All primary outcomes (both explicit and derived) 




New Primary Outcome 2 (2)* 2 (2) 
Upgrade of Primary Outcome 3 (3) 1 (1) 
Downgrade of Primary Outcome 6 (4) 3 (2) 
No Discrepancy 72 (46) 50 (29) 
 
New or upgrades (5/3 versus 72/50): Relative risk 1.06, 95 % CI 0.61 to 1.85 
New alone (2/2 versus 72/50): Relative risk 0.85, 95 % CI 0.31 to 2.28 
Upgrade alone (3/1 versus 72/50): Relative risk 1.27, 95 % CI 0.71 to 2.28 
Downgrade (6/3 versus 72/50): Relative risk 1.13, 95 % CI 0.70 to 1.83 
 
*Parentheses indicate the number of reviews affected. 
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Appendix Table G. Sensitivity analyses results, meta-analysis results by overall statistical 
significance: Explicitly reported primary outcomes alone 




T  New Primary Outcome 1 (1)* 1 (1) 
T  U a   P a  O  2 (2) 1 (1) 
T  D a   Primary Outcome 3 (2) 0 
T  N  D a  59 (37) 38 (25) 
 
New or upgrades (3/2 versus 59/38): Relative risk 0.99, 95 % CI 0.47 to 2.05 
New alone (1/1 versus 59/38): Relative risk 0.82, 95 % CI 0.20 to 3.32 
Upgrade alone (2/1 versus 59/38): Relative risk 1.10, 95 % CI 0.48 to 2.48 
Downgrade (3/0 versus 59/38): Relative risk 1.44, 95 % CI 0.96 to 2.16 
 
*Parentheses indicate the number of reviews affected. 
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Appendix Table H. Meta-analysis results for systematic reviews with funding and without 
funding 
  Direction & Significance of Meta-analysis Result 
Type of Discrepancy Favourable 




Favourable         
Non-
significant 

















New 1o Outcomes- with ANY 
funding 2 (2) 0 0 0 0 
New 1o Outcomes- with NO 
funding 0 2 (2) 0 0 0 
Upgrades of 1o Outcomes- with 
ANY funding 2 (2) 1 (1) 0 0 0 
Upgrades of 1o Outcomes- with 
NO funding 1 (1) 0 0 0 0 
Downgrades of 1o Outcome- with 
ANY funding 4 (2) 0 3 (1) 0 0 
Downgrades of 1o Outcome- with 
NO funding 1 (1) 3 (2) 2 (2) 1 (1) 0 
No Discrepancies- with ANY 
funding 45 (26) 21 (15) 11 (9) 6 (4) 2 (2) 
No Discrepancies- with NO 
funding 17 (14) 18 (11) 12 (8) 4 (4) 9 (4) 
 
Any funding:  
New or upgrades: 4/45 versus 1/40 = Relative risk 3.35, 95 % CI 0.39 to 28.78 
Downgrades: 4/45 versus 3/40 = Relative risk 1.17, 95 % CI 0.28 to 4.94 
 
No funding: 
New or upgrades: 1/17 versus 2/43 = Relative risk 1.25, 95 % CI 0.12 to 12.94 
Downgrades: 1/17 versus 6/43 = Relative risk 0.45, 95 % CI 0.06 to 3.51 
Notes: *Parentheses indicate the number of systematic reviews affected, which do not add up to 67 because some 




Appendix Table I. Sensitivity analyses, meta-analysis results by funding: All primary 
outcomes (both explicit and derived) 




New 1o Outcomes- with ANY funding 2 (2)* 0 
New 1o Outcomes- with NO funding 0 2 (2) 
Upgrades of 1o Outcomes- with ANY funding 2 (2) 1 (1) 
Upgrades of 1o Outcomes- with NO funding 1 (1) 0 
Downgrades of 1o Outcome- with ANY 
funding 4 (2)* 0 
Downgrades of 1o Outcome- with NO funding 2 (2) 3 (2) 
No Discrepancies- with ANY funding 51 (29) 22 (16) 
No Discrepancies- with NO funding 21 (17) 28 (13) 
 
Any funding: 
New or upgrades (4/1 versus 51/22): Relative risk 1.15, 95 % CI 0.72 to 1.82 
New alone (2/0 versus 51/22): Relative risk 1.20, 95 % CI 0.71 to 2.03 
Upgrade alone (2/1 versus 51/22): Relative risk 0.95, 95 % CI 0.42 to 2.15 
Downgrade (4/0 versus 51/22): Relative risk 1.29, 95 % CI 0.93 to 1.80 
 
No funding: 
New or upgrades (1/2 versus 21/28): Relative risk 0.78, 95 % CI 0.15 to 3.98 
New alone (0/2 versus 21/28): Relative risk 0.39, 95 % CI 0.03 to 4.97 
Upgrade alone (1/0 versus 21/28): Relative risk 1.74, 95 % CI 0.74 to 4.13 
Downgrade (2/3 versus 21/28): Relative risk 0.93, 95 % CI 0.30 to 2.86 
 
*Parentheses indicate the number of reviews affected.
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Appendix Table J: Sensitivity analyses, meta-analysis results by funding: Explicitly 
reported primary outcomes alone 




T  N  1o Outcomes- with ANY funding 1 (1)* 0 
T  N  1o Outcomes- with NO funding 0 1 (1) 
T  U a  of 1o Outcomes- with ANY 
funding 
2 (2) 1 (1) 
T  U a   1o Outcomes- with NO 
funding 
0 0 
T  D a   1o Outcome- with 
ANY funding 
2 (1) 0 
T  D a   1o Outcome- with NO 
funding 
1 (1) 0 
T  N  D a - with ANY funding 40 (22) 19 (13) 
T  N  D a - with NO funding 9 (7) 19 (12) 
 
Any funding: 
New or upgrades (3/1 versus 40/19): Relative risk 1.07, 95 % CI 0.66 to 1.74 
New alone (1/0 versus 40/19): Relative risk 0.96, 95 % CI 0.46 to 2.00 
Upgrade alone (2/1 versus 40/19): Relative risk 1.20, 95 % CI 0.67 to 2.16 
Downgrade (2/0 versus 40/19): Relative risk 1.04, 95 % CI 0.71 to 1.52 
 
No funding: 
New or upgrades (0/1 versus 9/19): Relative risk 0.76, 95 % CI 0.07 to 8.90 
New alone (0/1 versus 9/19): Relative risk 0.76, 95 % CI 0.07 to 8.90 
Upgrade alone (0/0 versus 9/19): Relative risk 1.53, 95 % CI 0.20 to 11.60 
Downgrade (1/0 versus 9/19): Relative risk 2.29, 95 % CI 0.88 to 5.95 




Appendix Table K. Conclusion results for all included systematic reviews 
  Categorization of Conclusions 
Type of Discrepancy Positive Neutral Negative Indeterminate 
New Primary Outcome 3 (3)* 1 (1) 1 (1) 2 (2) 
Upgrade of Primary Outcome 3 (3) 1 (1) 0 2 (2) 
Downgrade of Primary Outcome 11 (7) 5 (3) 1 (1) 17 (9) 
No Discrepancy 71 (46) 33 (26) 10 (9) 30 (24) 
*Parentheses indicate the number of systematic reviews affected, which do not add up to 96 
because some systematic reviews had multiple conclusions.
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Appendix Table L. Sensitivity Analyses results, Conclusions Statements: 
Type of Discrepancy Positive Negative, 
Neutral, or 
Indeterminate 
New Primary Outcome 3 (3)* 4 (4) 
Upgrade of Primary Outcome 3 (3) 3 (3) 
Downgrade of Primary Outcome 11 (7) 23 (13) 
No Discrepancy 71 (46) 73 (59) 
 
New or upgrades (6/7 versus 71/73): Relative risk 0.94, 95% CI 0.51 to 1.72 
Downgrade (11/23 versus 71/73): Relative risk 0.66, 95% CI 0.39 to 1.10 
 
*Parentheses indicate the number of reviews affected. 
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Detailing the planned methods for conducting a systematic 
review in advance of commencing the review is essential in 
order to minimise a range of potential biases1,2. The plan, set 
out in a protocol, should ideally be made available in the pub-
lic domain to facilitate transparency3,4. In addition, registration 
of key protocol details is encouraged as best practice in report-
ing guidelines5,6 by publishers like the British Medical Journal 
(BMJ), Public Library of Science (PLoS), and BioMed Central 
(BMC), and is mandated in their instructions to authors by jour-
nals such as BMC Systematic Reviews, BMJ, BMJ Open, PLoS 
One, and National Institute for Health Research (NIHR) journals.
There are a number of options for putting systematic review 
protocols into the public domain, such as publication in open 
access journals like BMC Systematic Reviews and upload-
ing to open data repositories like the Open Science Framework 
(OSF) (https://osf.io/registries/discover?q=protocols). PROSPERO 
(https://www.crd.york.ac.uk/prospero/) is a facility for regis-
tering key methodological details in advance of carrying out 
a review. Registration on PROSPERO requires completion of 
an internationally agreed minimum dataset for a systematic 
review protocol7,8. Registrants also have the option of uploading 
their protocol or providing a hyperlink to it.
PROSPERO remains the only free, open access registry of 
systematic review protocols, making it a single searchable 
source of the protocols of on-going and completed reviews. 
Uptake of registration has increased exponentially and by the 
end of 2019 there were over 60,000 registrations in PROSPERO. 
There is evidence that considerably more systematic reviews are 
registered in PROSPERO than have peer-reviewed protocols 
published. In 2016, 1058 records were accepted by PROS-
PERO; in the same time period, only 404 published system-
atic review protocols were identified3. Another study reported 
identifying 20,814 non-Cochrane systematic review protocols 
from web scraping PROSPERO and bibliographic database 
searches. Of these, 924 were only published in journals, 807 were 
published in journals and registered in PROSPERO and 19,890 
were only available as a record in PROSPERO9. There is fur-
ther evidence from Ge et al. (2018) that of the non-Cochrane 
reviews registered in PROSPERO, only 3% or 4% have a pub-
lished protocol9,10. This means that for a large number of reviews 
a PROSPERO record is likely to be the only source providing 
details of the planned methods.
Published protocols and registration records aim to provide 
transparency in the review process by allowing public access to 
the key pre-specified elements for the conduct of a review. One 
of the stated aims of PROSPERO is to facilitate comparison 
between planned review methods and reported results8. Such 
a comparison enables peer reviewers and other readers of the 
final review to assess for themselves the potential for bias in 
the findings. There is also a steadily growing body of research 
using PROSPERO records to assess the risk of biases in final 
review reports10–15. Given this reliance on the information pro-
vided in PROSPERO records, it is important to understand the 
level of detail provided in records. The focus of this study was 
on the stated aim of PROSPERO to reduce the opportu-
nity for bias by enabling comparison of the completed review 
with what was planned in the protocol8.
The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses extension for Protocols (PRISMA-P) were 
developed through expert consensus using internationally 
compiled datasets such as PROSPERO and SPIRIT4,6.
Key methodological aspects of a protocol are mandated for 
registration in PROSPERO; other items, mainly administra-
tive fields, are optional7,8. Submissions for registration are not 
subject to any form of peer review or critical appraisal, they 
are simply checked for sense but not methodological rigor. 
Therefore, there is the possibility that PROSPERO records do 
not provide all the necessary information identified by the 
PRISMA-P guidelines to enable comparison with the completed 
systematic review. The registration record may be the only place 
where a priori methods are available for users, in particular peer 
reviewers, to check for potential issues such as selection, out-
come reporting and publication biases. This study investigated 
the extent to which records in PROSPERO, where no protocol or 
other information was available, comply with each of the items 
for reporting of protocols set out in the PRISMA-P guidelines.
Methods
A random sample of PROSPERO registration records were 
assessed against the systematic review protocol reporting cri-
teria set out in the PRISMA-P 2015 checklist4. Key methods 
are provided here with further details available in the protocol 
for this study, which was prepared and made publicly available 
on the OSF, 17 March 2020 (Extended data16).
Study sample of PROSPERO records
A dataset of non-Cochrane PROSPERO records was provided 
by Metaxis, the software managers of PROSPERO. Records 
of reviews defined by the record holder as a health interven-
tion registered on or between 1 January 2018 and 31 December 
2018, were identified.
Cochrane reviews, reviews of animal studies, non-intervention 
reviews as identified in PROSPERO, i.e. Diagnostic accuracy, 
Prognostic factors, Prevention, Epidemiological reviews rel-
evant to health and social care, Public health, Service delivery 
in health and social care, Methodological reviews, reviews 
of reviews, and synthesis of qualitative studies, were all 
      Amendments from Version 1
In the discussion we have addressed the differences between 
a systematic review protocol and registration of key details, and 
explained the use of PRISMA-P guidelines, even though they do 
not align with PROSPERO fields. We have also added the use of a 
scoring system as a potential limitation of the study. Other minor 
issues raised in peer review have also been addressed.
Any further responses from the reviewers can be found at 




excluded as PROSPERO and PRISMA-P were developed for 
reviews of interventions. Only records with no evidence from 
the registration record of other protocol related information, 
for example in a published protocol or other links in the PROS-
PERO record, were included and we restricted the data set to 
those records with a single registry entry.
Records from the calendar year 2018 were used to allow time 
for dissemination and adoption of the PRISMA-P guidelines 
published in 2015. A sample of 20% of these records was 
randomly selected using simple random sampling for assessment 
against the PRISMA-P reporting criteria.
Assessment tool and scoring
The PRISMA-P checklist recommends 17 numbered items, 
with nine subdivisions, totalling 26 items be reported in a sys-
tematic review protocol4. Seven of the 26 items were excluded 
from the assessment as they would always or never meet regis-
tration requirements in PROSPERO. For example, registration 
is implicit for a record accepted in PROSPERO, and there is no 
field for author contributions or sponsor role so these would 
never be reported. The study assessment tool, developed spe-
cifically for this study as a Google Form, therefore contained 
19 of the PRISMA-P items. Where the PRISMA-P descrip-
tion for an item specified more than one piece of information, 
the individual elements were listed as subsets of the items4,6. 
For example, item 14. Risk of bias in individual studies, says: 
“Describe anticipated methods for assessing risk of bias of indi-
vidual studies, including whether this will be done at the out-
come or study level, or both; state how this information will be 
used in data synthesis.” Scoring for this item was for each of 
the following separate elements: No risk of bias assessment 
planned and justification provided; Risk of bias tools named 
for all study types included; Outcome or study level or both; 
Domains/outcomes for risk of bias assessment stated; Risk 
of bias assessment process described; How risk of bias find-
ings will be used in synthesis. Applying this approach to the 19 
items resulted in a list containing 63 elements to be reported.
Where an item was reported or not applicable, a score of 1 was 
assigned. Where the information was not reported this scored 
0. The maximum possible overall score for the PRISMA-P 
listed items was 19 per record. Scores for the breakdown of 
individual elements within the items was also reported, the 
maximum possible score was 63 per record.
Assessment procedure
The researchers undertaking the assessments (AB, ASM, AM, 
SJ, SC, SG) familiarised themselves with both PRISMA-P 
papers4,6. All had previously received training in systematic 
review methods and/or authored at least one systematic review. 
The draft assessment form and accompanying guidance notes 
were revised and finalised during a training session and piloted 
with the aim of achieving greater than 90% agreement.
Two researchers independently compared the information 
provided in each PROSPERO record with the relevant items in 
the study assessment tool. Options for decisions were: Reported 
(information provided as per PRISMA-P requirements); Not 
reported (some or all information not provided); and, Not 
applicable (where an item was not relevant to an individual 
record, e.g. a meta-analysis was not planned).
Records were randomly assigned to assessors by first creating 
a list of the sampled record unique identification numbers and 
dividing the list into 14 blocks of approximately equal size, with 
each block being assigned a colour. A copy of this list together 
with the block configuration was then placed alongside the 
original list. Seven sub-lists were then created by randomly 
selecting a block from the first list and a block from the second 
list, such that blocks of the same colour were not in the same 
sub-list, and each colour appeared in two sub-lists. Each sub-list 
was then randomly assigned to an assessor.
It was not feasible to blind the researchers to the authors of 
registrations in PROSPERO. None of the assessors were authors 
of included registrations. On completion of the pilot assess-
ments and the full set of records, disagreements were resolved 
through discussion or recourse to a third researcher.
The assessment form and the guidance notes are available 
on the OSF (Extended data16).
Analysis
The primary outcome for this study was the compliance of 
PROSPERO registration records to PRISMA-P reporting items. 
This was measured by the total mean score allocated by the 
two independent assessors to each of the 19 items assessed 
(maximum possible score 19) for each record and by the total 
mean score for the individual elements within items (maximum 
possible score 63). Overall scores for the assessed dataset, scores 
by the 19 PRISMA-P items and by the 63 elements were the 
planned outcome measures.
For the eligible 2018 records that were assessed and those not 
assessed, demographic data for month of registration, funding/ 
sponsor, planned meta-analysis, number of authors, stage of 
review at registration, topic and country of review were to be 
reported. Comparisons to identify any association between 
records registered before or after screening started; whether a 
meta-analysis was planned or not; and whether a review was 
funded/sponsored or not and completeness of reporting of items 
were planned.
Deviations from protocol
During piloting of the assessment form, it became clear that it 
would not be possible to assess records for PRISMA-P item 
5a Sources and 5b Sponsor. This would have required separat-
ing sources of financial support from sponsorship or any other 
form of support as reported in the single PROSPERO field, 
which was not possible. This item was therefore removed from 
the assessment form. Instead, a series of regular expression 
patterns was compared to the list of eligible records to identify 
those where the record contained any indication of funding/ 
sponsorship/support or indicated there was none. These data 





The PROSPERO dataset contained 5,313 records for reviews of 
health interventions first accepted in 2018 (excluding Cochrane 
and reviews of animal studies). Applying the other study 
inclusion/exclusion criteria resulted in 2,194 eligible registra-
tion records. The randomly selected sample of 20% for assess-
ment included 439 records. During assessment, six records were 
excluded, for not meeting the inclusion criteria (4), being a 
duplicate (1) or no longer available on PROSPERO (1). Assess-
ments were therefore carried out on 433 PROSPERO records. 
A flow chart of record selection is shown in Figure 1.
Agreement following initial piloting of the assessment form 
was 87%; after further discussions and revision of the assess-
ment guidance notes and form a second pilot achieved 92% 
agreement. For all the records assessed, agreement between 
researchers was 90%, all differences were resolved through 
discussion or referral to a third researcher.
Demographic details of the sample of PROSPERO records 
selected for assessment and those not assessed are provided 
in Table 1. The number of authors listed ranged between one 
and 17, with the exception of a single record, included in the 
assessed sample, where 47 authors were listed. The eligible 
sample for 2018 included records from 67 different countries: 
20 records listed two countries and 15 listed between three and 
nine countries involved in the review. There were no substan-
tial differences between the data sets in the month of registra-
tion; whether any details of funding and/or sponsorship were 
provided; whether a meta-analysis was planned or not; the 
number of authors listed per record; stage of review at regis-
tration; topic of review or country involved in undertaking the 
review.
Figure 1. Flow chart of record sample identification.
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Table 1. Demographic details of non-sample set and sample set of the eligible 2018 PROSPERO records.
Demographic Records for assessment 
(n = 439)
Records not assessed 
(n = 1755)
Month of registration n (%)
January 45 (10) 168 (10)
February 32 (7) 141 (8)
March 25 (6) 100 (6)
April 35 (8) 122 (7)
May 16 (4) 110 (6)
June 36 (8) 151 (8)
July 54 (12) 188 (11)
August 56(12) 200 (11)
September 31 (7) 151 (9)
October 37 (8) 138 (8)
November 37 (8) 160 (9)
December 35 (8) 126 (7)
Funding/support indicated n (%) 386 (88) 1572 (90)
Meta-analysis planned n (%) 253 (58) 1064 (61)
Number of listed authors (mean, range) 4.1 (0 – 47*) 3.9 (0 – 17)
Stage of review** 
n (%)
Not Started 96 (22) 385 (22)
Searches Start 65(15) 283 (16)
Searches Complete 12 (3) 57 (3)
Pilot Selection Start 56 (13) 252 (14)
Pilot Selection Complete 16 (4) 50 (3)
Screening Start 80 (19) 285 (16)
Screening Complete 13 (3) 56 (3)
Extraction Start 93 (21) 376 (21)
Extraction complete 2 (0) 8 (1)
None of the PROSPERO records assessed against the eligibil-
ity criteria reported on all elements in each of the items recom-
mended for a systematic review protocol in the PRISMA-P 
guidelines. The mean total score for individual PROSPERO 
records, where 1 point was gained for each of the 19 items in 
the PRISMA-P checklist, was 4.8, the standard deviation 1.8, 
the median 4, and range 2 to 11. Considering all items across all 
the assessed records, only 25% (2081/8227) of the items were 
scored as reported.
The mean total score for individual PROSPERO records 
where 1 point was gained for each of the 63 elements of the 
PRISMA-P reporting guidelines was 33.4, the standard devia-
tion 5.8, the median 33 and the range 18–47. Overall, 53% 
(14,469/27,279) of the elements were considered as reported.
Scoring for 19 PRISMA-P items
The highest scoring item was PRISMA-P 1b which requires 
the protocol to be identified as to whether it is an update of 
a review; the high score was the result of this being a not- 
applicable item for 423 (98%) of the 433 records (Table 2). 
Eligibility criteria (study design, setting, population, intervention, 
comparator, outcomes) was the next highest scoring item with 
386 (89%) reporting all of these elements. Selection proc-
ess (214, 49%), describing the criteria under which study data 
will be quantitatively synthesized (200, 46%), and describ-
ing the type of summary planned if quantitative synthesis is not 
appropriate (227, 52%) were the next highest scoring of the 19 
items assessed.
The scores by PRISMA-P item and by breakdown of items 
are presented in Table 2. The full dataset with assessment out-
comes and scores for individual records, and the subgroup 
analyses scoring are available on the OSF (Underlying data16).
Scoring for 63 elements of the PRISMA-P items
The score for some of the 19 items was reduced as a result 
of just one or two of the constituent elements being omitted 
from reports while others were relatively regularly identified.
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Demographic Records for assessment 
(n = 439)
Records not assessed 
(n = 1755)




12 (3) 28 (2)
Blood and immune system 13 (3) 90 (5)
Cancer 42 (10) 182 (10)
Cardiovascular 61 (14) 220 (13)
Care of the elderly 16 (4) 72 (4)
Child health 31 (7) 139 (8)
Complementary therapies 43 (10) 178 (10)
Crime and justice 0 (0) 2 (0)
Dental 30 (7) 138 (8)
Digestive system 34 8) 127 (7)
Ear, nose and throat 7 (2) 27 (2)
Education 10 (2) 23 (1)
Endocrine and metabolic 
disorders
35 (8) 144 (8)
Eye disorders 3 (1) 16 (1)
General interest 5 (1) 29 (2)
Genetics 3 (1) 5 (0)
Health inequalities/health 
equity
3 (1) 8 (1)
Infections and infestations 22 (5) 97 (6)
International development 0 (0) 2 (0)
Mental health and 
behavioural conditions
51 (12) 129 (7)
Musculoskeletal 70 (16) 253 (14)
Neurological 44 (10) 208 (12)
Nursing 11 (3) 45 (3)
Obstetrics and gynaecology 23 (5) 101 (6)
Oral health 21 (5) 100 (6)
Palliative 4 (1) 16 (1)
Perioperative care 14 (3) 81 (5)
Physiotherapy 36 (8) 129 (7)
Pregnancy and childbirth 13 (3) 60 (3)
Public Health 0 (0) 0 (0)
Rehabilitation 43 (10) 173 (10)
Respiratory disorders 16 (4) 87 (5)
Service delivery 0 (0) 0 (0)
Skin disorders 12 (3) 40 (2)
Social care 0 (0) 2 (0)
Surgery 49 (11) 209 (12)
Tropical medicine 0 (0) 0 (0)
Urological 20 (5) 71 (4)
Wounds, injuries and 
accidents
11 (3) 70 (4)
Violence and abuse 3 (1) 10 (1)
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Demographic Records for assessment 
(n = 439)
Records not assessed 
(n = 1755)
Country of review*** 
n (%)
Australia 33 (8) 143 (8)
Brazil 53 (12) 224 (13)
Canada 38 (9) 121 (7)
China 100 (23) 414 (24)
England 46 (10) 163 (9)
Germany 13 (3) 40 (2)
Italy 14 (3) 62 (4)
Netherlands 13 (3) 51 (3)
Spain 13 (3) 39 (2)
USA 48 (11) 160 (9)
57 other countries 127 (29) 562 (32)
* the record with 47 authors was a single outlier: range excluding this record was 0–15
** details for three records were not available on PROSPERO
*** all items reported by authors included; therefore totals are more than the number of records
















Section 1 Administrative information
1a. Identification in the title: 
Identify the report as a protocol of 
a systematic review 22 (5) 411 (95)
Identify the report as a 
protocol
22 (5) 411 (95) /
Identify the report as a 
systematic review
342 (79) 91 (21) /
1b. Update: If the protocol is 
for an update of a previous 
systematic review
424 (98) 9 (2) Identify the report as an 
update
1 (0) 9 (2) 423 (98)
Section 2 Introduction
6. Rationale: Describe the 
rationale for the review in the 
context of what is already known
38 (9) 395 (91)
Rationale described 44 (10) 389 (90) /
Context provided** 108 (25) 325 (75) /
7. Objectives: Provide an explicit 
statement of the question(s) the 
review will address with reference 
to participants, interventions, 
comparators, and outcomes 
(PICO)*
134 (31) 299 (69)
Population 397 (92) 36 (8) /
Intervention 416 (96) 17 (4) /
Comparator 142 (33) 264 (61) 27 (6)
Outcomes 237 (55) 196 (45) /
Section 3 Methods
8. Eligibility criteria: Specify the 
study characteristics (e.g., PICO, 
study design, setting, time frame) 
and report characteristics (e.g., 
years considered, language, 
publication status) to be used 
as criteria for eligibility for the 
review*
386 (89) 47 (11)
Study design specified* 427 (99) 6 (1) /
Setting (condition or 
domain) specified*
410 (95) 23 (5) /
Population* 429 (99) 4 (1) /
Intervention* 428 (99) 5 (1) /
Comparator* 392 (91) 14 (3) 27 (6)


















9. Information sources: Describe 
all intended information sources 
(e.g., electronic databases, contact 
with study authors, trial registers, 
or other grey literature sources) 
with planned dates of coverage*
2 (1) 431 (99)
Electronic database(s) 
named
431 (99) 2 (1) /
Grey literature sources 100 (23) 333 (77) /
Study registries 289 (67) 144 (33) /
Contact with study authors 
planned or statement that 
contact not planned
27 (6) 406 (94) /
Other: e.g. hand searching 
reference lists of included 
studies
152 (35) 281 (65) /
Planned search dates 238 (55) 195 (45) /
10. Search strategy: Present draft 
of search strategy to be used for 
at least one electronic database, 
including planned limits, such that 
it could be repeated 75 (17) 358 (83)
Draft search strategy 
provided
91 (21) 342 (79) /
Search terms given alone 100 (23) 242 (56) 91 (21)
Approach to limits/
restrictions reported 
e.g. language or dates/
statement of no limits*
332 (77) 101 (23) /
11a. Data management: Describe 
the mechanism(s) that will be 
used to manage records and data 
throughout the review
17 (4) 416 (96)
Software named/type 
indicated**
56 (13) 377 (87) /
De-duplication planned 42 (9) 391 (91) /
11b. Selection process: State 
the process that will be used 
for selecting studies (e.g., two 
independent reviewers) through 
each phase of the review (i.e., 
screening, eligibility, and inclusion 
in meta-analysis)
214 (49) 219 (51)
Initial screening process 
described**
232 (54) 201 (46) /
Full paper screening 
process described**
219 (51) 214 (49) /
11c. Data collection process: 
Describe planned method of 
extracting data from reports 
(e.g., piloting forms, done 
independently, in duplicate), 
any processes for obtaining 
and confirming data from 
investigators*
50 (12) 383 (88)
Data extraction form 169 (39) 264 (61) /
Data extraction process 
described
258 (60) 175 (40) /
Obtain missing data 76 (18) 357 (82) /
12. Data items: List and define all 
variables for which data will be 
sought (e.g., PICO items, funding 
sources), any pre-planned data 
assumptions and simplifications
6 (1) 427 (99)
List of data for 
extraction**
219 (51) 214 (49) /
Variables defined** 29 (7) 404 (93) /
Any data assumptions 
reported
17 (4) 416 (96) /
13. Outcomes and prioritisation: 
List and define all outcomes 
for which data will be sought, 
including prioritisation of main 
and additional outcomes, with 
rationale
3 (1) 430 (99)
Primary/main outcome(s)* 
specified as such
418 (97) 15 (3) /
Primary/main outcome(s) 
measure specified**
235 (54) 198 (46) /
Additional outcomes 
specified/ state None*
430 (99) 3 (1) /
Additional outcomes: 
measures specified**
131 (30) 180 (42) 122 (28)
Rationale for choice of 
outcome(s)


















14. Risk of bias in individual 
studies: Describe anticipated 
methods for assessing risk of bias 
of individual studies, including 
whether this will be done at the 
outcome or study level, or both; 
state how this information will be 
used in data synthesis*
41 (9) 392 (91)
No risk of bias assessment 
planned, and justification 
provided
4 (1) 3 (1) 426 (98)
Risk of bias tools named 
for all study types included
362 (84) 67 (16) 4 (1)
Outcome or study level or 
both
310 (71) 119 (28) 4 (1)
Domains/outcomes for risk 
of bias assessment stated
342 (79) 87 (20) 4 (1)
Risk of bias assessment 
process described
296 (68) 133 (31) 4 (1)
How risk of bias findings 
will be used in the 
synthesis
64 (15) 365 (84) 4 (1)
15a. Synthesis: Describe criteria 
under which study data will be 
quantitatively synthesized
200 (46) 233 (54) Criteria for doing a 
quantitative synthesis/
meta-analysis described*
131 (30) 233 (54) 69 (16)
15b. If data are appropriate for 
quantitative synthesis, describe 
planned summary measures, 
methods of handling data, and 
methods of combining data from 
studies, including any planned 
exploration of consistency (e.g., I2, 
Kendall’s tau) 70 (16) 363 (84)
Summary measures* 202 (46) 163 (38) 68 (16)
Statistical method* 89 (20) 276 (64) 68 (16)
Use of fixed or random 
effects or both*
194 (44) 171 (40) 68 (16)
Data handling: conversion 
to same format
106 (24) 259 (60) 68 (16)
Data handling: missing 
data
14 (3) 351 (81) 68 (16)
Combining data/ 
exploration of consistency
179 (41) 186 (43) 68 (16)
Name of software to be 
used for meta-analysis
204 (47) 161 (37) 68 (16)
15c. Describe any proposed 
additional analyses (e.g., sensitivity 
or subgroup analyses, meta-




344 (79) 21 (5) 68 (16)
Methods for subgroup 
analyses reported
25 (6) 280 (65) 128 (29)
Sensitivity analyses 
planned
85 (19) 280 (65) 68 (16)
15d. If quantitative synthesis is 
not appropriate, describe the type 
of summary planned*
227 (52) 206 (48)
Descriptive, narrative, 
or qualitative synthesis 
planned
194 (45) 55 (12) 184 (43)
Descriptive, narrative 
or qualitative synthesis 
methods described
49 (11) 200 (46) 184 (43)
Other analyses planned 3 (1) 11 (3) 419 (96)
16. Meta-bias(es): Specify any 
planned assessment of meta-
bias(es) (e.g., publication bias 
across studies, selective reporting 
within studies)
72 (17) 361 (83)
Publication bias to be 
assessed
94 (21) 271 (63) 68 (16)
Outcome reporting bias to 
be assessed
4 (1) 361 (83) 68 (16)
17. Confidence in cumulative 
evidence: Describe how the 
strength of the body of evidence 
will be assessed (e.g., GRADE)
37 (9) 396 (91)
Overall assessment of 
included studies planned
40 (9) 393 (91) /
Methods specified 38 (9) 395 (91) /
* Item/element required in PROSPERO **Item/element identified in PROSPERO but as optional
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Although overall the review question (item 7) was not found 
to contain all the expected elements, most did specify the ele-
ments of population (397, 92%) and the intervention (416, 96%) 
and just over half included the outcomes (237, 55%). The com-
parator was less frequently included (142, 33%); this may have 
been because of the intention of the review but where 
this was clear, the item was scored as not applicable 
(6%).
Information sources (item 9) was scored as completed in only 
two records (1%) overall; however, for the individual elements 
431 (99%) did name the electronic databases to be searched, 
289 (67%) said whether they planned to search study registries, 
and 238 (55%) indicated search dates. In item 10, provision 
of a draft search strategy (91, 21%) or search terms (100, 23%) 
was poor; but restrictions such as to English language papers 
were reported in 332 (77%).
Reporting of item 13, outcomes, scored badly overall (3, 1%) as, 
although the outcomes were included in most records (Primary 
418, 97%; Secondary 430, 99%) only 8 (2%) were assessed as 
having provided a rationale for their choice of outcomes. Simi-
larly, in item 14, the absence of information on how the risk of 
bias would be used in the synthesis, detracted from the high 
rate of inclusion of risk of bias tools and use. Reporting of 
the details for a quantitative synthesis, item 15b, had one ele-
ment with a very low score (handling missing data, 14, 3%), the 
other six elements scored between 89 (20%) and 204 (47%).
In three items, the overall score reflected the general picture 
from the included elements. In item 6, rationale, both the rea-
son for undertaking the review and the context were infrequently 
identified. PRIMSA-P items 16, meta-bias(es) and 17, confi-
dence in cumulative evidence, were rarely reported. Only con-
text is classified as optional information in PROSPERO, the 
remainder of these elements are not explicitly requested.
There appears to be a trend towards higher frequency of report-
ing of elements that are mandatory in PROSPERO, for exam-
ple, in the eligibility criteria (item 8) and risk of bias (item 14). 
The trend is also seen in item 13, the required specification of 
primary and secondary outcomes, both frequently reported, 
but with a drop in specifying measures, which was optional.
Subgroup comparisons
The subgroup comparisons, which were all pre-defined, investigated 
the stage of review at registration; whether or not information 
was reported on source of funding, sponsorship or support and 
where none was indicated; and whether or not the relevant box in 
the registration form had been ticked to indicate a meta-analysis 
was planned.
There were no differences in total scores for the 19 PRISMA-P 
items or the 63 elements, between those records registered 
before screening against eligibility criteria had started and 
those records registered after screening had commenced. This 
held true for the mean, standard deviation, median and range 
of scores.
A 6% difference was seen in the total score achieved for the 
meta-analysis (23%) vs no meta-analysis (29%) groups in the 
assessment of the 19 PRISMA-P items. The difference was 
reduced to 2% when considering the breakdown of 63 ele-
ments within the reported items (52% vs 54%). At both item 
and element level, the group of records with no planned 
meta-analysis scored slightly higher, but with a higher 
standard deviation from the mean and wider range of scores 
achieved.
Across all results for both the 19 items and 63 elements, the 
group with funding, sponsorship or support, scored slightly 
higher than those not receiving funding, sponsorship or support.
The results of the subgroups investigated are presented in 
Table 3. The subgroup scores by individual PRISMA-P 
reporting item are available on the OSF (Underlying data16).
We present the scores by the 19 PRISMA-P items and by the 
breakdown of 63 elements for the ten countries and topics 
with the highest number of assessed records, and for number 
of authors listed in Table 4. None of these factors appear to 
have a marked influence on the number of PRISMA-P items or 
elements reported in PROSPERO records.
Discussion
Publication and registration of a systematic review protocol 
provides transparency in the review process, allowing readers to 
see the efforts made to minimise biases and where biases may 
still have influenced the final review findings. There is empiri-
cal evidence that few of the protocol registrations in PROSPERO 
have a corresponding published report9. Where there is no pro-
tocol, the registration provides the only public record of what 
was originally planned. This study set out to establish to what 
extent PROSPERO registrations of systematic review protocols 
of healthcare interventions reported on items in the PRISMA-P 
reporting guidelines.
Using a random sample of 433 PROSPERO records from 2018, 
two researchers independently assessed the frequency of report-
ing of 19 PRISMA-P items, with 63 individual elements. The 
results show that while some key methodological details are 
relatively frequently reported, much of the information recom-
mended in PRISMA-P is missing. Reporting was unsurprisingly 
more frequent for items that are mandatory in PROSPERO 
than those that are optional. Comparisons by stage of review at 
registration, whether meta-analysis was planned and whether 
funding or sponsorship was reported showed no meaning-
ful differences between groups. The slight difference between 
groups with a planned meta-analysis or none may be because 
in PRISMA-P more details are specified for the reporting of a 
meta-analysis than for a descriptive, narrative or qualitative 
analysis. 
The review protocol is a detailed record of the planned 
methods developed through an iterative process5.  Once finalised 
or close to finalising, the key methodological details should be 
registered in PROSPERO8. These are two separate but 
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Table 4. Overall scores by country, number of authors and topic of review.
No of 
records
For the 19 PRISMA-P items assessed For the 63 elements assessed
Overall score 




















Country (10 with most assessed records)
Australia 33 179 (28) 5.4 (2.1) 5 2–11 1115 (54) 33.8 (6.2) 32 21–47
Brazil 53 272 (27) 5.1 (1.9) 5 2–9 1826 (55) 34.5 (6.0) 35 18–46
Canada 37* 197 (28) 5.3 (2.1) 5 2–9 1301 (56) 35.2 (6.7) 35 21–45
China 101 418 (22) 4.1 (1.3) 4 2–10 3385 (54) 33.5 (4.5) 34 23–45
England 46 259 (29) 5.6 (2.2) 5 2–10 1620 (55) 35.2 (6.9) 35.5 22–47
Germany 11* 59 (28) 5.4 (2.3) 4 3–10 380 (55) 34.5 (6.2) 33 26–47
Italy 15 71 (27) 4.7 (1.8) 4 3–9 499 (57) 33.3 (6.2) 32 24–47
Netherlands 13 68 (28) 5.2 (2.1) 5 2–9 439 (53) 33.8 (7.0) 33 23–47
Spain 13 64 (26) 4.9 (1.8) 4 2–7 426 (52) 32.8 (5.6) 33 22–42
USA 48 242 (27) 5.0 (2.2) 4 2–10 1526 (51) 31.8 (6.4) 31 21–47
Number of authors
0–3 202 956 (25) 4.7 (1.8) 4 2–10 6648 (52) 32.9 (5.9) 32 18–47
4–6 179 867 (25) 4.8 (1.9) 5 2–11 6008 (53) 33.6 (5.7) 34 21–47
7+ 52 258 (27) 5.0 (1.9) 4 2–9 1813 (56) 34.9 (5.9) 34 21–47
Table 3. Subgroup comparisons.














For 19 PRISMA-P reporting items





245 4655 1181 (25) 4.8 (1.9) 5 2–11
After screening 
started 188 3572 900 (25) 4.8 (1.8) 4 2–10
Meta-analysis planned M-A 250 4750 1088 (23) 4.4 (1.5) 4 2–9
No M-A 183 3477 993 (29) 5.4 (2.1) 5 2–11
Funded / Sponsored / 
Supported
Funded etc. 381 7239 1841 (25) 4.8 (1.9) 4 2–11
Not funded etc. 52 988 240 (24) 4.6 (1.6) 4 2–8
For 63 PRISMA-P reporting elements





245 15435 8214 (53) 33.5 (5.9) 33 18–47
After screening 
started 188 11844 6255 (53) 33.3 (5.8) 33 21–47
Meta-analysis M-A 250 15750 8244 (52) 33.0 (5.2) 32 21–45
No M-A 183 11529 6225 (54) 34.0 (6.6) 34 18–47
Funded / Sponsored / 
Supported
Funded etc. 381 24003 12804 (53) 33.6 (5.9) 33 18–47
Not funded etc. 52 3276 1665 (51) 32.0 (5.3) 31 22–46
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inter-related activities. PROSPERO was launched in 2011, 
a time when there were few opportunities to publish proto-
cols, however, registration is not meant to be a substitute for 
preparation of a protocol. PROSPERO and PRISMA-P 2015 
requirements are not aligned as they serve different purposes. 
However, a stated aim of registration is to facilitate comparison 
of what was planned with what is reported. Even if limited 
information were registered, we would expect the mandatory 
fields in PROSPERO to be fully completed. This was not the case, 
particularly for details related to outcome measures, assessment 
of risk of bias and quantitative analysis methods. It would 
not be reasonable to expect that PROSPERO records meet all 
the PRISMA-P recommended items, given the differences in 
purpose between a protocol and registration, but it is important 
to understand what information is available where registration 
is the only public source.
Eligibility criteria and type of analysis planned were most 
frequently reported and are all separate required fields in 
PROSPERO. However, study selection process, which is optional, 
was also a higher frequency reported item. This may be explained 
by considering that some elements of items, such as eligibility 
criteria, study selection and risk of bias have what might be con-
sidered a standard, recognisable format that facilitates reporting. 
Other items need a more nuanced approach underpinned by a 
clear understanding of systematic review methods, and there-
fore may be associated with being less frequently reported 
due to a lack of confidence or experience with these aspects 
of review methods. For example, how risk of bias will be used 
in the synthesis, data handling in a meta-analysis, meta-biases 
and confidence in cumulative evidence, all had low scores. Part 
of the problem may be the uncertainty of what the searches will 
find when designing a systematic review but needing to know 
so the design is appropriate. For example, the intention may 
be to perform a meta-analysis, this may not be possible once 
the studies for inclusion have been identified. While, both 
PROSPERO and PRISMA-P acknowledge that protocols 
are iterative documents and may need to be amended, changes 
should be documented, justified and the stage of review at 
the time of the amendment made clear. Therefore, it is bet-
ter to record alternative options for activities such as how data 
will be analysed and the conditions for selection of option 
when finalising the protocol.
Differences in frequency of reporting may also reflect where 
researchers considered items to be less or more impor-
tant than others. For example, naming the software used for 
data management may not be seen as crucial, whereas the 
eligibility criteria and approach to synthesis are.
There are strengths and limitations to this study. The assessed 
sample of 433 records was representative of all the eligi-
ble 2018 non-Cochrane intervention reviews registered in 
PROSPERO. As a result, the findings may reasonably be 
generalised to other registrations of healthcare interventions, but 
not necessarily other types of registered reviews excluded from 
our sample.
PRISMA-P is a reporting guideline and not a rating scale, so 
judgements about whether sufficient information had been pro-
vided for some items carried a degree of subjectivity. The assess-
ment guide and form developed for the study aimed to maximise 
No of 
records
For the 19 PRISMA-P items assessed For the 63 elements assessed
Overall score 




















Topic of review (10 with most assessed records)
Cancer 42 184 (23) 4.4 (1.8) 4 2–10 1326 (50) 31.6 (5.6) 31 21–47
Cardiovascular 58* 278 (25) 4.8 (1.8) 4 2–10 1952 (53) 33.7 (5.5) 33 21–46
Complementary 
therapies








51 266 (27) 5.2 (2.0) 5 2–10 1762 (55) 34.5 (5.7) 33 21–44
Musculoskeletal 70 335 (25) 4.8 (2.0) 4 2–11 2295 (52) 32.8 (6.2) 32 18–47
Neurological 42* 221 (28) 5.3 (1.9) 5 2–11 1443 (55) 34.4 (6.1) 33.5 23–47
Physiotherapy 36 174 (25) 4.8 (1.8) 4 2–8 1194 (53) 33.2 (5.8) 32.5 18–43
Rehabilitation 42* 201 (25) 4.8 (2.1) 4 2–11 1393 (53) 33.2 (5.7) 32.5 23–47
Surgery 49 251 (27) 5.1 (1.8) 5 2–10 1644 (53) 33.6 (5.2) 33 23–47
*numbers differ from Table 1 because of the record(s) excluded at assessment
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objectivity but in accordance with PRISMA-P did not weight 
importance of items. Although two researchers independently 
carried out the assessments, achieving an overall agreement 
rate of 90%, subjectivity was minimised but not eliminated.
PROSPERO was developed in 2011 to record key protocol 
details and does not necessarily accord with everything subse-
quently recommended in the 2015 PRISMA-P reporting guide-
lines. Some registration items are mandatory and others optional. 
However, this study looked at records that had no other protocol 
output and arguably should therefore have provided PRISMA-P 
level detail. The evidence that protocol details are only 
available in PROSPERO for around 96% of non-Cochrane 
reviews makes the infrequency of reporting of items a concern9,10. 
Based on the findings of other studies, promoting improved 
reporting of protocol details may help increase the quality of 
systematic reviews17,18.
Protocols are iterative documents and even after a review has 
started there may be legitimate reasons for amendments. Such 
changes should and can be reported in a registration record, 
with their justification and timing. Just over two thirds of 
PROSPERO records have more than one version (Figure 1). 
While focussing on single entry records to be certain that any 
changes were not made after completion of the review this 
may have excluded records where more complete information 
was added to the record over time at key points in the review 
process.
This study simply looked at whether items were reported and not 
at the level of detail or suitability/appropriateness of the planned 
methods. Use of a scoring system giving equal weight to all 
items and elements as PRISMA-P does, is a limitation of this 
study because PROSPERO identifies information as either 
mandatory or optional. However, the scoring used in this study 
only relates to the presence or absence of information, and we 
have indicated the mandatory/optional fields in Table 2. The 
option of ‘partially reported’ could have been used at assessment 
but was avoided to minimise subjectivity. The focus was on 
simply establishing whether items were reported or not. The 
assessors focussed on whether the information was reported or 
could reasonably be inferred from what was reported. Assessing 
the quality of planned methods inprotocol registrations needs 
to be the subject of further research.
This study shows that there is work to be done to promote the 
complete reporting of items recommended in the guidelines for 
systematic review protocols when the registration in PROSPERO 
is the only place they can be accessed. This is in line with other 
research that has identified issues with the quality of reporting, 
publication and outcome reporting biases in systematic review 
protocols in general3,9,11,13,19,20. As proposed in the PRISMA-P 
statement paper, actions and potential benefits to encour-
age adherence to PRISMA-P will take a joint effort on the 
part of a host of stakeholders, including reviewers, registries, 
and journal editors5,21.
Conclusions
PROSPERO provides reviewers with the opportunity to be 
transparent in their planned methods and demonstrate efforts 
to reduce bias. However, where the PROSPERO record is 
the only available source of a priori reporting, there is a sig-
nificant shortfall in the items reported, compared to those 
recommended in PRISMA-P. This presents peer reviewers and 
others wishing to assess the validity of the final review with 
challenges in interpretation. PROSPERO records are not peer 
reviewed or assessed for methodological quality, it is the respon-
sibility of those registering their review to complete the reg-
istration form fully or provide access to a complete protocol. 
There are several areas requiring particular attention when 
completing the registration form. These include explaining the 
rationale for undertaking the review in the context of what is 
known; providing information sources beyond a list of databases 
to be searched; and reporting reproducible process methods 
for data management, study selection and risk of bias assess-
ment. In addition, defining variables for data extraction, how 
specified outcomes will be measured, and the planned analy-
ses, with criteria for undertaking a quantitative synthesis 
should all be included in detail.
This study only looked at whether recommended items were 
reported or not in PROSPERO records. Further research 
is needed to assess the quality of the planned methods in 
systematic review protocol registrations.
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Xin S n   
Chinese E idence-Based Medicine Center and Cochrane China Center, West China Hospital, 
Sichuan Uni ersit , Chengdu, China 
This stud  conducted a methodological sur e  to assess the e tent to hich the contents of 
PROSPERO records meet the s stematic re ie  protocol reporting items in PRISMA-P. This paper 
addresses an important research question, and the findings ma  ha e implications for the 
reporting of s stematic re ie  protocols. Ho e er, there are a fe  issues for authors to consider:
One aim of PRISMA-P is to aid authors in transitioning their s stematic re ie  protocols 
prepared in accordance ith PRISMA-P into full te t, hile the authors used records from 
PROSPERO (i.e., not full-te t) to assess the compliance to PRISMA-P reporting items, hich 
ma  be a limitation that should be discussed in this paper. 
1. 
In the methods part, it could be desirable that the authors could clearl  report ho  the 17 
numbered items of PRISMA-P ere broken do n into 63 elements. 
2. 
The author should clearl  report hether the subgroup anal ses reported in table 3 ere 
pre-planned. 
3. 
The use of a scoring scheme for PRISMA-P and the 63 elements ma  not be optimal, gi en 
the potential difference in item importance, hich should be added to the discussion part 
as a limitation. 
4. 
In table 2, alues in parentheses are percentages, hich should be indicated in the table.5. 
 
I  he k clea l  and acc a el  e en ed and d e  i  ci e he c en  li e a e?
Yes




A e fficien  de ail  f me h d  and anal i  ided  all  e lica i n b  he ?
Yes
If a licable, i  he a i ical anal i  and i  in e e a i n a ia e?
Partl
A e all he ce da a nde l ing he e l  a ailable  en e f ll e d cibili ?
Yes
A e he c ncl i n  d a n ade a el  ed b  he e l ?
Yes
Competing Interests: No competing interests ere disclosed.
Re ie er E pertise: Clinical Epidemiolog
I c nfi m ha  I ha e ead hi  bmi i n and belie e ha  I ha e an a ia e le el f 
e e i e  c nfi m ha  i  i  f an acce able cien ific anda d.
Author Response 01 Sep 2020
Ali n B h, Uni ersit  of York, UK, York, UK 
We thank ou for our peer re ie  and gi e our responses as follo s: 
 
1. O e ai  f PRISMA-P i   aid a h  i  a i i i g hei  e a ic e ie  c  
e a ed i  acc da ce i h PRISMA-P i  f  e , hi e he a h  ed ec d  f  
PROSPERO (i.e.,  f - e )  a e  he c ia ce  PRISMA-P e i g i e , hich a  be 
a i i a i  ha  h d be di c ed i  hi  a e . 
 
Thank ou for raising this point. We agree and ha e addressed this point in the addition of 
the follo ing to the discussion: 
 
PROSPERO and PRISMA-P 2015 requirements are not aligned as the  ser e different 
purposes. Ho e er, a stated aim of registration is to facilitate comparison of hat as 
planned ith hat is reported. E en if limited information ere registered, e ould e pect 
the mandator  fields in PROSPERO to be full  completed. This as not the case, particularl  
for details related to outcome measures, assessment of risk of bias and quantitati e 
anal sis methods. It ould not be reasonable to e pect that PROSPERO records meet all the 
PRISMA-P recommended items, gi en the differences in purpose bet een a protocol and 
registration, but it is important to understand hat information is a ailable here 
registration is the onl  public source. 
 
2. I  he e h d  a , i  c d be de i ab e ha  he a h  c d c ea  e  h  he 17 
be ed i e  f PRISMA-P e e b ke  d  i  63 e e e . 
 
We ha e added an e ample from the stud  protocol to illustrate the description of ho  the 




Where the PRISMA-P description for an item specified more than one piece of information, 
the indi idual elements ere listed as subsets of the items. For e ample, item 14. Risk of 
bias in indi idual studies, sa s: Describe anticipated methods for assessing risk of bias of 
indi idual studies, including hether this ill be done at the outcome or stud  le el, or 
both; state ho  this information ill be used in data s nthesis.  Scoring for this item ill be 
for each of the follo ing separate elements: No risk of bias assessment planned and 
justification pro ided; Risk of bias tools named for all stud  t pes included; Outcome or 
stud  le el or both; Domains/outcomes for risk of bias assessment stated; Risk of bias 
assessment process described; Ho  risk of bias findings ill be used in s nthesis. Appl ing 
this approach to the 19 items resulted in a list containing 63 elements to be reported. 
 
3. The a h  h d c ea  e  he he  he bg  a a e  e ed i  ab e 3 e e e-
a ed. 
 
We can confirm the  ere all included in the stud  protocol, a ailable at
https://doi.org/10.17605/OSF.IO/7PW4G. We ha e added hich ere all pre-defined  to the 
section on Subgroup comparisons in the manuscript. 
 
4.The e f a c i g che e f  PRISMA-P a d he 63 e e e  a   be i a , gi e  he 
e ia  diffe e ce i  i e  i a ce, hich h d be added  he di c i  a  a  a 
i i a i . 
 
This is an important point thank ou, hich e ha e incorporated into the discussion as 
follo s: 
 
This stud  simpl  looked at hether items ere reported and not at the le el of detail or 
suitabilit /appropriateness of the planned methods. Use of a scoring s stem particularl  as 
all items and elements carried the same eight is a limitation of this stud . The scoring 
does not accord ith the PROSPERO dataset hich identifies information as either 
mandator  or optional. For this reason e ha e indicated the mandator /optional fields in 
Table 2. The scoring onl  relates to the presence or absence of information. The option of 
partiall  reported  could ha e been used at assessment but as a oided to minimise 
subjecti it . The focus as on simpl  establishing hether items ere reported or not. The 
assessors focussed on hether the information as reported or could reasonabl  be 
inferred from hat as reported. Assessing the qualit  of planned methods in protocol 
registrations needs to be the subject of further research. 
 
We ha e also amended ho  the mandator /optional fields are indicated in Table 2 so the 
difference is clearer.  
 
5. I  ab e 2, a e  i  a e he e  a e e ce age , hich h d be i dica ed i  he ab e. 
 
Apologies for this omission, this has been corrected in the re ised ersion.  
Competing Interests: No competing interests ere disclosed.
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This article is an anal sis of ho  PROSPERO records adhere to the PRISMA-P guideline. The 
Anal sis is based on a random sample of 439 PROSPERO records published in 2018. The authors 
conclude that reporting in PROSPERO should be impro ed gi en the fact that the PROSPERO 
record is often the onl  a ailable source of a priori reporting. 
 
The manuscript is methodologicall  sound and ell ritten. What I think can be impro ed is the 
discussion. I onder hat is the implication of this stud . Do the authors ant to make the point 
that PROSPERO records should follo  PRISMA-P? To the best of m  kno ledge PRISMA-P is e en 
not mentioned in the PROSPERO guidance. If this ould be the intention then  not allign 
PROSPERO ith the PRISMA-P items. I admit that PRISMA-P has been primaril  designed for SRs of 
healthcare inter entions, but most items are General and ould be applicable to other re ie  
t pes as ell. I do not ant to make the point that this is a great idea, but it is someho  a logical 
question resulting from our manuscript and this should be mentioned in the discussion. 
Registries and protocols should be seen as different entities, and thus I think that a perfect result 
of all PROSPERO records meeting all PRISMA-P items cannot be hat e aiming for. If this ould 
be the case, this ould probabl  dilute the difference bet een a PROSPERO record and a protocol.
 
I  he k clea l  and acc a el  e en ed and d e  i  ci e he c en  li e a e?
Yes
I  he d  de ign a ia e and i  he k echnicall  nd?
Yes
A e fficien  de ail  f me h d  and anal i  ided  all  e lica i n b  he ?
Yes
If a licable, i  he a i ical anal i  and i  in e e a i n a ia e?
Not applicable
A e all he ce da a nde l ing he e l  a ailable  en e f ll e d cibili ?
Yes




Competing Interests: No competing interests ere disclosed.
Re ie er E pertise: Research methods, clinical epidemiolog
I c nfi m ha  I ha e ead hi  bmi i n and belie e ha  I ha e an a ia e le el f 
e e i e  c nfi m ha  i  i  f an acce able cien ific anda d.
Author Response 01 Sep 2020
Ali n B h, Uni ersit  of York, UK, York, UK 
We thank ou for our peer comments and agree this is an important point. We ha e added 
the follo ing paragraph to the discussion section: 
 
The re ie  protocol is a detailed record of the planned methods de eloped through an 
iterati e process. Once finalised or close to finalising, the ke  methodological details should 
be registered in PROSPERO. These are t o separate but inter-related acti ities. PROSPERO 
as launched in 2011, a time hen there ere fe  opportunities to publish protocols, 
ho e er, registration is not meant to be a substitute for preparation of a protocol. 
PROSPERO and PRISMA-P 2015 requirements are not aligned as the  ser e different 
purposes. Ho e er, a stated aim of registration is to facilitate comparison of hat as 
planned ith hat is reported. E en if limited information ere registered, e ould e pect 
the mandator  fields in PROSPERO to be full  completed. This as not the case, particularl  
for details related to outcome measures, assessment of risk of bias and quantitati e 
anal sis methods. It ould not be reasonable to e pect that PROSPERO records meet all the 
PRISMA-P recommended items, gi en the differences in purpose bet een a protocol and 
registration, but it is important to understand hat information is a ailable here 
registration is the onl  public source.  
Competing Interests: No competing interests ere disclosed.
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Items, scoring options and guidance/rules for assessment of PROSPERO records compared to 
PRISMA-P reporting requirements 
PILOT Version1 15 March 2020 
The assessment form contains a breakdown of PRISMA-P reporting items re-organised to match 
the order in which information is presented in PROSPERO. Numbering of items matches the 
numbering in PRISMA-P for ease of referral to the field in the E&E paper. 
A number of fields have been excluded: details of these and the reasons for exclusion are 
documented in the study protocol.  
Sub-questions have been included for sections as not all the information for PRISMA-P is 
required/requested in PROSPERO. These elements will be included in the total scoring for each 
item, and then reported in the detailed breakdown of items in the context of what PROSPERO 
requires. 
Information required by PRISMA-P may be contained in any field within PROSPERO – it does not 
have to be in the expected field. E.g. Context may be indicated in the research question, or 
objectives fields. The exceptions are Q1 where the information must be in the title and Q7 
where the information must be included in the objectives (see below). 
If you are really unsure about something, don’t let it hold you up – make a decision and 
remember we are double assessing and discrepancies will be discussed. 
Rules for specific fields 
 
Item Options Scoring rules 
1a. Identification in the 
title: Identify the report 
as a protocol  
Yes/No Refers to information in the title only. If it does not state in 
the title that it is a protocol, the score is ‘No’ 
1a. Identification in the 
title: Identify the report 
as a systematic review / 
meta-analysis / or 
other form of 
systematic review such 
as a rapid review 
Yes/No Refers to information in the title only. If it does not state in 
the title that it is a systematic review or meta-analysis or 
variation on a systematic review such as a rapid review, the 
score is ‘No’ 
1b. Update: If the 
protocol is for an 
update of a previous 
systematic review, 




Refers to information in the title only. If it says Update in 
the title then clearly the score is Yes. Updates are rare 
therefore most frequent response is likely to be N/A. 
However, if in the course of completing the assessment it 
becomes clear that the reviewers are in fact updating an 
existing review, this should be revisited and scored as ‘No’. 
PROSPERO contains the field “Details of any existing review 




of the same topic by the same authors”, which if completed 
appears in the record and will indicate that this is an update 
(unless of course they indicate ‘none’!) 
 
Looking for pre-existing reviews is an essential part of 
avoiding duplication of reviews; this does not count as them 
planning to update a review. Updates of reviews are still 
rare in PROSPERO registered non-Cochrane review 
INTRODUCTION   
7. Objectives: Provide 
an explicit statement of 
the question(s) the 
review will address 







Refers to the information given in the research question, 
which should include reference to participants, 
interventions, comparators, and outcomes (PICO) – score 
Yes/No/ Not applicable for each element. N.B while 
PROSPERO then asks for each of these elements separately, 






METHODS   
9. Information sources: Describe all intended information sources (e.g., electronic databases, 






‘Yes’ if any bibliographic database(s) are named e.g. 
PubMed, MedLine, Embase, CENTRAL, LILACS  
Grey literature sources 
named or statement of 
no grey lit searches 
planned 
e.g. databases of theses, conference abstracts, OpenGrey, 
System for Information on Grey Literature in Europe (Sigle)  
Study registries e.g. PROSPERO, clinicaltrials.gov 
Contact with study 
authors planned or 
statement that contact 
not planned 
Will they be contacting authors, leaders in the field to ask 
them to identify studies/provide information on 
unpublished work? 
Other: e.g. hand 
searching reference 
lists of included studies 
Anything not included above that relates to getting hold of 
study papers or data relevant to the review 
Planned search dates ‘Yes’ if they say e.g. databases to be searched from 
inception or a date (July 2000) or they indicate a date when 
the searches will be carried out. Don’t give either = ‘No’ 
10. Search strategy: Present draft of search strategy to be used for at least one electronic 
database, including planned limits, such that it could be repeated 




e.g. list of search terms and how they will be combined for a 
specific database e.g. PubMed This may or may not include 




combining results to arrive at a final dataset: some topics 
are so niche they only require a simple search 
Search terms given 
alone i.e. not formal 
strategy for a database 
List of words with no information about how they will be 
combined or where they will be used 
Approach to 
limits/restrictions 
reported e.g. dates; 
statement of no limits  
Any mention of limiting the searches by date, language or 
any other parameter. A statement that there will be no 
limitations/restrictions used should score a ‘Yes’ as they 
have reported on this item 
6. Rationale: Describe the rationale for the review in the context of what is already known 
Rationale described 
(e.g. existing evidence 
base) 
Yes/No Statement about why this review is needed. E.g. 
unanswered question - no existing review; to inform 
guideline development; new studies since last review = 
update or new review 
Context provided (e.g. 
scale of 
problem/condition) 
Background on clinical condition 
8. Eligibility criteria: Specify the study characteristics (e.g., PICO, study design, setting, time frame) 
and report characteristics (e.g., years considered, language, publication status) to be used as 
criteria for eligibility for the review 
Study design specified Yes/No/Not 
applicable 
Types of study designs to be included are listed, or if no 
restriction on type of design, statement saying so 
Setting (condition or 
domain) specified 
Should be in specific PROSPERO field: Condition or domain 
being studied. There may be more info in the non-
mandatory ‘Context’ field 
Population detailed Population identified in sufficient detail to enable data 
extraction 
Intervention specified Intervention described in sufficient detail to enable data 
extraction 
Comparator specified This may be an alternate specific intervention, usual care or 
for network M-A interventions are compared with each 
other 
Outcome(s) specified Outcome(s) listed 
13. Outcomes and prioritisation: List and define all outcomes for which data will be sought, 
including prioritisation of main and additional outcomes, with rationale 
Primary/main 




Primary/main outcome(s) described and identified as such 
Primary/main outcome 
measure(s) specified 
Measure(s) specified / included in description of outcome(s) 
Additional outcomes 
specified as such 
Other outcomes specified  
Additional outcome(s): 
measure(s) specified 
Measure(s) specified / included in description of outcome(s) 
Study records   
11a. Data management: Describe the mechanism(s) that will be used to manage records and data 
throughout the review 








Details of how the search results will be handled e.g 
RevMan, Covidence, Eppi-reviewer, or unspecified 
‘software’ 
De-duplication planned A statement anywhere to say that search results will be de-
duplicated or how multiple reports of the same study will 
be handled 
11b. Selection process: State the process that will be used for selecting studies (e.g., two 






Title and abstract screening – number of reviewers/ 
resolution of disagreements 
Full paper screening 
process detailed 
Description of how the eligibility criteria will be applied to 
the records from initial screening – number of 
reviewers/resolution of disagreements 
11c. Data collection process: Describe planned method of extracting data from reports (e.g., 
piloting forms, done independently, in duplicate), any processes for obtaining and confirming data 
from investigators 
Pilot extraction form Yes/No 
[Unclear] 
Mechanism for consistent recording of extracted data, e.g. 
form to be developed and piloted 
Data extraction process 
described 
How data extraction be performed, e.g. double blind with 
disagreements resolved by discussion/third reviewer 
Obtain missing data Statement about how missing data will be dealt with: e.g. 
contact study authors/account for in statistical analyses 
12. Data items: List and define all variables for which data will be sought (e.g., PICO items, funding 
sources), any pre-planned data assumptions and simplifications 




Items to be included in data extraction listed 
Variables defined Definitions for the items for extraction 
Any data assumptions 
reported 
Statement of any pre-specified assumptions e.g. what they 
will do with unclear information or missing data 
14. Risk of bias in individual studies: Describe anticipated methods for assessing risk of bias of 
individual studies, including whether this will be done at the outcome or study level, or both; state 
how this information will be used in data synthesis 






Statement to say the authors are not going to carry out a 
risk of bias assessment and provide an explanation to justify 
this = Yes. Anything less = No 
Risk of bias tools 
named for all study 
types included 
Risk of Bias tool named for assessment of each study design 
to be included in the review 
Outcome or study level 
or both 
Statement to indicate if ROB results will be used at study 
level or specifically at outcome level or both. N.B. 
identifying a ROB tool that is designed to assess both study 
and outcome levels (e.g. Cochrane RoB or Newcastle 
Ottawa Scale (NOS) = Yes 





risk of bias assessment 
stated 
The constructs for assessment are listed, defined and 
judgment options (e.g. high low unclear) reported 
If constructs listed and defined but judgement options not 
specifically given – consider if tool to be used has pre-
specified judgement options if so = Yes 
Risk of bias assessment 
process described 
Statement of how risk of bias will be undertaken e.g. two 
reviewers independently/blinded – method for resolution of 
disagreements 
How risk of bias 
findings will be used in 
synthesis 
Statement of whether studies will/will not be excluded 
based on risk of bias score. Or include all studies meeting 
criteria but account for risk of bias in statistical analyses 
(sub-group/sensitivity analyses) 
Data   
15a. Synthesis: Describe criteria under which study data will be quantitatively synthesized 
Criteria for doing a 
quantitative synthesis 
planned / statement 
that quantitative 
synthesis not planned 
Yes/No/Not 
applicable 
Statement to say under what circumstances a meta-analysis 
(M-A) will be undertaken or that a M-A will not be 
undertaken  
Statement that descriptive stats only/narrative synthesis 
planned = Yes 
15b. If data are appropriate for quantitative synthesis, describe planned summary measures, 
methods of handling data, and methods of combining data from studies, including any planned 
exploration of consistency (e.g., I2, Kendall’s tau) 
Summary measures Yes/No/Not 
applicable 
Details of measure of treatment effects / statistical method 
/ use of fixed or random effects or both / assessment of 
heterogeneity. Any of these = Yes 
Data handling Details of how data will be handled to ensure measures are 
converted/presented in the same format. Approach to 
handling of rare events and imputation of missing data. Any 




Plans for how data will be combined and how they will 
evaluate between study inconsistency (heterogeneity) 
Name of software to be 
used for meta-analysis 
Type or name of software to be used for performing the M-
A e.g. Stata, R, RevMan 







Statement that sub-group analyses are planned - must 
include the co-variants. Statement that no-subgroup 
analyses are planned = yes 
Methods for subgroup 
analyses reported 
How groups will be divided, use of fixed or random effects 
Sensitivity analyses 
planned 
Statement that sensitivity analyses are planned or not 
planned, to include items to be examined 





Usually performed along with a M-A or a Narrative 
synthesis: literally a plan to describe the included studies 








For a narrative synthesis details of how studies/findings will 
be combined/stratified narratively (in text or tables): i.e. 
some form of synthesis beyond providing a description of 
the studies and data extracted 
For reviews of qualitative studies, plans how the synthesis 
will be carried out e.g. thematic analysis or framework 
development etc should be provided 
Other analyses planned Details of any other analyses such as cost effectiveness are 
provided. If no mention in record of data being collected for 
other analyses = Not applicable. If e.g. cost data collected 
but no analysis planned = No 
16. Meta-bias(es): Specify any planned assessment of meta-bias(es) (e.g., publication bias across 
studies, selective reporting within studies) 




Methods for testing for publication bias should be given e.g. 
funnel plot; Egger’s test 
Outcome reporting bias 
to be assessed 
Methods for assessing potential for outcome reporting bias 
should be given, e.g. ORBIT system; sensitivity analysis 
17. Confidence in cumulative evidence: Describe how the strength of the body of evidence will be 
assessed (e.g., GRADE) 
Overall assessment of 
included studies 
planned or statement 
that no overall 




Is there a plan to look at overall study quality in addition to 
the ROB assessment of individual studies? 
Methods specified (eg 
GRADE) 
If an overall assessment is planned, are the methods 
specified? (Not applicable if not planned – Score No if No to 
previous question) 
Support   
5a. Sources: Indicate sources of financial or other support for the review 
5b. Sponsor: Provide name for the review funder and/or sponsor 
Source of financial/ 
other support provided 
or statement of no 
financial/other support 
Yes/No Straightforward Yes they make a statement about 
funding/no funding = Yes or no statement = No 
Name of sponsor given 
or statement of no 
sponsorship 
Straightforward Yes they make a statement about 
sponsor/no sponsor = Yes or no statement = No 
Comment or 
observations on this 
record 
 For any observations you may have about this record or any 
issue you may want to raise. Please also feel free to make 
use of the questions sheet in the shared drive 
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Background 
High quality systematic reviews start with the preparation of a protocol. The methods for 
conducting the review should be identified and recorded in the protocol in advance of 
commencing the review in order to minimise a range of potential biases.1 2 Ideally protocols 
should be made available in the public domain to facilitate transparency.3 4 In addition, 
registration of key protocol details is encouraged as best practice in reporting guidelines, 5 6 by 
publishers like the British Medical Journal (BMJ), Public Library of Science (PLoS), and BioMed 
Central (BMC) and is mandated in their instructions to authors by journals such as BMC 
Systematic Reviews, BMJ, BMJ Open, PLoS One, British Journal of Radiology and National 
Institute for Health Research (NIHR) journals. 
PROSPERO is a facility for making key methodological details publicly available in advance of 
carrying out a systematic review. Registration on PROSPERO requires completion of an 
internationally agreed minimum dataset from a systematic review protocol.7 8 
The database was launched in 2011, at a time when there were few options for publishing 
protocols outside of major organisations such as the Cochrane and Campbell Collaborations, 
Joanna Briggs Institute, or on the websites of major funders and commissioners of research 
such as the NIHR in the UK and the Agency for Healthcare Research and Quality (AHRQ) in the 
USA. There are now more options for publication of systematic review protocols, such as open 
access journals like Systematic Reviews and open data repositories like the Open Science 
Framework (https://osf.io/registries/discover?q=protocols). PROSPERO remains the only free, 
open access registry of systematic review protocols, making it a single searchable source of on-
going and completed reviews. Uptake of registration has increased exponentially and by the 
end of 2019 there were over 60,000 registrations in PROSPERO. There is evidence that 
considerably more systematic reviews are registered in PROSPERO than have peer-reviewed 
protocols published. In 2016, 1058 records were accepted by PROSPERO, in the same time 
period, only 404 published systematic review protocols were identified.3 Another study 
reported identifying 20,814 [sic] non-Cochrane systematic review protocols from web scraping 
PROSPERO and bibliographic database searches. Of these, 924 were only published in journals, 
807 were published in journals and registered in PROSPERO and 19,890 were only available as a 
record in PROSPERO.9 There is further evidence from Ge et al (2018) that of the non-Cochrane 
reviews registered in PROSPERO, only 3% or 4% have a published protocol.9 10 This means that 




for a large number of reviews a PROSPERO record is likely to be the only source providing 
details of the planned methods. 
Published protocols and registration records aim to provide transparency in the review process 
by allowing public access to the key pre-specified elements for the conduct of a review. One of 
the stated aims of PROSPERO is to facilitate comparison between planned review methods and 
reported results.8 Such a comparison enables peer reviewers and other readers of the final 
review to assess for themselves the potential for bias in the findings. There is also a steadily 
growing body of research using PROSPERO records to assess the risk of biases in final review 
reports.10-15 Given this reliance on the information provided in PROSPERO records, it is 
important to know whether the level of detail in the records is sufficient. Our focus in this study 
is on the stated aim of PROSPERO to reduce opportunity for bias by enabling comparison of the 
completed review with what was planned in the protocol. 8 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for 
Protocols (PRISMA-P) were informed by the international consultation research that 
established the PROSPERO dataset.4 6 Key methodological aspects of a protocol are mandated 
for registration in PROSPERO; other items, mainly administrative fields, are optional.7 8 
Submissions for registration are checked to make sure information makes literal sense and is in 
the appropriate field, but they are not subject to any form of peer review or critical appraisal. 
There is therefore the possibility that PROSPERO records do not provide all the necessary 
information identified by the reporting guidelines to enable comparison with the completed 
systematic review. The registration record may be the only place where a priori methods are 
available for users, in particular peer reviewers, to check for potential issues such as selection, 
outcome reporting and publication biases. This study will investigate the extent to which 
records in PROSPERO comply with each of the items for reporting of protocols set out in the 
PRISMA-P guidelines, when no protocol or other information is available.  
There is evidence from studies of compliance with the PRISMA statement that the 
demographics of reviews can vary considerably. Characteristics of reviews included in 
methodological studies of reporting include; type of journal, year of publication, article word 
count, country, number of authors, funding, topic, planned meta-analysis and registration.9 14 16-
18 We therefore also aim to examine the same characteristics where the data are available in 
our sample. We will explore whether country, number of authors, funding, topic, and planned 
meta-analysis have any association with the completeness or otherwise of reporting specific 
items. 
Methods 
This study protocol has been prepared and agreed in advance of commencing the study. There 
are no reporting guidelines for protocols of methodological research studies as far as we are 
aware. We have aimed to provide as much information about our planned methods in this 
protocol as possible. There is also a lack of a single point of registration for protocols of 
methods studies. However, the protocol will be made available on the open access platform 




Open Science Framework prior to identification of the study sample and the assessment 
process. 
We will assess a random sample of PROSPERO registration records against the protocol 
reporting criteria set out in the PRISMA-P 2015 checklist. PRISMA-P will be used as it is the only 
reporting guideline specifically for systematic review protocols and meta-analyses and was 
developed in line with guideline development methods.19 A dataset of PROSPERO records for 
reviews of health interventions from 2018, where no additional information about the planned 
methods are available in a publicly available protocol (e.g. published paper or additional 
documents attached to the PROSPERO record) will be analysed to give an overview of the 
register content and the extent to which the information recommended in PRISMA-P is 
reported.  
The study will focus on reviews of health care interventions as this is the type of review for 
which the PROSPERO minimum dataset was originally designed.8 As was the long term aim for 
the register, it now contains records for a wide range of types of reviews. The sample size 
required to assess all of these is beyond the capacity of this un-funded study. In addition, the 
PRISMA-P reporting guidelines were written primarily for reviews of health care interventions. 
Records from the calendar year 2018 will be used to allow time for dissemination and adoption 
following publication of the PRISMA-P papers in 2015. A complete dataset for 2018 will be 
obtained. This will be used to provide the contextual overview and from which a random 
sample of records will be taken for assessment.  
Peer review is an important part of the publication process and compliance with reporting 
guidelines and protocols are expected as part of peer review of a completed systematic review. 
The focus of this study is therefore the large body of registrations where the registered record 
is the sole source of publicly available information about the pre-planned methods. PROSPERO 
registrations with an associated protocol will be excluded. Included records will have indicated 
that the planned methods were agreed at some point prior to the completion of data extraction 
in order to have met the PROSPERO acceptance criteria in 2018.  
We will exclude records with multiple versions as these are registrations where changes have 
been made. By only including single version records we will be assessing the version a peer 
reviewer would use and excluding any potential post-hoc amendments, that is, changes to the 
initial registration information following work on the review commencing/being 
complete/having peer reviewer feedback. Accounting for changes in planned methods within 
different versions in relation to the timing of the changes within the review process is a topic 
for a different study.  
The implications of the chosen inclusion and exclusion criteria on external validity of the study 
will be explored in the results paper.  





The primary outcome for this study will be the compliance between registration records and 
PRISMA-P reporting items. Each of the 21 items will carry a score of 1 where reporting is 
complete, making the maximum possible score 21. 
We will also report on the number of elements within PRISMA-P items assessed as completely 
reported in PROSPERO.  
Demographic data for both the full set of eligible 2018 registrations and the sample set of 
records assessed will be reported, to include: month of registration, funding, country, number 
of authors, topic of review, stage of review, meta-analysis planned. The following definitions 
will be used. 
Funding: Field 12. Funding sources/sponsors in PROSPERO is a single free text field which 
prohibits consistent differentiation between funder/funding and sponsor/sponsorship for the 
full 2018 dataset. We will therefore categorise the information provided as either ͚no listed 
funder or sponsor͛ or ͚listed sponsor or funder͛. 
Topic of review: will be reported as self-defined by authors in PROSPERO. The PROSPERO topic 
of review options are based on the Health Research Classification system 
(https://hrcsonline.net/health-categories/). Additional codes are included in PROSPERO to 
accommodate the broad nature of the inclusion criteria. 
Stage of review: authors are required to indicate the stage of their review at the time of 
registration in a matrix as below. We will define stage of review as the furthest point in the 
review process indicated by authors of records. This could be either an activity started or 
completed. For example, the following record would be counted as ͚Started Data extraction͛. 
Stage Started Completed 
Preliminary searches Yes Yes 
Piloting of the study selection process Yes Yes 
Formal screening of search results against eligibility criteria Yes No 
Data extraction Yes No 
Risk of bias (quality) assessment No No 
Data analysis No No 
 
Meta-analysis planned: assessor responses to PRISMA-P item 15b, sub-question about whether 
a meta-analysis is planned will be used. 




Sample size and selection 
Using a PROSPERO dataset made available to us for research purposes, [we are grateful to 
Professor Lesley Stewart, Director of CRD and Gordon Dooley of METAXIS] we will apply the 
inclusion and exclusion criteria to generate a set of eligible records for 2018. A 20% random 
sample will be drawn from all eligible records, using simple random sampling without 
replacement. This will be done using the sample function in the base functionality of R.20 
The PROSPERO dataset contains 5,313 records for reviews of interventions first accepted in 
2018 (excluding Cochrane and reviews of animal studies). Applying the other study inclusion/ 
exclusion criteria results in 2,194 eligible registration records. We will assess the reporting of 
information in the random sample of 439 (20%) of these records.  
Inclusion criteria 
x Registration published in PROSPERO on or between 1 January 2018 and 31 December 
2018 
x Systematic review of a health care intervention (as self-defined by authors in 
PROSPERO) 
x Single registration record (i.e. no amendments have been made) 
x PROSPERO record does not state there is a peer reviewed published protocol or provide 
information about or access to a protocol  
Exclusion criteria 
x Cochrane reviews 
x Reviews of animal studies 
x Non-intervention reviews as identified in PROSPERO i.e. Diagnostic accuracy, Prognostic 
factors, Prevention, Epidemiological reviews relevant to health and social care, Public 
health, Service delivery in health and social care, Methodological 
x Reviews of reviews 
x Synthesis of qualitative studies 
x Provides any files, question response, or reference to a protocol 
Data assessment: 
Two researchers will independently compare the information provided in the public interface of 
the PROSPERO register with the relevant items in the PRISMA-P checklist. Disagreements will 
be resolved through discussion or recourse to a third researcher. 
For each PROSPERO record, assessment will involve the researchers completing an assessment 
form containing the PRISMA-P items as set out in the fields for assessment  belo , but ordered 
to match PROSPERO public record items. Options for decisions will be: Yes (information 
provided as per PRISMA-P requirements); No (some or all information not provided); and, 
where relevant, Not applicable/None Stated. The option of [Unclear] will be available for some 
items, but use discouraged at training. Where PRISMA-P items specify more than one piece of 
information, the individual elements will be listed separately and scored as above. The items as 
listed are from the summary checklist; the breakdown elements are informed by the 
information presented in the expansion and explanation paper.4 6  For example, item 14. Risk of 




bias in individual studies, says: ͞Describe anticipated methods for assessing risk of bias of 
individual studies, including whether this will be done at the outcome or study level, or both; 
state how this information will be used in data synthesis.͟ Scoring for this item will be for each 
of the following separate elements: No risk of bias assessment planned and justification 
provided; Risk of bias tools named for all study types included; Outcome or study level or both; 
Domains/outcomes for risk of bias assessment stated; Risk of bias assessment process 
described; How risk of bias findings will be used in synthesis.  
 
Where the required information is present (Yes) the score for an item will be 1; if the 
information is not reported (No) the score for the item will be 0. Where an item is sub-divided, 
scoring will be assigned on the basis that if any of the responses are No the overall score for the 
item will be 0; if all the responses to the elements are Yes, the item score is 1. The maximum 
possible overall score will be 21. The scores for the individual elements of items will also be 
presented to demonstrate where registration information partially meets the PRISMA-P 
requirements and whether there are any persistent gaps in reporting. 
 
The assessment tool has been developed as a Google Form for: ease of access by multiple users 
at the same or different times; accuracy of recording decisions; and ability to export the data in 
a Microsoft Excel spreadsheet for identifying discrepancies, recording the final decision and 
producing the study results. 
 
The researchers undertaking the assessment have familiarised themselves with the PRISMA-P 
checklist and the detailed information provided in the Explanation and Elaboration paper.4 6 
Prior to identification of the dataset and starting the study, the lead author (AB) developed the 
pilot assessment form. All the authors met for a training session where all the items and 
elements were discussed. Potential issues were resolved and all authors agreed the content of 
the revised pilot form. The agreed items, elements, scoring and assessment guidance are set 
out in Appendix 1 of this protocol. The form contains a link to the PRISMA-P explanation and 
elaboration paper for ease of access at any time during the assessment phase. The assessment 
Google Form will be piloted with all researchers assessing the same 10 PROSPERO records from 
the study data set. Level of agreement, setup of the form and consistency of use will be 
reviewed and discussed with the assessors until a high level of agreement is achieved (>90%). 
The form will be amended as necessary following piloting, additional training or support 
materials supplied as required and assessment of the study dataset undertaken.  
Each assessor will be given a list of allocated records containing a hyperlink to the record in the 
PROSPERO database. Allocation will be random as will pairings of researchers for dual 
independent assessment. It will not be possible to blind the researchers to the authors of 
registrations in PROSPERO. Should any of the researchers be authors of included registrations, 
they will not assess their own records. 
PRISMA-P fields for assessment 
ADMINISTRATIVE INFORMATION 
Title 













8. Eligibility criteria 
9. Information sources 
10. Search strategy 
Study records 
11a. Data management 
11b. Selection process 
11c. Data collection process 
12. Data items 
13. Outcomes and prioritization 
14. Risk of bias in individual studies 
Data 
15a. (criteria for synthesis) 
15b. (summary measures and data handling) 
15c. (additional analyses) 
15d. (alternative to quantitative synthesis) 
16. Meta-bias(es) 
17. Confidence in cumulative evidence 
PRISMA-P fields excluded from assessment 
The following reporting requirements will be excluded for the reasons given. 
x 2. Registration:  as the study only includes records registered in PROSPERO the answer to 
this ill al a s be Yes  
x Authors: 3a. Contact: only the person registering the protocol is required to give their name 
and email address: postal address is optional, so the answer to this would always be No  
x Authors: 3b. Contributions: this is not information that is collected anywhere in the 
PROSPERO record so the ans er to this ould al a s be No  
x 4. Amendments: Amended versions of records are automatically displayed with dates in the 
public interface of PROSPERO, but what the changes are is unclear as the revision notes 
explaining the changes are not currently made publicly available. We are excluding records 
with amendments for other reasons, but the assumption would be that Yes  amendments 
have been identified but the justification probabl  Unclear   
Results 
The numbers and process used to identify the registrations assessed will be reported in the 
results. 




For the complete set of all eligible registration records for 2018, we will present descriptive 
statistics of demographic information on country, number of authors, topic of review, stage of 
review at registration, funding and sponsorship status, and whether a meta-analysis is planned.  
We will present the same demographic information for the sample of assessed records to set 
them in the context of the whole dataset to demonstrate the representativeness of the sample 
used. Month of publication of the record will be reported as an indicator that the sample 
records were randomly selected. 
For compliance between registration record entry and PRISMA-P reporting item we will 
tabulate the number of records scoring 1 in response to the PRISMA-P reporting items. Where 
items have been broken down into separate elements, we will also tabulate the result for each 
element to demonstrate were information has been assessed as missing. For each individual 
item (and sub item), we will present the number and percentage to score 1.  
For the overall total score for records (maximum possible 21) we will present the mean, 
standard deviation, median, and inter-quartile range.  
The influence of the following variables on compliance with reporting guidelines will be 
presented as number and percentage to score 1: country; number of authors; topic of review; 
stage of review at the time of registration. Number and percentage to score 1 for assessed 
items will be reported for: no listed funder or sponsor vs listed sponsor or funder; and whether 
authors indicate a meta-analysis is planned or not. Graphical representation of results will be 
used where appropriate. 
Dissemination 
The results paper will be submitted for publication in a peer reviewed journal. The paper is 
intended for inclusion in AB s thesis for PhD by publication. The findings will be shared and 
discussed with the team at CRD who produce and manage PROSPERO. All relevant data and 
outputs from the study will also be placed with the protocol in the Open Science Framework. 
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Items, scoring options and guidance/rules for assessment of PROSPERO records compared to 
PRISMA-P reporting requirements 
FINAL Version1.1 8 April 2020 
The assessment form contains a breakdown of PRISMA-P reporting items re-organised to match 
as far as possible the order in which information is presented in PROSPERO. Numbering of 
items matches the numbering in PRISMA-P for ease of referral to the field in the E&E paper. 
A number of fields have been excluded: details of these and the reasons for exclusion are 
documented in the study protocol.  
Sub-questions (items) have been included for sections as not all the information for PRISMA-P is 
required/requested in PROSPERO. These elements will be included in the total scoring for each 
item, and then reported in the detailed breakdown of items in the context of what PROSPERO 
requires. 
Information required by PRISMA-P may be contained in any field within PROSPERO – it does not 
have to be in the expected field. E.g. Context may be indicated in the Context, Condition or 
domain, Research question, or Objectives fields. The exceptions are: Q1 where the information 
must be in the Title; and Q7 where the information must be included in the Review question 
(see below). 
If you are really unsure about something, remember we are assessing whether they have 
reported how they are approaching something, not judging the quality of their methods. You 
can make a comment in the final text box and we are doing a blind assessment and any 
discrepancies will be discussed. 
Rules for specific fields 
Item Options Scoring rules 
1a. Identification in the 
title: Identify the report 




Refers to information in the title only. If it does not state in 
the title that it is a protocol, the score is ‘Not reported’. 
1a. Identification in the 
title: Identify the report 
as a systematic review / 
meta-analysis / or other 
form of systematic 





Refers to information in the title only. If it does not state in 
the title that it is a systematic review or meta-analysis or 
variation on a systematic review such as a rapid review, the 
score is ‘Not reported’. 
1b. Update: If the 
protocol is for an update 
of a previous systematic 
review, identify as such 






Refers to information in the title only. If it says Update in the 
title then clearly the score is Yes. Updates are rare therefore 
most frequent/default response is likely to be Not an 
update. However, if in the course of completing the 
assessment it becomes clear that the reviewers are in fact 
updating an existing review, this should be revisited and 




scored as ‘Not reported’. PROSPERO contains the field 
“Details of any existing review of the same topic by the same 
authors”, which if completed appears in the record and may 
indicate that this is an update (unless of course they just say 
‘none’!). 
 
Looking for pre-existing reviews is an essential part of 
avoiding duplication of reviews; this does not count as them 
planning to update a review. Updates of reviews are still rare 
in PROSPERO registered non-Cochrane review. 
INTRODUCTION   
7. Objectives: Provide an 
explicit statement of the 
question(s) the review 











Refers to the information given in the research question, 
which should include reference to participants, interventions, 
comparators, and outcomes (PICO) – score Reported/ Not 
reported/Not applicable for each element. N.B while 
PROSPERO then asks for each of these elements separately, 
PRISMA-P guidance for this is specific to the research 
question. We will accept anything that alludes to an element 
as = Reported (e.g. P: “aging individuals”, I “which treatment 
is most likely to be effective”, C: “other interventions” O: 
“manage uncertainty” = Reported. However, something like 
“effective and safe” as an outcome here is too vague = Not 
reported.  
 
For non-comparative reviews (e.g. efficacy and safety), 





METHODS   
9. Information sources: Describe all intended information sources (e.g., electronic databases, contact 







‘Reported’ if any bibliographic database(s) are named e.g. 
PubMed, MedLine, Embase, CENTRAL, LILACS  
Grey literature sources 
named or statement of 
no grey lit searches 
planned 
e.g. databases of theses, conference abstracts, OpenGrey, 
System for Information on Grey Literature in Europe (Sigle)  
Study registries (inc. 
CENTRAL) 
e.g. PROSPERO, clinicaltrials.gov. N.B. CENTRAL includes 
details of on-going trials from clinicaltrials.gov and the WHO 
registries platform = Reported. Likewise, searching Cochrane 
Library includes CENTRAL. 
Contact with study 
authors planned or 
statement that contact 
not planned 
Will they be contacting authors, leaders in the field to ask 
them to identify studies/provide information on unpublished 
work? 
Other: e.g. hand 
searching reference lists 
of included studies 
Anything not included above that relates to getting hold of 
study papers or data relevant to the review 




Planned search dates ‘Reported’ if they say e.g. databases to be searched from 
inception or a date (July 2000) or they indicate a date when 
the searches will be carried out. Plan to update searches 
before final analysis = Reported. Don’t give any indication = 
‘Not reported’ 
10. Search strategy: Present draft of search strategy to be used for at least one electronic database, 
including planned limits, such that it could be repeated 







e.g. list of search terms and how they will be combined for a 
specific database e.g. PubMed This may or may not include 
combining results to arrive at a final dataset: some topics are 
so niche they only require a simple search. If ‘strategy 
attached’ = Reported even if not accessible. 
Search terms given alone 
i.e. not formal strategy 
for a database 
List of words with no information about how they will be 
combined or where they will be used (Not applicable if full 
search strategy provided) 
Approach to 
limits/restrictions 
reported e.g. dates; 
statement of no limits  
Any mention of limiting the searches by one or more items 
such as date, language or any other parameter(s). A 
statement that there will be no limitations/restrictions used 
should score a ‘Reported’ as they have reported on this item. 
This item should never = Not applicable. 
6. Rationale: Describe the rationale for the review in the context of what is already known 
Rationale described (e.g. 





Statement about why this review is needed. E.g. unanswered 
question - no existing review; to inform guideline 
development; new studies since last review = update or new 
review. The focus for this item is more on how the findings 
will be used. 
Context provided (e.g. 
scale of 
problem/condition) 
Background on clinical condition; thinking behind the planned 
review eligibility criteria e.g. informed by PPI work. Focus for 
context is more on how important the issue is. 
 
NB. The rationale and context are often presented as a single 
statement rather than separate elements so may need 
unpicking. 
8. Eligibility criteria: Specify the study characteristics (e.g., PICO, study design, setting, time frame) 
and report characteristics (e.g., years considered, language, publication status) to be used as criteria 
for eligibility for the review 





Types of study designs to be included are listed, or if no 
restriction on type of design, statement saying so 
Setting (condition or 
domain) specified 
Should be in specific PROSPERO field: Condition or domain 
being studied. There may be more info in the non-mandatory 
‘Context’ field 
Population detailed Population identified in sufficient detail to enable data 
extraction 
Intervention specified Intervention described in sufficient detail to enable data 
extraction 
Comparator specified This may be an alternate specific intervention, usual care or 
for network M-A interventions are compared with each other 




Outcome(s) specified Outcome(s) listed 
13. Outcomes and prioritisation: List and define all outcomes for which data will be sought, including 
prioritisation of main and additional outcomes, with rationale 
Primary/main 







Primary/main outcome(s) described and identified as such. 
Where a list of outcomes is presented under the Primary 
outcome heading = Reported 
Primary/main outcome 
measure(s) specified 
Any measure(s) specified / included in description of 
outcome(s) = Reported.  
Additional outcomes 
specified as such 
Other outcomes specified = Reported 
None = Reported 
Additional outcome(s): 
measure(s) specified 
Any measure(s) specified / included in description of 
outcome(s) = Reported. 
If No additional outcomes stated = Not applicable 
Rationale for choice of 
outcome(s) 
Do they say why the outcomes are appropriate, give reason 
for choice? 
Study records   
11a. Data management: Describe the mechanism(s) that will be used to manage records and data 






Details of how the search results will be handled e.g RevMan, 
Covidence, Eppi-reviewer, or unspecified ‘software’. 
De-duplication planned A statement anywhere to say that search results will be de-
duplicated or how multiple reports of the same study will be 
handled. 
11b. Selection process: State the process that will be used for selecting studies (e.g., two 
independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in 
meta-analysis) 





Title and abstract screening – number of reviewers/ 
resolution of disagreements: if any elements of the process 
described = Reported. 
Full paper screening 
process described 
Description of how the eligibility criteria will be applied to the 
records from initial screening – e.g. number of 
reviewers/resolution of disagreements: if any elements of the 
process described = Reported. 
11c. Data collection process: Describe planned method of extracting data from reports (e.g., piloting 
forms, done independently, in duplicate), any processes for obtaining and confirming data from 
investigators 






Mechanism for consistent recording of extracted data, e.g. 
form to be developed or use of standardised form such as 
Cochrane data extraction – ideally piloted but not essential. 
Data extraction process 
described 
How data extraction to be performed, e.g. double blind/ 
disagreements resolved by discussion/third reviewer. N.B. 
data extraction and risk of bias assessment may be 
undertaken at the same time i.e. as part of a single process. 
Obtain missing data Statement about how missing data will be dealt with: e.g. 
contact study authors/account for in statistical analyses 
12. Data items: List and define all variables for which data will be sought (e.g., PICO items, funding 
sources), any pre-planned data assumptions and simplifications 




List of data for extraction Reported 
/Not 
reported 
Items to be included in data extraction listed 
Variables defined Definitions for the items for extraction e.g. unit of 
measurement for items presented such as time points for the 
review outcomes 
Any data assumptions 
reported 
Statement of any pre-specified assumptions e.g. what they 
will do with unclear information or missing data 
14. Risk of bias in individual studies: Describe anticipated methods for assessing risk of bias of 
individual studies, including whether this will be done at the outcome or study level, or both; state 
how this information will be used in data synthesis 
No risk of bias 







If risk of bias details are provided, this item = Not applicable.  
A statement to say the authors are not going to carry out a 
risk of bias assessment and provide an explanation to justify 
this = Reported (and following items would be Not 
applicable). Anything less = Not reported.  
Risk of bias tools named 
for all study types 
included 
Risk of Bias tool named for assessment of each study design 
to be included in the review. If just one tool named but 
implication is same tool used for different study designs 
included = Reported. If specifically say using a named tool for 
type of study but then don’t name tools for other study 
designs to be included = Not reported. If clearly using a 
recognised tool but do not actually name it = Reported. 
 
[Examples of tools for study designs other than RCTs: 
Cochrane has ROBINS-I, SIGN, CASP, JBI, Newcastle Ottawa 
Scale (NOS), Down and Blacks, PEDRo. N.B. There are 
probably about 200 such tools – if in doubt do a quick google 
search]  
Outcome or study level 
or both 
RoB should look at assessing the potential for bias: 
a) in specific domains within each of the included studies 
such as incomplete outcome data, selective outcome 
reporting, and/or  
b) the overall risk of bias for each study.  
 
N.B. some RoB tools are designed to assess at both study and 
outcome levels (e.g. Cochrane RoB/RoB2, NOS, ROBINS-I, 
ROBINS-E, QUADAS, JBI, Downs and Black) If one of these is 
used or the authors state they will assess at either or both 
levels = Reported.  
N.B Jadad, PEDRo and Drummond are not RoB tools but 
assess methodological quality of RCTs/Economic evaluations 
= Not reported.  
Domains/outcomes for 
risk of bias assessment 
stated 
The constructs for assessment are listed, defined and 
judgment options (e.g. high low unclear) given = reported 
If constructs listed and defined but judgement options not 
specifically given – consider if tool to be used has pre-
specified constructs and judgement options if so = Reported 




[Those listed above have judgement options assigned – 
including Jadad and PEDRo].  
Risk of bias assessment 
process described 
Any statement of how risk of bias will be undertaken e.g. two 
reviewers independently/blinded +/- method for resolution 
of disagreements 
How risk of bias findings 
will be used in the 
synthesis 
Statement of whether studies will/will not be excluded based 
on risk of bias score. Or include all studies meeting criteria 
but account for risk of bias in statistical analyses (sub-
group/sensitivity analyses) 
Data   
15a. Synthesis: Describe criteria under which study data will be quantitatively synthesized 








Statement to say under what circumstances a quantitative 
synthesis/ meta-analysis (M-A) will be undertaken (e.g. if 
studies are sufficiently homogeneous) = Reported 
Quant/M-A planned but no mention of criteria for going 
ahead = Not reported 
M-A will not be undertaken (e.g. narrative or qualitative 
synthesis planned = Not applicable 
15b. If data are appropriate for quantitative synthesis, describe planned summary measures, 
methods of handling data, and methods of combining data from studies, including any planned 
exploration of consistency (e.g., I2, Kendall’s tau) 





Details of effect measures; e.g. RR or mean difference 
Statistical method Method to be used should be stated e.g. inverse variance, 
DerSimonian-Laired, Mantel-Haenszel, Baysian 
Use of fixed or random 
effects or both 
Statement about which model(s) they will apply = Reported 
Data handling: 
conversion to same 
format 
Details of how data will be handled to ensure measures are 
converted/presented in the same format. E.g. plan to 
calculate standardised mean difference 
Data handling: missing 
data 





Plans for how data will be combined and how they will 
evaluate between study inconsistency (heterogeneity) 
Name of software to be 
used for meta-analysis 
Type or name of software to be used for performing the 
meta-analysis e.g. Stata, R, RevMan 










Statement that sub-group analyses are planned - must 
include the co-variants. Statement that no-subgroup analyses 
are planned = Reported 
Post-hoc analyses planned without co-variants = Reported 
Methods for subgroup 
analyses reported 
How groups will be divided, use of fixed or random effects. 




Statement that sensitivity analyses are planned or not 
planned, to include items to be examined 




15d. If quantitative synthesis is not appropriate, describe the type of summary planned 









Statement of how data not suitable for reporting in the M-A 
will be presented. Where no M-A, description of method for 
data synthesis e.g. narrative or qualitative. If all data to be 
presented in M-A = Not applicable 
Narrative or qualitative 
synthesis methods 
described 
For a narrative synthesis details of how studies/findings will 
be combined/stratified/prioritised narratively (in text or 
tables): i.e. some form of synthesis beyond providing a 
description of the studies and data extracted, may reference 
method e.g. CRD guidance. Any methods information beyond 
statement of type = Reported.  
For reviews of qualitative studies, plans how the synthesis 
will be carried out e.g. thematic analysis or framework 
development etc should be provided. Either reported or Not 
reported 
Other analyses planned 
e.g. cost data 
Details of any other analyses such as cost effectiveness are 
provided = Reported. If no mention in record of data being 
collected for other analyses = Not applicable. If e.g. cost data 
collected but no analysis planned = Not reported 
16. Meta-bias(es): Specify any planned assessment of meta-bias(es) (e.g., publication bias across 
studies, selective reporting within studies) 







Methods for testing for publication bias should be given e.g. 
funnel plot; Egger’s test. NB Not applicable for Narrative 
Synthesis 
Outcome reporting bias 
to be assessed 
Methods for assessing potential for outcome reporting bias 
should be given, e.g. ORBIT system; sensitivity analysis. NB 
Not applicable for Narrative Synthesis 
17. Confidence in cumulative evidence: Describe how the strength of the body of evidence will be 
assessed (e.g., GRADE) 
Overall assessment of 
included studies planned 
or statement that no 







Is there a plan to look at overall study quality in addition to 
the ROB assessment of individual studies? 
Methods specified (e.g. 
GRADE) 
If an overall assessment is planned, are the methods 
specified? (Not applicable if not planned – Score Not 
reported if previous question is Not reported) 
Comment or 
observations on this 
record 
 For any observations you may have about this record or any 
issue you may want to raise. Please also feel free to make use 
of the questions sheet in the shared drive 
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2.









Elaboration and explanation paper: https://www.bmj.com/content/349/bmj.g7647
3.
Tick all that apply.
Reported
Not reported
PRISMA-P scoring sheet for PROSPERO
records
Assessment form Version 1.1 08 April 2020
*Required
PROSPERO RECORD UNIQUE ID: 11 digit number only *
RESEARCHER ID *
1a. Identi!cation in the title: Identify the repo" as a protocol *
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Elaboration and explanation paper: https://www.bmj.com/content/349/bmj.g7647
6.
Mark only one oval per row.
METHODS
Elaboration and explanation paper: https://www.bmj.com/content/349/bmj.g7647
1a. Identi!cation in the title: Identify the repo" as a systematic review / meta-analysis / or
other form of systematic review such as a rapid review *
1b. Update: If the protocol is for an update of a previous systematic review, identify it as such
in the title *
7. Objectives: Provide an explicit statement of the question(s) the review will address with
reference to pa"icipants, interventions, comparators, and outcomes (PICO) *
This should be in the Review Question Peld.
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7.
Mark only one oval per row.
8.
Mark only one oval per row.
9. Information sources: Describe all intended information sources (e.g., electronic databases,
contact with study authors, trial registers, or other grey literature sources) with planned
dates of coverage *
Reported Not reported
Electronic database(s) named
Grey literature sources named or statement
of no grey lit searches planned
Study registries (inc. CENTRAL)
Contact with study authors planned or
statement that contact not planned
Other: e.g. hand searching reference lists of
included studies
Planned search dates
10. Search strategy: Present dra# of search strategy to be used for at least one electronic
database, including planned limits, such that it could be repeated *
Reported Not reported Not applicable
Draft search strategy provided
Search terms given alone i.e. not formal
strategy for a database
Approach to limits/restrictions reported e.g.
language or dates/statement of no limits
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9.
Mark only one oval per row.
10.
Mark only one oval per row.
6. Rationale: Describe the rationale for the review in the context of what is already known *
Do they explain why the review is needed and refer to what is already know? This information may be in the context Peld
or provided elsewhere.
Reported Not reported
Rationale described (e.g. existing evidence
base)
Context provided (e.g. scale of
problem/condition)
8. Eligibility criteria: Specify the study characteristics (e.g., PICO, study design, se$ing, time
frame) and repo" characteristics (e.g., years considered, language, publication status) to be
used as criteria for eligibility for the review *
Reported Not reported Not applicable
Study design speciPed
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Mark only one oval per row.
STUDY RECORDS
Elaboration and explanation paper: https://www.bmj.com/content/349/bmj.g7647
12.
Mark only one oval per row.
13. Outcomes and prioritisation: List and de!ne all outcomes for which data will be sought,
including prioritisation of main and additional outcomes, with rationale *
Reported Not reported Not applicable
Primary/main outcome(s) speciPed as such
Primary/main outcome(s) measure speciPed
Additional outcomes speciPed/ state None
Additional outcomes: measures speciPed
Rationale for choice of outcome(s)
11a. Data management: Describe the mechanism(s) that will be used to manage records and
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13.
Mark only one oval per row.
14.
Mark only one oval per row.
15.
Mark only one oval per row.
11b. Selection process: State the process that will be used for selecting studies (e.g., two
independent reviewers) through each phase of the review (i.e., screening, eligibility, and
inclusion in meta-analysis) *
Reported Not reported
Initial screening process described
Full paper screening process described
11c. Data collection process: Describe planned method of extracting data from repo"s (e.g.,
piloting forms, done independently, in duplicate), any processes for obtaining and
con!rming data from investigators *
Reported Not reported
Data extraction form (develop own/use
template/pilot)
Data extraction process described
Obtain missing data
12. Data items: List and de!ne all variables for which data will be sought (e.g., PICO items,
funding sources), any pre-planned data assumptions and simpli!cations *
Reported Not reported
List of data for extraction
Variables dePned
Any data assumptions reported
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16.
Mark only one oval per row.
DATA
Elaboration and explanation paper: https://www.bmj.com/content/349/bmj.g7647
17.
Mark only one oval per row.
14. Risk of bias in individual studies: Describe anticipated methods for assessing risk of bias
of individual studies, including whether this will be done at the outcome or study level, or
both; state how this information will be used in data synthesis *
Reported Not reported Not applicable
No risk of bias assessment planned and
justiPcation provided
Risk of bias tools named for all study types
included
Outcome or study level or both
Domains/outcomes for risk of bias
assessment stated
Risk of bias assessment process described
How risk of bias Pndings will be used in the
synthesis
15a. Synthesis: Describe criteria under which study data will be quantitatively synthesized 
Reported Not reported Not applicable
Criteria for doing a quantitative synthesis/M-
A described
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18.
Mark only one oval per row.
19.
Mark only one oval per row.
15b. If data are appropriate for quantitative synthesis, describe planned summary measures,
methods of handling data, and methods of combining data from studies, including any
planned exploration of consistency (e.g., I squared, Kendall’s tau)
Reported Not reported Not applicable
Summary measures
Statistical method
Use of Pxed or random effects or both
Data handling: conversion to same format
Data handling: missing data
Combining data/ exploration of consistency
Name of software to be used for meta-
analysis
15c. Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses,
meta-regression)
Reported Not reported Not applicable
Subgroup analyses planned: co-variants
named
Methods for subgroup analyses reported
Sensitivity analyses planned
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20.
Mark only one oval per row.
21.
Mark only one oval per row.
22.
Mark only one oval per row.
15d. If quantitative synthesis is not appropriate, describe the type of summary planned *
Reported Not reported Not applicable
Descriptive, Narrative, or Qualitative
synthesis planned




16. Meta-bias(es): Specify any planned assessment of meta-bias(es) (e.g., publication bias
across studies, selective repo"ing within studies) *
Reported Not reported Not applicable
Publication bias to be assessed
Outcome reporting bias to be assessed
17. Con!dence in cumulative evidence: Describe how the strength of the body of evidence
will be assessed (e.g., GRADE) *
Reported Not reported Not applicable
Overall assessment of included studies
planned or statement that no overall
assessment will be made
Methods speciPed (e.g. GRADE)
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23.
This content is neither created nor endorsed by Google.
Comment or observations on this record
Please add anything
 Forms
Scores for all sub-group analyses 
PRISMA-P REPORTING ITEM 





























1a. Identification in the title: Identify the report as a protocol of a systematic review 14 8 11 11 15 7 
1b. Update: If the protocol is for an update of a previous systematic review 241 183 242 182 234 190 
6. Rationale 24 14 22 16 15 23 
7. Objectives: Provide an explicit statement of the question(s) the review will address with reference to participants, 
interventions, comparators, and outcomes (PICO) 
60 45 67 38 68 37 
8. Eligibility criteria: Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report 
characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review 
218 168 223 163 206 180 
9. Information sources: Describe all intended information sources (e.g., electronic databases, contact with study 
authors, trial registers, or other grey literature sources) with planned dates of coverage 
1 1 2 0 2 0 
10. Search strategy: Present draft of search strategy to be used for at least one electronic database, including planned 
limits, such that it could be repeated 
34 42 40 36 37 39 
11a. Data management: Describe the mechanism(s) that will be used to manage records and data throughout the 
review 
11 6 8 9 11 6 
11b. Selection process: State the process that will be used for selecting studies (e.g., two independent reviewers) 
through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) 128 88 119 97 131 85 
11c. Data collection process: Describe planned method of extracting data from reports (e.g., piloting forms, done 
independently, in duplicate), any processes for obtaining and confirming data from investigators 
33 19 32 20 37 15 
12. Data items: List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-
planned data assumptions and simplifications 
3 3 3 3 3 3 
13. Outcomes and prioritisation: List and define all outcomes for which data will be sought, including prioritisation of 
main and additional outcomes, with rationale 
2 1 3 0 3 0 
14. Risk of bias in individual studies: Describe anticipated methods for assessing risk of bias of individual studies, 
including whether this will be done at the outcome or study level, or both; state how this information will be used in 
data synthesis 
24 19 30 13 25 18 
15a. Synthesis: Describe criteria under which study data will be quantitatively synthesized 122 78 91 109 127 73 
15b. If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling 
data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I2, Kendall’s 
tau) 
36 34 5 65 45 25 
15c. Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) 40 45 12 73 56 29 
15d. If quantitative synthesis is not appropriate, describe the type of summary planned 127 100 146 81 109 118 
16. Meta-bias(es): Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective 
reporting within studies) 
38 34 6 66 46 26 
17. Confidence in cumulative evidence: Describe how the strength of the body of evidence will be assessed (e.g., 
GRADE) 
25 12 26 11 20 17 
